The Effect of Manipulating the IL-6 Response to Exercise on Biomarkers and Exercise Performance by Walshe, Ian
  
 
The Effect of Manipulating the IL-6 
Response to Exercise on Biomarkers 
and Exercise Performance 
 
 
Ian Howard Walshe 
  
 
A thesis submitted in partial fulfilment of the 
requirements of the University of Northumbria at 
Newcastle for the degree of Doctor of Philosophy 
 
 








Interleukin-6 (IL-6) is a pluripotent cytokine which has inflammatory 
properties.  It is suggested to mediate a variety of processes including 
increased perception of fatigue during inflammatory states.  In addition, 
prolonged exercise can cause a marked increase in circulating IL-6, and 
although there is a widely reported association between plasma IL-6 and 
fatigue in disease and inflammatory conditions, this relationship has 
remained relatively unexplored in healthy individuals during exercise.   
Therefore, the aims of this thesis were firstly, to develop a repeatable pre-
load time trial in order to examine the variability of circulating IL-6 and 
other signalling molecules in response to an exercise challenge; secondly, 
to investigate the effect of plasma IL-6 and signalling molecules on fatigue 
and performance during a pre-loaded time trial; and thirdly, to evaluate the 
impact of nutritional interventions (glutamine intake during exercise, 
manipulation of pre-exercise diet and carbohydrate intake during exercise) 
on the response of circulating IL-6, IL-6 signalling molecules and 
biomarkers associated with IL-6 during exercise and their effect on pre-
load time trial performance.  
 Results from the studies determined that there was large variability 
in the plasma IL-6 and signalling receptors response to the pre-loaded 
time trial (8-20%) but that the exercise protocol was repeatable. Nutritional 
interventions did not alter the signalling receptor response, nor biomarkers 
associated with IL-6, including hepcidin.  However, carbohydrate intake 
during exercise attenuated the circulating IL-6 response to exercise by 
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49% which correlated well with an improved time trial performance.  
Regardless of the intervention, a consistent finding in all studies indicated 
that a greater plasma IL-6 response to the preload exercise bout 
correlated well with a reduced relative exercise performance as a 
percentage of velocity at OV 2max during the subsequent time trial.   
 To summarise, the findings from this thesis indicate that elevated 
levels of plasma IL-6 are associated with a decrement in exercise 
performance.  Associated IL-6 signalling molecules are elevated in 
response to exercise but are not associated with performance and are 
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1.1  Introduction 
 Endurance exercise can place a high demand on the body which 
requires an increase in oxidative metabolism that can be met by utilisation 
of a selection of fuel substrates, including a proportion of lipids and 
carbohydrates (Maughan and Gleeson, 2004).  During a prolonged period 
of moderate intensity exercise, liver and muscle glycogen stores can 
become depleted (Bergstrom and Hultman, 1967; Baldwin et al., 1975) 
which can not only lead to fatigue and a decrement in performance, but 
can also cause a disruption in homeostasis to biological systems relating 
to circulating glucose regulation.   
 In order to maintain homeostasis from such a biological stressor, a 
number of hormones and cytokines are released into the circulation which 
counteracts the actions of metabolic stress (Galbo et al., 1975; Lundberg 
et al., 1985; Ostrowski et al., 1998; Febbraio et al., 2004).  During 
prolonged exercise, an increase in different subtypes of cytokines can be 
observed in the circulation, including interleukin-1 receptor antagonist (IL-
1ra), interleukin-10 (IL-10) and soluble tumor necrosis factor receptor 
(sTNFR).  However, interleukin-6 (IL-6) demonstrates the largest 
circulating increase during prolonged exercise which can increase up to 
100 fold (Fischer, 2006). 
 Interleukin-6 is a cytokine that was originally thought to be a protein 
released by immune cells for the sole purpose to initiate the response of 
the immune system.  However, it has been reported more recently that IL-
6 can act in a hormone like manner to mediate the actions of non-immune 
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cells and organs (Lancaster, 2006).  IL-6 is involved in cellular 
communication that initiates the function of a range of organs throughout 
the body, including the brain (Tsigos et al., 1997; Sparkman et al., 2006).  
 Circulating IL-6 can communicate with the brain through both direct 
and indirect mechanisms.  IL-6 has been shown to cross the blood brain 
barrier (Banks et al., 1994) where it can interact with the brain.  IL-6 may 
also interact with neurons extending from the brain where concentrations 
of blood borne proteins and peptides can be detected.  Greater circulating 
levels of IL-6 have often been associated with fatigue and poor functional 
performance in healthy populations (Cappola et al., 2003; Cesari et al., 
2004).  However, despite a widely reported association between 
circulating IL-6 and fatigue in inflammatory states, the association 
between circulating IL-6 and fatigue in exercise performance in healthy 










1.1.1  Aims and Objectives   
Accordingly, the aims of this thesis were explore the association between 
increased circulating IL-6 from prolonged exercise and subsequent 
exercise performance. 
 The primary purpose of this thesis was to examine the influence of 
increased circulating IL-6 from an exercise challenge on 
subsequent time trial performance.   
 In addition, a second aim of this thesis was to investigate the role of 
the circulating soluble receptors of IL-6 (sIL-6R and sgp130) and 
their association with fatigue in response to the exercise challenge. 
 Nutirional interventions employed to manipulate the exercise 
induced circulating IL-6 and signaling receptor response will 
determine the role of IL-6 and sIL-6R in exercise performance.   
 Additionally, a further objective was to assess the influence of 
manipulated circulating IL-6 and sIL-6R response to exercise on 








1.2  Interleukin-6 
1.2.1  Background of IL-6  
 IL-6 is a polypeptide molecule that is relatively small in mass, 
ranging from 21-30 kDa in size and is initially generated from 212 amino 
acids which are cleaved during the post-translational process to become a 
184 amino acid peptide (Hirano et al., 1985; Van Snick et al., 1986).  
Although initially named interferon-β2 (IFN- β2) (Gauldie et al., 1987), the 
cytokine has also been termed B-cell stimulatory factor-2 (BSF-2) (Hirano 
et al., 1985), 26 kDa protein (Haegeman et al., 1986) and hepatocyte-
stimulating factor (Gauldie et al., 1987) amongst others before its current  
identity as IL-6 with a diverse role in biology (Haegemen et al., 1986).   
 IL-6 can be released from various cell types and this release is 
dependent on the circumstance of cell stimulation.  Monocytes (Maloponte 
et al., 2002; Neuner et al., 1991), smooth muscle cells (Wang et al., 2001), 
adipose tissue (Mohamed-Ali et al., 1997; Fain et al., 2004) and skeletal 
muscle cells (Steensberg et al., 2000; Keller et al., 2001) have all been 
shown to stimulate IL-6 release along with other cells which can contribute 
to a pro-inflammatory or anti-inflammatory environment (Opal and DePalo, 
2000). The pro-inflammatory properties of IL-6 have been previously 
reported with functions such as a pyrogenic action which is associated 
with fever (Weber et al., 1993; Tsigos et al., 1997).  Furthermore, 
circulating IL-6 has also been associated with many inflammatory states 
such as rheumatoid arthritis (Knudsen et al., 2008), cancer (Coussens and 
Werb, 2002) as well as type 2 diabetes mellitus and cardiovascular 
disease (Abeywardena et al., 2009).  Adipose tissue can also secrete IL-6 
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(Mohamed-Ali et al., 1997; Fain et al., 2004) which has led to the proposal 
that this can lead to chronic inflammation in obese individuals 
(Abeywardena et al., 2009), thus, increasing the risk of type 2 diabetes 
mellitus and cardiovascular disease (McKeigue et al., 1991; Goran et al., 
2003).  Moreover, greater basal levels of systemic IL-6 have been 
associated with an increased prevalence of type 2 diabetes mellitus which 
is independent of body mass index (Pradhan et al., 2001).  In cell culture, 
IL-6 has been shown to reduce insulin receptor substrate-1 (IRS-1) in 
human adipose cells (Rotter et al., 2003) and in murine hepatocytes (Senn 
et al., 2002) which may lead to insulin resistance.  Although insulin 
resistance can be a risk factor for cardiovascular disease, the association 
between high levels of IL-6 and prevalence of cardiovascular disease 
could also be due to direct mechanisms of atherosclerosis.  Increased 
expression of IL-6 is found in a number of atherosclerotic plaques 
(Schieffer et al., 2000) and also in vascular smooth muscle cells (Wang et 
al., 2001).  Pro-inflammatory cytokines such as IL-1β and TNF-α have 
also been shown to initiate an increase in systemic IL-6 (Akira et al., 1993) 
which can disrupt the permeability of the vascular wall and increase fatty 
deposits (Abeywardena et al., 2009), suggesting that IL-6 may exert 
negative actions in chronic low level inflammation.    
 In contrast, IL-6 has also been reported to have anti-inflammatory 
properties with positive health effects (Pedersen and Fischer, 2007; 
Mathur and Pedersen, 2008).  Infusion of recombinant human (rh) IL-6 
into humans improves insulin-stimulated glucose uptake (Carey et al., 
2006) and furthermore can increase fat oxidation (Petersen et al., 2005).  
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Studies have also shown that IL-6 down-regulates expression of TNF-α 
and also initiates the release of the anti-inflammatory cytokines IL-1 
receptor antagonist (IL-1ra) and IL-10 (Schindler et al., 1990; Jones et al 
2001; Ostrowski et al., 1998).  Lipopolysaccharide (LPS) induced TNF-α 
production can be suppressed by IL-6 (Schindler et al., 1990) which may 
indicate that the purpose of the induction of IL-6 could be to prevent 
excessive pro-inflammatory actions.   During prolonged exercise, a similar 
anti-inflammatory pattern is also seen as a large increase in systemic IL-6 
is followed by increases in IL-1ra and IL-10 (Ostrowski et al., 1998).  
Furthermore, only slight increases in pro-inflammatory cytokines are seen 
following prolonged exercise, such as TNF-α (Ostrowski et al., 1998).  
Therefore, when taken together, these apparently contradicting findings 
may indicate that although IL-6 may contribute to chronic low level 
inflammation; exercise induced IL-6 release may initiate anti-inflammatory 
effects that may be beneficial to health. 
 During prolonged exercise, skeletal myocytes are a predominant 
source of circulating IL-6 (Steensberg et al., 2000); however other tissues 
can contribute to the circulating pool of IL-6 (Langberg et al., 2002; 
Fischer et al., 2004). Systemic IL-6 appears to increase in accordance 
with the intensity and duration of exercise (Fischer, 2006), and may also 
be affected by the mode of exercise (Nieman et al., 1998) as well as 
individual endurance capacity (Fischer et al., 2004).  As the duration of 
exercise increases, so does the response of circulating IL-6 levels.  
Fischer (2006) illustrated that a linear regression of results from 67 trials 
showed that 51% of the increase seen in IL-6 during the trials can be 
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explained by the duration of exercise.  Furthermore, the author reported 
that the relationship could be even more pronounced if the data were 
adjusted for relative exercise intensity.  Exercise intensity has also been 
shown to be related to increases in circulating IL-6 among marathon 
participants when expressed in relative terms (Ostrowski et al., 2000). 
However, when running is compared to cycling at the same intensity 
running appears to increase plasma IL-6 to a greater extent than cycling 
(Nieman et al., 1998) suggesting that mode of exercise can impact on the 
IL-6 response which can be attributed to larger muscle groups being 
activated during exercise. Table 1.1 shows typical circulating IL-6 
increases following prolonged running. 
 
Table 1.1 Circulating IL-6 Increases Following Prolonged Running 
Duration Intensity Fold increase (n) Reference 
 
2.5 h  75-80% VO2max  8 30  Nehlsen Cannarella et al., 1997 
2.5 h  75% VO2max  25 10  Ostrowski et al., 1998 
2.5 h  75% VO2max  29 7  Steensberg et al., 2001 
2.5 h  75% VO2max  30 9  Steensberg et al., 2001 
2.5 h  75% VO2max  52 10  Nieman et al., 1998 
2.5 h  16.4 km·h
-1  
109 16  Suzuki et al., 2000 
2.6 h  16.1 km·h
-1 
 80 10  Suzuki et al., 2003 
3 h  70% VO2max  10 16  Nieman et al., 2002 
3 h  12 km·h
-1  
50 6  Langberg et al., 2002 
3.75 h  11.2 km·h
-1  





1.2.2  Production of IL-6   
 The relationships between the duration, intensity and mode of 
exercise and circulating IL-6 levels may be accounted for by the extent of 
metabolic stress produced by exercise, since greater demands of exercise 
require greater CHO oxidation rates.  During prolonged exercise, it is often 
observed that circulating glucose concentrations are maintained with a 
simultaneous increase in circulating IL-6 (Nhelsen-Cannarella et al., 1997; 
Steensberg et al., 2001; Ronsen et al., 2002; Pedersen et al., 2003),  
suggesting that muscle glycogen is the stimulus for increased circulating 
IL-6 production, rather than blood glucose concentration (Ronsen et al 
2002).  Therefore, it has been suggested that there is a relationship 
between systemic IL-6 and levels of muscle glycogen.  Work by Keller et 
al. (2001) and Steensberg et al. (2001) have confirmed this hypothesis by 
demonstrating that contracting muscle releases IL-6 in relation to muscle 
glycogen levels.  Keller et al. (2001) demonstrated that a ~40% reduction 
in muscle glycogen led to a 40% increase in circulating IL-6 during the 
exercise bout when compared to a control condition.  Furthermore, 
transcription of the IL-6 gene and increased IL-6mRNA were enhanced 
during low glycogen conditions.  Although this indicated that IL-6 
production was receptive to muscle glycogen levels, it could not discount 
that exposure to an increase in hormonal activity or substrate was 
accountable for the increase in circulating IL-6 and IL-6mRNA.  
Steensberg et al. (2001) overcame this by depleting muscle glycogen 
levels in one leg and maintaining glycogen levels in the other leg.  The 
results showed that an increased release of IL-6 from the glycogen 
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depleted leg was in accordance with a marked increase in IL-6mRNA 
compared to the control leg.   
 Increases in IL-6mRNA in glycogen depleted muscle following 
prolonged exercise has been demonstrated in numerous studies (Keller et 
al., 2001; Steensberg et al., 2001; Chan et al., 2004; Hiscock et al., 2004) 
and could be due to a number of signalling events.  Mitogen-activated 
protein kinases (MAPK) and nuclear transcription factors are involved in 
signalling pathways in a variety of circumstances including cellular stress 
as a result of  prolonged exercise (Kramer and Goodyear, 2007).  
Subclasses of MAPK such as extracellular signal-regulated kinases 
(ERK), p38 MAPK and c-Jun NH2-terminal kinases (JNK) can increase in 
response to exercise according to the duration (Sakamoto and Goodyear, 
2002), intensity (Widegreen et al., 2000) and mode of exercise (Nader et 
al., 2001). p38 MAPK is expressed in skeletal muscle (Baeza-Raja et al., 
2004; Chan et al., 2004; Akimoto et al., 2005) and phosphorylation of p38 
MAPK can increase in response to cycling after 30 min (Widegren et al., 
1998; Widegren et al., 2000) which is in accordance with increases 
observed in IL-6 (Keller et al., 2001).  Therefore, this could suggest that 
exercised induced IL-6 could be related to p38 MAPK phosphorylation.  
Chan et al. (2004) investigated this relationship and showed that exercise 
with low muscle glycogen resulted in an increase in phosphorylated p38 
MAPK within myocytes; moreover, a significant correlation between pre-
exercise p38 MAPK and the IL-6 mRNA response to exercise was 
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observed, providing support for the proposal that p38 MAPK may, in part, 
regulate IL-6mRNA expression. 
 Marked increases in p38 MAPK and JNK phosphorylation are also 
seen during high intensity exercise (Widegreen et al., 2000; Martineau and 
Gardiner, 2001; Yu et al., 2003) which could be a result of Ca2+ release 
during exercise, acting as a potent stimulus for a variety of biological 
processes (Berridge et al., 2001).   In vitro studies have shown that Ca2+  
ionophore ionomycin increases p38 MAPK phosphorylation in L6 
myotubes (Elzi et al., 2001; Chan et al. 2004), and furthermore, work by 
Chan et al. (2004) also showed that 60 min of cycling increased 
phosphorylation of JNK in skeletal muscle in vivo.  Therefore, collectively 
these findings may indicate that an increase in Ca2+ levels from skeletal 
muscle contraction can increase p38 MAPK phosphorylation, which in turn 
may lead to an increase in IL-6mRNA.   
 Prolonged exercise can lead to an increase in oxidative stress (Ji, 
1999), particularly if the individual performing the exercise bout is 
unaccustomed to the exercise (Kramer and Goodyear, 2007).  As 
contracting skeletal muscle can increase reactive oxygen species (ROS), 
this can stimulate activation of the transcription factor NF-κβ (Schmidt et 
al., 1995; Zhang et al., 2001).  It has been previously been shown that NF-
κβ can stimulate IL-6 expression.  Kosmidou et al. (2002) demonstrated 
that in skeletal myotubes, IL-6 production can be triggered by ROS, and 
furthermore, a pharmacological inhibitor of NF-κβ inhibited ROS 
stimulated IL-6.  Whether this phenomenon occurs in vivo in response to 
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exercise or not is unclear, but work from Fischer et al. (2004) 
demonstrated that antioxidant supplementation blunted the exercise 
induced circulating IL-6 response to exercise, although it did not 
significantly blunt IL-6mRNA within skeletal muscle.   
 Taken together, it is clear that IL-6mRNA transcription in skeletal 
muscle can be stimulated by a variety of factors including low skeletal 
muscle glycogen, a rise in Ca2+ levels from skeletal muscle contraction 
and increased ROS activity associated with prolonged exercise.  Although 
a combination of these factors could be responsible for IL-6 transcription, 
it is possible that p38 MAPK, NF-κβ and JNK could all play a role in 
transcription of IL-6, perhaps through a cross-talk pathway (Febbraio and 
Pedersen, 2002). 
1.3  Interleukin-6 Receptors 
 For IL-6 to instigate any biological actions, it must interact with the 
receptor which is situated on the surface of the target cell.  Interaction 
must occur via two different membrane bound glycoproteins, firstly, IL-6 
must bind with its receptor (IL-6R), then to the non ligand binding receptor, 
glycoprotein 130 (gp130).  As a complex, signaling can then occur on cells 
expressing gp130 (figure 1.1) (Heirich et al., 1998; Jones et al., 2001).  
Many cells can express IL-6R including different regions of the brain such 
as the hippocampus and hypothalamus (Schobitz et al., 1993; Gadient 
and Otten, 1993), skeletal muscle cells (Keller et al. 2005), hepatocytes 
and leukocytes (Jones et al., 2001); whereas the gp130 receptor is 
ubiquitously expressed throughout the body (Hibi et al., 1990).  This can 
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render the actions of IL-6 dependent and limited to the amount of IL-6R 
expression on target cells.  However, a cognate receptor, soluble IL-6 
receptor (sIL-6R) can shed from the cell surface and act in the same 
manner as IL-6R which can ‘transsignal’ through membrane bound gp130 
(Muller-Newen et al., 1998).   Therefore this can potentially increase the 
range of cells that can be stimulated from IL-6. 
1.3.1  sIL-6R  
 sIL-6R is a 50-55 kDa protein which binds to IL-6 with a similar 
affinity as the membrane bound IL-6 receptor (Mitsuyama et al., 1995; 
Muller-Newen et al., 1998) to form an IL-6/sIL-6R complex which 
increases the duration of biologically active IL-6 by preventing its 
degradation (Gerhartz et al., 1994).  Several studies have shown that sIL-
6R can augment the actions of IL-6 in various biological processes.  The 
presence of sIL-6R can increase the sensitisation of many cells to IL-6 
including neuronal cells (Marz et al., 1999), hepatic cells (Mackiewicz et 
al., 1992) and muscle cells (Gray et al., 2009) when associated with sIL-
6R.    Schobitz et al. (1995) demonstrated that administration of IL-6 
intracerebroventricularly into rats increased core temperature which was 
accompanied by a decrease in activity and food intake.  When sIL-6R was 
also administered, symptoms were enhanced and prolonged.  This 
phenomenon was also observed with skeletal muscle glucose uptake 
(Gray et al., 2009).  Mouse skeletal muscle was incubated with IL-6 which 
showed no effect on glucose uptake.  However when skeletal muscle was 
incubated with both IL-6 and sIL-6R, glucose uptake was increased.  
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When greater concentrations of IL-6 and sIL-6R were incubated, this 
augmented glucose uptake further.  Mackiewicz et al. (1992) also 
illustrated this phenomenon by demonstrating that HepG2 cells that were 
chronically exposed to IL-6 were desensitised to the actions of IL-6; 
however, the addition of sIL-6R to the incubation increased the 
responsiveness, potentiating the effects of IL-6.  Collectively, this indicates 
that sIL-6R increases the biological potency of IL-6 and can also increase 
the duration of its activity, which illustrates the importance of the 
interaction between sIL-6R and IL-6 and must be considered when 
examining the effects of IL-6.  
  sIL-6R can be produced via two different pathways comprising of 
alternative or differential mRNA splicing (DS-sIL-6R) or proteolytic 
cleavage of a membrane bound receptor (PC-sIL-6R).  Membrane bound 
receptors that encode mRNA transcripts differentially splice to yield DS-
sIL-6R  production (Horiuchi et al., 1994) which can be detected 8-24 h 
after stimulation using specific antibodies against the peptide (Cichy et al., 
1997).  In contrast to DS-sIL-6R, PC-sIL-6R production is rapid and can 
be detected within 30-120 min of stimulation and is produced as a result of 
shedding from membrane bound receptors at a site close to the cell 
surface (Jones et al., 1999).  PC-sIL-6R has been shown to increase with 
age (Muller-Newen et al., 1996), during certain conditions such as an 
inflammatory state (Hurst et al., 2001) and also during exercise (Leggate 
et al., 2010).  The precise mechanism for proteolytic cleavage of IL-6R is 
unclear with a number of mechanisms proposed to be responsible for IL-
6R shedding.  IL-6R may be cleaved via a number of enzymes including 
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protein kinase C (Mullberg et al. 1992), mellatoproteases (Gallea-Robache 
et al., 1997), or could be as a result of Ca2+ mobilisation (Jones et al., 
1998).   Neutrophil apoptosis can increase shedding which is regulated by 
metalloproteases (Gaellea-Robache et al., 1997; Chalaris et al., 2007).  
However, neutrophils exposed to CRP demonstrated an increase in 
shedding which was not regulated by a metalloprotease inhibitor (Jones et 
al., 1999). 
 Numerous studies have previously shown that during prolonged 
exercise plasma sIL-6R increases (Gray et al., 2008; Gray et al., 2009; 
Leggate et al., 2010), but this is not consistently shown (Keller et al., 
2005) which may be a consequence of low subject numbers and large 
inter-individual variability.  The cause of the release of plasma sIL-6R in 
response to prolonged exercise is unknown, however, Robson-Ansley et 
al. (2009) observed that very prolonged exercise (>6 h) each day, over 6 
days resulted a large increase in plasma CRP which was maintained and 
correlated with sIL-6R.  This may suggest that CRP increased the 
circulating sIL-6R increase; however it is uncertain which isoform  
demonstrated the predominant increase.  During and immediately 
following prolonged exercise, plasma PC-sIL-6R significantly increases 
whereas increases in DS-sIL-6R are observed during the recovery period 
at 6 h post exercise (Leggate et al., 2010) which may be reflected by the 
time course of stimulation of each of the isoforms.  
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1.3.2  sgp130 
 For transsignaling to occur as a complex, IL-6, (s)IL-6R and gp130 
are required to construct a hexamer of two IL-6, two IL-6 receptor and two 
gp130 proteins (Boulanger et al., 2003).  Furthermore, like IL-6R, a 
soluble form of gp130 (sgp130) has been detected in human plasma, of 
which different isoforms of sgp130 exist, including differential mRNA 
splicing and as well as proteolytic cleaved sgp130.  Both isoforms can act 
as an antagonist to the actions of the IL-6/sIL-6R complex (Montero-Julian 
et al., 1997; Muller-Newen et al., 1998).  Since transsignaling occurs 
through gp130, the IL-6/sIL-6R complex binds to sgp130 with the same 
affinity to form an IL-6/sIL-6R/sgp130 complex.  The molar excess of this 
complex leads to biological inactivity (Jostock et al., 2001) thus, regulating 
excessive signalling (figure 1.1).  The source of sgp130 is unclear with 
only a small number of sites known to release sgp130 (Montero-Julian et 
al. 1997) however, an increase in plasma sgp130 has been shown in 
response to exercise (Gray et al., 2008).  The relevance of the increase in 
sgp130 is unknown, however it could be postulated that sgp130 may 
regulate the actions initiated by the IL-6/sIL-6R complex by inhibiting 
transsignalling via membrane bound gp130.  Evidence to support this from 
Rebouissou et al. (1998) demonstrated that an increase of sIL-6R 
preceded an increase in sgp130.  Furthermore, the actions of sgp130 
have been shown to inhibit the response of IL-6 mediated actions through 
sIL-6R without impeding the responses through membrane-bound IL-6R 
(Hurst et al., 2001; Jostock et al., 2001).  Together, this can suggest that 
























































Figure 1.1 The signalling process of IL-6, sIL-6R and gp130.  IL-6 in 
circulation readily binds onto IL-6R and gp130 on the cell surface to 
initiate transsignaling, however IL-6 is unresponsive to gp130 alone (figure 
1.1a).  In circulation, sIL-6R binds to IL-6 to form an IL-6/sIL-6R complex 
which can associate with membrane bound gp130 increasing IL-6 
signalling (figure 1.1b).  sgp130 binds to the IL-6/sIL-6R complex 
disrupting transsignaling of membrane bound gp130, therefore acting as 










1.3.3  Signalling 
  The signal transduction process allows for target cells to be 
activated from IL-6 signalling.  Following IL-6 binding to the receptor IL-6R 
to form a complex, the IL-6/IL-6R complex then binds to the signalling 
receptor gp130; and through homodimerization of two membrane bound 
gp130 molecules, signaling occurs on the target cell (Murakami et al., 
1993; Davis et al., 1993).  Homodimerization activates the tyrosine 
kinases of the janus kinase family (JAK) JAK1, JAK2 and TYK2 (Vila-Coro 
et al., 1999) which associate with the receptor at multiple sites.  Activation 
of JAKs then phosphorylate signal transducers and activators of 
transcription (STAT) in the cytoplasm, in particular, STAT1 and STAT3 
(Gerhartz et al., 1996).  STAT1 and STAT3 then translocate to the nucleus 
possibly with a shuttle protein carrying a nuclear localisation sequence for 
gene transcription (Strehlow and Schindler, 1998) allowing for tissue 
specific actions to take place.   
   
1.4  Biological Roles of IL-6 
   IL-6 can exert both a local and global effect in the body.  When in 
the circulation, IL-6 can exert a multitude of biological roles; therefore, 
increasing the potential to render IL-6 a stimulus to almost any cell in the 
body when in the presence of sIL-6R and membrane bound gp130. This 
reflects the pluripotent nature of the cytokine. 
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1.4.1  Metabolism  
 IL-6 plays a role in energy balance (Hoene and Weigert, 2007) 
which is enhanced during an energy crisis when energy substrates are low 
(Gleeson, 2000).  IL-6 mobilizes extracellular substrates and also aids the 
delivery of substrates to target organs (Pedersen et al., 2003) which 
suggests an important role for IL-6 in metabolic control.  Adipose tissue 
releases IL-6 into the circulation in healthy humans without the presence 
of inflammation; of which a greater proportion is secreted from visceral 
adipose tissue than subcutaneous adipose tissue (Bastard et al., 2006).  
At rest, 10-35% of the body’s basal plasma IL-6 is derived from adipose 
tissue (Febbraio and Pedersen, 2002) and furthermore, it has been 
reported that infusion of IL-6 increases triglyceride and free fatty acid 
concentration in the circulation (Petersen et al., 1995; Southard et al., 
1995; van Hall et al., 2003) and also affects liver metabolism, with 
increased VLDL secretion and hypertriglyceridemia (Bastard et al., 2006).  
Southard et al. (1995) demonstrated that infusion of rhIL-6 increased fatty 
acid oxidation, although it could not be determined if this increase was due 
to IL-6 per se or due to the IL-6 mediated increases in adrenaline and nor-
adrenaline.  A more recent study has shown an increase in fat oxidation 
without an increase in catecholamines, cortisol and glucagon when 
humans are infused with a low dose of rhIL-6.  However, the fat oxidation 
was not enhanced when infused a high dose of rhIL-6 (van Hall et al., 
2003).  This is in accordance with a study from Hiscock et al. (2005) who 
demonstrated that during low intensity exercise, infusion of IL-6 did not 
further increase lipolysis when compared to exercise alone.  Collectively, 
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these studies suggest that IL-6 can play a role in lipolysis at rest but the 
role of IL-6 in lipolysis is not effective during exercise.  Although the 
effects of IL-6 on lipolysis are clear, the effects of IL-6 on insulin actions 
appear to be more controversial (Pedersen and Febbraio, 2007; Mooney, 
2007).   
 IL-6 is elevated in the circulation during conditions that are 
associated with low grade inflammation, such as obesity, type 2 diabetes 
mellitus and is often associated with insulin resistance (DeFronzo and 
Ferrrannini, 1991; Kern et al., 2001).  It has been demonstrated that IL-6 
can inhibit the phosphorylation and the transcription of the insulin receptor 
IRS-1 and the glucose transporter GLUT-4 in cell cultured adipocytes and 
hepatocytes (Senn et al., 2002; Rotter et al., 2003).  However in contrast, 
IL-6 can have mobilising properties by promoting glucose uptake and 
increasing insulin sensitivity in myocytes (Carey et al., 2006).  
Furthermore, chronic exposure to IL-6 in cell culture appears to increase 
the mRNA expression of GLUT-4 and the transcription regulators 
peroxisome proliferator activator receptors (PPARα, PPARγ and PPARδ) 
in skeletal muscle (Al-Khalili et al., 2006).  Incubation of IL-6 also 
increases skeletal muscle glucose incorporation into glycogen (Glund et 
al., 2007).  In addition, IL-6 and sIL-6R combined can increase glucose 
uptake in mouse skeletal muscle which could not be stimulated by IL-6 
alone (Gray et al., 2009). The apparent discrepancy may be accounted for 
by differences in the expression of IL-6R as previously discussed; or by 
tissue specific insulin sensitivity.  Skeletal muscle is responsible for over 
75% of insulin actions in vivo (Stump et al., 2006); therefore it could be 
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possible that myocytes are more sensitive to insulin compared to other 
organs. This is in accordance with the work by Weigert and colleagues 
(2005) who reported that the effects of IL-6 on insulin are tissue specific.   
 As well as the role of a glucose transporter, previous studies have 
also demonstrated the actions of IL-6 to be associated with endogenous 
glucose production (Southard et al.,1995; Tsigos et al., 1997; Kanemaki et 
al., 1998), although the mechanisms for this action is unclear and is not 
consistently demonstrated (Steensberg et al., 2003; Carey et al., 2006).  
Infusion of rhIL-6 has been shown to increase endogenous glucose 
production during exercise when compared to exercise at the same 
intensity when insulin, glucagon and catecholamines remained constant 
(Febbraio et al., 2004).  Furthermore, Banzet et al. (2009) have also 
demonstrated that murine muscle derived IL-6 contributes to hepatic 
glucose production in a dose dependant manner, with observed increases 
in phosphoenolpyruvate-carboxykinase (PEPCK), a key enzyme for 
gluconeogenesis. However, IL-6 does not increase glucose-6-
phosphatase concentrations which allow glucose to leave the hepatocyte 
(Mithieux, 1997).  Together, this may suggest that the actions of IL-6 in 
glucose metabolism may differ between resting and exercising conditions 
or possibly that muscle contraction may induce a cofactor concurrently 
with IL-6 for hepatic glucose release (Febbraio et al., 2004).  Collectively, 
these results indicate that the liver can be a target organ for IL-6 (figure 
1.2).  Work from Castell et al. (1988) support this concept by 
demonstrating that rats infused with 125I-labelled rhIL-6 had a high 
clearance rate from the circulation, and that within 20 min, the majority of 
 23 
 
IL-6 had disappeared from circulation with 80% subsequently being 
present in the liver.  Although this suggests that the liver is a target organ 
for glucose production, this does not fully elucidate the function of IL-6 in 
the liver due to the complex roles that the liver is responsible for such as 
clearance of cytokines, glycogenolysis and the acute phase response.  
1.4.2  Acute Phase Response 
 An inflammatory stimulus such as injury or disruption of 
homeostasis leads to an increase in acute phase proteins which are 
synthesised predominantly from hepatocytes that are released into the 
circulation (Baumann and Gauldie, 1994).  A 25% change from baseline 
values of acute phase proteins has been defined as an acute phase 
response (Gabey and Krushner, 1999) with Interleukin-1β (IL-1β), Tumor 
Necrosis Factor α (TNFα), Interferon-γ (IFNγ) and IL-6 all shown to be 
activators (Heinrich et al., 1990).  IL-6 has a major role in the acute phase 
response, stimulating a range of acute phase proteins in humans via the 
JAK/STAT3 signalling pathway (Gao, 2005) which can be amplified by sIL-
6R when cells are desensitised to IL-6 (Mackiewicz et al., 1992).  During 
an acute phase response, IL-6 is responsible for deceases in acute phase 
proteins such as albumin and transferrin whilst also being responsible for 
increases in several proteins including serum amyloid A and C-reactive 
protein (CRP) which can increase up to 1000 fold during inflammatory 
conditions (Heinrich et al., 1990).  
 CRP is an acute-phase protein that can be produced from multiple 
sites in the body (Kuta and Baum 1986; Calabro et al., 2003) but is largely 
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produced in the liver (Hurlimann et al., 1966).  CRP consists of five 23-
kDa subunits (Agrawal et al., 2002) and has multiple biological roles 
including pro and anti-inflammatory functions depending on the context of 
it being released.  These include the clearance of damaged and apoptic 
cells (Gershov et al., 2000), as well as opsonisation and initiation of the 
complement cascade to play a role in host defence (Kilpatrick et al., 1985; 
Mold et al., 2002).  Both IL-1β and IL-6 in combination stimulates maximal 
levels of CRP (Calabro et al., 2003), however, when measured 
independently, only IL-6 alone stimulates CRP (Castell et al., 1990) which 
can be regulated not only by the STAT3 pathway, but also by a CCAAT 
enhancer binding protein (C/EBP) (Agrawal et al., 2001).  Disrupting 
phosphorylation of STAT3 attenuates the signalling of IL-6 induced CRP 
synthesis in hepatocytes (Arnaund et al., 2005).  Together, this is in 
accordance with in vivo work since infusion of rhIL-6 into humans 
increased plasma levels of CRP 3 h post infusion with peak levels 
occurring 24 h post infusion (Steensberg et al., 2003); a similar pattern to 
those observed following prolonged exercise.   
  Exercise induced plasma CRP can increase 4 h post exercise 
(Seigal et al., 2001) with peak levels occurring 24 h post exercise 
remaining elevated at 72 h post exercise (Strachen et al., 1984).  Strachan 
et al. (1984) reviewed the effect of long distance running on circulating 
CRP levels and found that greater levels of circulating CRP post exercise 
were present in those running longer distances.  Since IL-6 is the 
predominant cytokine released during exercise it can be assumed that IL-
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6 is responsible for the plasma response of CRP (figure 1.2).  Evidence to 
support this is found in the study from Miles et al. (2006) who 
demonstrated that participants who took part in a 32 km mountain trail 
race had increased plasma IL-6 levels immediately following the race with 
significant increases seen with plasma CRP the following day.  In contrast, 
Scharhag et al. (2006) found that following 4 h of cycling an increase in 
plasma IL-6 did not result in a significant elevation in plasma CRP 19 h 
post exercise.  However, it could be speculated that the lack of increase is 
possibly due to the relatively low levels of IL-6 observed following exercise 
(~4 pg·ml-1).         
 A type II acute phase protein, hepcidin has also been shown to 
increase in the circulation as part of the acute phase response (Nemeth et 
al., 2003; Nemeth et al., 2004; Lee et al., 2005).  Like CRP, hepcidin has 
been suggested to have a role in the defence against invading pathogens 
thus leading to its original name liver-expressed antimicrobial peptide 
(LEAP-1) before later being termed hepcidin (Park et al., 2001).  Hepcidin 
protects against pathogens by depriving pathogenic bacterium of iron by 
inhibiting iron release from macrophages (Lee et al., 2005) which can in 
turn, reduce circulating plasma iron levels.  Over expression of hepcidin in 
mice leads to anaemia (Nicolas et al., 2002) and conversely, iron overload 
has been shown to increase hepcidin release.  Whether this is a direct 
action of hepcidin or not is unclear (Nemeth et al., 2003). 
 Hepcidin is predominantly produced and released from hepatocytes 
(Park et al., 2001) which is triggered by IL-6 in cell culture (Nemeth et al., 
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2003) and is blocked when IL-6 antibodies are added to the cell culture 
(Nemeth et al., 2004). However, in contrast, Lee and co-workers (2005) 
have reported that IL-1α and IL-1β stimulates hepcidin in IL-6 deficient 
cells, proposing that hepcidin is released in the absence of IL-6, thus 
providing equivocal findings in vitro.  An increase in circulating IL-6 
following administration of LPS in humans also results in an increase in 
plasma hepcidin.  Circulating IL-6 levels peaked at 3 h with peak urinary 
hepcidin concentrations at 6 h post injection which resulted in a decrease 
in serum iron the following morning (Kemna et al., 2005).  The findings 
from Kemna et al. (2005) support previous work by Nemeth et al. (2004) 
who have demonstrated that infusion of rhIL-6 resulted in a large increase 
in urinary hepcidin and a decrease in serum iron concentrations following 
the infusion.  
 Since IL-6 stimulates an increase in concentrations of hepcidin, it 
would reasonable to assume that exercise induced increases in IL-6 can 
initiate a similar hepcidin response.  Roecker et al. (2005) examined 
female athletes after a marathon race and found an increase in urinary 
hepcidin the following day after the race.  However, it is not clear if urinary 
hepcidin was related to IL-6 levels since plasma IL-6 and iron were not 
reported in the study by Roecker et al. (2005).  A later study by Peeling et 
al. (2009) examined the effects of cumulative running sessions in a day 
and found an increase in IL-6, with urinary concentrations of hepcidin 
following a similar pattern 3 h post exercise.   
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 Taken together, this can indicate that an increase of IL-6 levels can 
initiate an acute phase response leading to an increase in plasma CRP 
and hepcidin which is also seen when examining the effects of prolonged 
exercise (figure 1.2).  Although muscle derived IL-6 interacts with the liver 
to initiate the acute phase response and mediate an increase in glucose 
production during prolonged exercise; IL-6 in the circulation pathways also 
interacts with brain to mediate central effects.   
1.4.3  Central Effects of IL-6   
 IL-6 is well known to interact with the brain mediating many central 
effects such as initiating fever (Chai et al., 1996; Lenczowski et al., 1999), 
altering sleep architecture (Spath-Schwalbe et al., 1998; Hong et al., 
2005) and inducing  sickness behaviour (Bluthe et al., 2006; Konsman et 
al., 2002; Harden et al., 2006), all of which can possibly be attributed to 
activation of the hypothalamus (Mastorakos et al., 1993; Lenczowski et al., 
1999; Spath-Schwalbe et al., 1994).  To activate regions of the brain such 
as the hypothalamus, IL-6 may communicate with the brain through direct 
and indirect mechanisms including crossing the blood brain barrier (BBB), 
activation of neurons extending to the hypothalamus and also binding to 
the endothelial cells at the BBB to induce central mediators.  Studies have 
demonstrated that IL-6 can directly cross the BBB in murine models 
(Banks et al., 1994; Blatteis and Sehic, 1997).  Banks and colleagues 
demonstrated that infusion of radioactively labelled IL-6 at the periphery 
can be found in particular regions of the murine brain and can also be 
transported through a different system from those of TNF-α and IL-1α.  
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The authors also reported that IL-6 is able to cross the BBB in larger 
quantities when compared to TNF-α and IL-1α.  Peripheral infusion of IL-6 
resulted in ~0.2% entering the brain (Banks et al., 1994) whereas ~0.05% 
was observed with TNF-α and ~0.07% with IL-1α (Banks et al., 1991).  In 
addition, IL-6R mRNA is found in the hypothalamus of rats as well as in 
neurons of the habenular nucleus, known to release dopamine and 
serotonin (Gadient and Otten, 1993; Schobitz et al., 1993).  Low 
expression of IL-6R in the paraventricular nucleus (PVN) of the 
hypothalamus was also found to be rapidly upregulated during an 
endotoxemia challenge (Vallieres and Rivest, 1999).  Therefore, 
collectively this provides evidence that IL-6 can cross the BBB where it 
interacts at particular sites of the brain that express IL-6 receptors.  
 Another possible mechanism for cytokines to communicate with the 
brain is via circumventricular organs (CVO) which are known to lack a 
BBB (Gross et al., 1987; Watkins et al., 1995).  Previous research has 
shown that cytokines are transported to the brain passing through CVOs 
(Stitt, 1990; Katsuura et al., 1990) where concentrations of blood borne 
proteins and peptides can be detected, which subsequently, signal to the 
brain  through neurons situated at the CVO site extending to the PVN in 
the hypothalamus (Xin and Blatteis., 1992; Marvel et al., 2003).  In support 
of this notion, inhibition thermosensitive neurons and the dorsal vagal 
complex can block the actions of infused rhIL-6 and LPS.  This 
consequently reduces c-fos expression in the PVN and also reduces fever 
and social withdrawal in rats (Marvel et al., 2003).    
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 Cells that form the BBB are astrocytes, microglia and endothelial 
cells, all of which form tight junctions which create a barrier between the 
circulation and the central nervous system and maintain the functionality 
of the brain (Ballabh et al., 2004).  At the BBB, IL-6 appears to interact 
with its corresponding receptors IL-6R and gp130 situated on endothelial 
cells (Vallieres and Rivest, 1997) which subsequently produces central 
mediators such as prostaglandins, which are well known to induce central 
effects such as fever (Xin and Blatteis, 1992; Blatteis and Sehic, 1997; 
Yamagata et al., 2001).  It has been shown previously that IL-6 induces 
prostaglandin E2 (PGE2) both in vivo (Dinarello et al., 1991) and in vitro 
(Navarra et al., 1992) which is known to be a potent mediator of fever. 
 Although it is not known what the predominant pathway for IL-6 
communication with the brain is, it is possible that IL-6 may use all the 
discussed pathways (figure 1.2).  This underlines the role that IL-6 has in 
psychoneuroimmunology linking the endocrine system with the central 
nervous system.  Thus, activation of the hypothalamic-pituitary-adrenal 
(HPA) axis by IL-6 can initiate many biological actions through secretion of 
hormones. 
1.4.4  Cortisol Production 
 An increase in corticotropin-releasing hormone (CRH) and IL-6 
secretion is observed in response to a stressor such as exercise; 
therefore, it could be assumed that IL-6 initiates CRH production as part of 
a cascade of events in response to stress.  Activation of the hypothalamus 
can produce CRH in response to stress (Bethin et al., 2000; Inder et al., 
 30 
 
1998) which regulates the activation of the HPA axis stimulating the 
production and the release of adrenocorticotropic hormone (ACTH) from 
the anterior pituitary gland (Farell et al., 1983; Swaine, 2000).  ACTH in 
turn, can produce glucocorticoids such as cortisol (Farraell et al., 1983; 
Tsigos et al., 1997) to initiate a range of biological actions throughout the 
body.   
 IL-6 can stimulate cortisol production at various levels of the central 
pathway and although IL-6 alone does not initiate PVN stimulated CRH 
production (Vallieres et al., 1997); upregulation of IL-6R increases the 
sensitivity of the PVN to IL-6, consequently elevating CRH release 
(Vallieres and Rivest, 1999).  Therefore an increase in CRH is dependent 
not only on IL-6 but also IL-6R or possibly sIL-6R to initiate an increase in 
ACTH.  IL-6 also stimulates the release of ACTH independently of CRH.  
CRH deficient mice produces ACTH in response to IL-6 stimulation which 
can be attributed to IL-6 receptor expression on the pituitary (Bethin et al., 
2000) indicating that although ACTH is stimulated through the PVN-CRH 
pathway, direct stimulation of ACTH is also possible depending on the 
dose of IL-6 present.  Tsigos et al. (1997) demonstrated that ACTH 
increased in response to IL-6 in a dose dependent manner.  Humans 
infused with IL-6 at doses ranging from 0.1 µg·kg-1 to 10 µg·kg-1 showed 
that doses of ≥3 µg·kg-1 resulted in stimulated ACTH release in a dose 
dependent manner.  Moreover, plasma cortisol release followed a 
corresponding pattern to ACTH release in the same dose dependent 
manner.  Recombinant human IL-6 infusion into humans subsequently 
increases plasma cortisol (Tsigos et al., 1997; Steensberg et al., 2003), 
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however, unlike CRH, IL-6 must depend on the actions of ACTH to 
produce cortisol (Silverman et al., 2004); therefore the cortisol response to 
plasma IL-6 appears to be an indirect action through ACTH release 
(Zarcovic et al., 2008). 
 During prolonged exercise, an increase in CRH (Tabata et al., 
1991; Inder et al., 1998), ACTH (Fraioli et al., 1980; Inder et al., 1998) and 
cortisol is observed (Few, 1974; Kuoppasalmi et al., 1980; Kindermann et 
al., 1982; Utter et al., 1999) which could be attributed at least in part to 
exercise induced plasma IL-6 mediating the activation of the HPA axis.  
Typical roles for cortisol in exercise include a metabolic role (Del Corral et 
al., 1998; Khani andTayek, 2001) and also an anti-inflammatory role 
(Steensberg et al., 2003; Rhen and Cidlowski, 2005).  Since exercise 
induced IL-6 has been shown to have similar roles as cortisol, it would be 
conceivable that IL-6 can stimulate the secretion of cortisol as part of a 
cascade to regulate metabolism and inflammation during exercise.   
1.4.5  Fatigue  
 IL-6 is well known for its association with fatigue in both chronic 
(Wratten et al., 2004; Nishimoto et al., 2005; Genovese et al., 2008) and 
acute conditions (Weber et al., 1993; Mastorakos et al., 1993; Gordon et 
al., 1995).  IL-6 mediated acute fatigue is associated with IL-6 infusion 
where fatigue usually begins within an hour of the infusion and is 
accompanied with fever and chills which subside within a few hours.  In 
contrast, IL-6 mediated chronic fatigue is often accompanied by a medical 
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illness lasting longer than 6 months which can not be relieved by rest 
(Swaine, 2000).   
 In chronic inflammatory conditions, patients experience increased 
levels of fatigue which can be debilitating.  Cancer patients experience 
fatigue during therapy which can often persists for months and even years 
following treatment (Schubert et al., 2007).   Rheumatoid arthritis is an 
autoimmune disorder which is characterised by joint pain, stiffness and 
fatigue (Davis et al., 2008) and furthermore, Castleman disease, a rare 
lymphoproliferative disorder is characterised by fever and fatigue 
(Nishimoto et al., 2005).  Many of the inflammatory conditions show 
elevated plasma levels of cytokines such as TNF-α, IL-1and IL-6 which 
are either correlated with fatigue or sensations of fatigue which are 
reduced when an IL-6 antibody is administered.    
 A study by Wratten and colleagues (2004) demonstrated that 
plasma IL-6 was associated with levels of fatigue during treatment of 
breast cancer which was in accordance with a later study by Costanzo et 
al. (2005) and Meyers et al. (2005) which showed that plasma IL-6 
correlated with levels of fatigue in ovarian cancer and leukemia patients 
respectively.  Although these findings demonstrate an association 
between IL-6 and fatigue, this does not specify a causal effect and 
furthermore these findings are not consistently seen (Ahlberg et al., 2004).  
However, studies have shown that when IL-6 antibodies are administered 
to patients with chronic disorders, fatigue is alleviated.  For example, 
rheumatoid arthritis patients treated with an IL-6 antibody have shown to 
improve the condition of the disease with diminished symptoms of fatigue 
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(Genovese et al., 2008); a finding that is also seen when an IL-6 antibody 
is administered to patients with Castleman disease (Nishimoto et al., 
2005). 
 When IL-6 is infused into humans, it has been consistently shown 
to induce fever, chills as well as increase of sensations fatigue (Weber et 
al., 1993; Mastorakos et al., 1993; Gordon et al., 1995).  Furthermore, the 
acute effects of IL-6 can mediate loss of appetite, reduce physical activity 
and lower mood states (Spath-Schwalbe et al., 1998); all of which can 
collectively be termed as sickness behaviour (Dantzer et al., 1998).   
 A range of doses of rhIL-6 infusion (1-30 µg·kg-1) into hospitalised 
patients during clinical trials have induced symptoms of anorexia, 
headaches, fatigue and fever in all patients which increases in a dose 
dependent manner (Mastorakos et al., 1993; Weber et al., 1993; Gordon 
et al., 1995).  Spath-Schwalbe et al. (1998) demonstrated in a blinded 
crossover study that even a low dose of rhIL-6 (0.5 µg·kg-1) reduces mood 
state, increases fatigue and also reduces sleep quality compared to a 
placebo. 
 As well as directly causing fever, chills and fatigue, IL-6 can also 
potentiate the sickness behaviour response of LPS and IL-1.  Bluthe et al. 
(2000) showed that IL-6 deficient mice reduced the response of sickness 
behaviour to LPS and IL-1 infusion when compared to wild type mice.  
Furthermore the work of Harden et al. (2006) demonstrated that LPS 
infusion reduced food intake and voluntary wheel running in mice.  These 
symptoms of sickness behaviour were diminished when an antibody 
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against IL-6 was administered, suggesting that IL-6 could be necessary to 
mediate the activities of LPS and IL-1.   
 When taken together, these findings indicate that IL-6 can initiate 
fatigue directly in humans and can also potentiate the activities of LPS and 
IL-1 mediated sickness behaviour in rats.  As well as the potential for IL-6 
to directly and indirectly interact with the brain as discussed earlier; IL-6 
may also cause fatigue by initiating monoamine neurotransmitters 
associated with reduced appetite or fatigue.  Serotonin or 5-
hydroxytryptamine (5-HT) is a monoamine neurotransmitter that is found 
throughout the body including the central nervous system which is 
associated with depressed mood, lethargy, sleep and reduced appetite 
(Davis et al., 2000; Young and Leyton, 2002).   5-HT is derived from 
tryptophan and although 5-HT cannot cross the BBB, tryptophan and 
another precursor of 5-HT, 5-hydroxytryptophan (5-HTP) can cross the 
BBB (Bell and Janzen, 1971).  This subsequently leads to an increase in 
brain and neuronal 5-HT synthesis (Fernstrom and Wurtman, 1971; Davis 
et al., 2000; Young and Leyton, 2002; Fernstrom and Fernstrom, 2006) 
which has been shown to mediate central fatigue (Yamamoto and 
Newsholme, 2000).    
 Increased 5-HT in the brain is associated with negative mood, 
fatigue, altered sleep cycles and appetite regulation changes (Davis et al., 
2000; Young and Leyton, 2002) and is also implicated as inducing central 
fatigue during exercise (Davis et al., 2000; Yamamoto and Newsholme, 
2000).  Bailey et al. (1993) demonstrated that a 5-HT agonist decreased 
exercise time to exhaustion in a dose dependent manner in rats; 
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conversely, in the same study, rats that were administered a 5-HT 
antagonist increased time to exhaustion also in a dose dependent 
manner.   
 IL-6 has also been shown to induce serotonergic pathways both at 
rest in rats (Yamaguchi et al., 1990; Wang and Dunn, 1998; Song et al., 
1999; Zhang et al., 2001) and also during exercise in humans (Robson-
Ansley et al., 2004).  Yamaguchi et al. (1990) demonstrated that infusion 
of rhIL-6 infused into rats increased plasma levels of prolactin from the rat 
pituitary.  In contrast with the findings from Yamaguchi and co-workers, 
Robson-Ansley et al. (2004) infused a low dose of IL-6 (0.5 µg·kg-1) into 
humans and found no difference in prolactin levels at rest.  However 
following exercise, prolactin levels were significantly elevated following 
rhIL-6 infusion compared to a placebo. Prolactin secretion is regulated by 
5-HT neurons therefore it could be postulated that brain 5-HT activity can 
reflect the activity of prolactin in plasma (Meeusen et al., 2001).  Infusion 
of IL-6 into rats alters neurotransmitter levels including elevating levels of 
5-HT (Song et al., 1999; Wang and Dunn, 1998; Zhang et al., 2001) in the 
rat striatum.  Moreover, infusion of IL-6 appears to not only increase 5-HT 
levels, but also concurrently reduce levels of dopamine (Song et al., 
1999), which is linked to elevated motivation and arousal (Davis et al., 
2000). 
 From the data it is clear that IL-6 induces sensations of fatigue 
which could be a result of direct interaction with the brain or possibly 
through indirect actions through central mediators or neurotransmitters 
such as serotonin and dopamine.  An alteration in such neurotransmitters 
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appears to alter perception of effort and/or reduce motivational drive, 
ultimately which can lead to a decrement in performance of a given task.     
1.4.6  Physical Performance 
 Given that IL-6 mediates increased sensations of fatigue among 
other biological roles, it would seem plausible that this in turn may have an 
affect on both functional and athletic performance.  Chronic low grade 
inflammatory conditions that are characterised by elevated levels of 
plasma IL-6 are commonly associated with poor functional performance.  
Nicklas et al (2005) reported that in a cross sectional study of individuals 
with osteoarthritis, walking distance and stair climbing speed were 
negatively associated with plasma levels of IL-6.  A finding that is in 
accordance with studies that have examined the functionality of aging 
populations (Taaffe et al., 2000; Cappola et al., 2003; Cesari et al., 2004).  
Markers of low grade inflammation including plasma levels of IL-6 tend to 
increase with age (Wei et al., 1992; Ferrucci et al., 2002).  However, within 
a given elderly population, it has been shown that individuals with greater 
levels of IL-6 tend to have poorer physical functional performance such as 
slower walking speed, stair climbing speed and lower grip strength (Taaffe 
et al., 2000; Cesari et al., 2004; Pereira et al., 2008). 
 Hospitalised elderly patients have shown that fatigue resistance 
using hand grip strength negatively correlates with plasma IL-6 (Mets et 
al., 2004); a finding that was also shown in a later study by Bautmans et 
al. (2010) who demonstrated that greater surgery-induced IL-6 
concentrations correlated with poorer muscular endurance using grip 
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strength.  This finding is also consistent with those found from community 
dwelling studies (Pereira et al., 2008; Cesari et al., 2004).  A study 
examining the performance of elderly persons demonstrated not only that 
plasma IL-6 negatively correlated with grip strength but also with other 
physical functional tasks such as walking speed (Cesari et al., 2004).  
Cross sectional studies by Taaffe et al. (2000), Ferrucci et al. (2002) and 
Cappola et al. (2003) have all shown that walking speed is negatively 
correlated with plasma IL-6 concentrations in older persons.  Furthermore, 
this negative correlation can be attenuated by exercise training which has 
been shown to reduce systemic IL-6 and improve functional performance 
in individuals with the highest levels of IL-6 and lowest functional 
performers (Nicklas et al., 2008). 
 Although there is a plethora of literature examining the effects of 
plasma IL-6 in chronic low grade inflammation and the association with 
functional performance, the literature concerning the acute effects of 
plasma IL-6 in athletic performance is limited.  Although Papanicolaou et 
al. (1998) has reported that IL-6 correlates with exercise induced fatigue; 
only one study to date has examined the effects of acute IL-6 on exercise 
performance.  Robson-Ansley et al. (2004) infused athletes with a small 
dose of rhIL-6 (0.5 µg·kg-1) to produce levels in circulation to those 
typically seen following prolonged running.  The study found that athletes 
ran a 10 km time trial slower following rhIL-6 infusion when compared to a 
placebo trial.  The authors also observed increases cortisol, ACTH and 
prolactin, suggesting the infusion caused an activation of the HPA axis as 
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well as serotonergic pathways which may mediate the decrement in 
performance.    
 When taken together, it is clear that circulating IL-6 performs a 
myriad of biological roles at rest and during prolonged exercise which can 
be potentiated by the effects of sIL-6R.  At present, it is not known what 
the effects of sIL-6R are with regard to exercise performance, and 
furthermore, it is not known if the sIL-6R can be manipulated with non 
pharmacological methods.  If the IL-6 and signalling receptor response to 
prolonged exercise can be blunted through an intervention, this may in 
turn attenuate markers of the acute phase response, reduce stress 
markers associated with activation of the HPA axis, and attenuate the 
sensations of fatigue, potentially improving performance.  Conversely, if 
the response of IL-6 and signalling receptor can be augmented, this can 
increase these effects and potentially cause a decrement in performance 
(figure 1.2).   
 Since nutritional interventions have been shown to manipulate the 
IL-6 response to exercise (Starkie et al., 2001; Keller et al., 2001; Hiscock 
et al., 2003) and also alter exercise performance (Coggan and Coyle, 
1991; El-Sayed et al., 1997; Rauch et al., 2005), it could be hypothesised 
that plasma IL-6 and its signalling receptors act as an integrator between 
metabolism of skeletal muscle and the central nervous system.  Therefore, 
the aims of this thesis were to investigate the response of circulating IL-6, 
sIL-6R and sgp130 to prolonged exercise and examine their relationship 
with exercise performance with nutritional manipulation.   
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2.1  Exercise Protocol 
2.1.1  Preliminary Testing 
Before the preloaded time trials, preliminary testing was conducted 
to obtain participants’ maximal oxygen uptake ( OV 2max) and running 
velocity at OV 2max (v OV 2max) on a motorised treadmill (hp Cosmos Pulsar, 
Germany). Participants performed an incremental exercise test on a 
treadmill with the gradient set at 1%.  Treadmill speed was initially set at 
12 km·h-1 and was increased by 1 km·h-1 for 3 min stages until volitional 
exhaustion.  It was considered a maximal effort if participants met any two 
of the following criteria: a change in OV 2 < 2 ml·kg
-1 ·min-1 across the last 
two stages of the incremental test; a respiratory exchange ratio of 1.15 or 
greater, or ≥ 90% age predicted maximum heart rate (220-age).  Expired 
air was measured using an online gas analyser (Cortex meta analyser 3B, 
Germany) and heart rate was measured using short range telemetry 
(Polar RS400, Finland).  
2.1.2  Experimental Protocol   
Participants performed the trials which were separated by one 
week.  They were asked to ensure they were hydrated before the exercise 
protocol and to refrain from exercise, alcohol and caffeine 24 h prior to the 
study and during the 24 h post exercise. 
 Participants arrived at the laboratory in the morning after a 12 h 
fast.  Following a void, body mass was recorded and subjects sat quietly 
for 10 min before a baseline venous blood sample was obtained.   
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2.1.3  Preload Exercise Bout  
Before the exercise bout participants completed a 5-min 
standardised warm up.  The preload component required participants to 
run at 60% v OV 2max for 2 h.  To ensure a marked circulating IL-6 response 
from a mixture of muscle fiber types, the preload component was 
interspersed with a 30 s run at 90% v OV 2max every 10 min.  Heart rate 
was measured immediately before each 30 s run at 90% v OV 2max.   
Expired gas samples were obtained for 60 s along with rating of perceived 
exertion (RPE) (Borg, 1982) at 20 min intervals prior to every alternate 
sprint.  Background music was allowed only during the preload 
component. On completion of the preload component, subjects were 
allowed to rest for 5 min whilst a venous blood sample (PL) was taken.    
2.1.4  Performance Trial 
Prior to the time trial component, participants were instructed to 
complete a 5 km time trial as fast as possible.  During the time trial 
participants controlled the speed manually but were not provided any 
performance feedback or encouragement and were only informed of every 
kilometre completed at which point heart rate, RPE and time elapsed were 
recorded.  On completion of the time trial a further blood sample was 
obtained (PostTT) and body mass was recorded.  Further blood samples 
were taken one hour post time trial (1hPost) and a final blood sample was 
taken the following morning, 24 h from baseline (24hPost).  Figure 2.1 
shows a schematic time line for each trial.  
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2.1.5  Blood Sampling 
 At each blood sampling point, 18 ml of blood was taken from an 
antecubital vein and collected into monovette tubes (9 ml K3EDTA and 9 
ml serum).  Blood samples were immediately centrifuged at 3000 
revs·min-1 for 10 min at 4°C, aspirated, and the supernatant was stored at 
-80°C until the day of analysis. 
 





2.2  Blood Plasma Analysis 
2.2.1  IL-6 Analysis 
 IL-6 was measured from K3EDTA treated tubes, in duplicate, with a 
commercially available high sensitivity chemiluminescent Enzyme-Linked 
Immunosorbant Assay (ELISA) kit (R&D Systems, Abingdon, UK).  100 µl 
of a buffered protein base and 100 µl of plasma were added with to the 
plates which were pre-coated with a mouse monoclonal antibody against 
IL-6.  The plates were incubated on a microplate shaker (Heidolph, 
Saffron Walden, UK) at 500 rev·min-1 for 2 h.  The plates were washed in 
buffered surfactant solution (Bio Tek, Potton, UK), 200 µl of polyclonal 
antibody against IL-6 conjugated to horseradish peroxidase was added to 
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the wells and incubated for 3 h on the microplate shaker at 500 rev·min-1.  
The plates were washed and added with 100 µl of glo reagent (one part 
stabilised enhanced luminal and two parts stabilised hydrogen peroxide) 
which was incubated for 10 min.  The relative luminescence units (RLU) 
was then determined using a luminometer (Bio Tek, Potton, UK).  
Manufacturer’s instructions report minimum detection limit of 0.16 pg·ml-
1and inter-assay and intra-assay variation of 7.7-9.6% and 3.0-5.8% 
respectively for IL-6. 
2.2.2  sIL-6R Analysis 
 sIL-6R was measured in duplicate from blood plasma using an 
ELISA technique from a commercially available kit (R&D systems, 
Abingdon, UK).  Plasma was collected from K3EDTA treated tubes and 
diluted 1:100 in a buffered protein base and then added to plates pre-
coated with a mouse monoclonal antibody against sIL-6R. The plates 
were then incubated for 2 h and washed (Bio Tek, Potton, UK) in a 
buffered surfactant.  200 µl of polyclonal antibody against sIL-6R 
conjugated to horseradish peroxidase was added to the plates and 
incubated for a further 2 h, then washed.  Stabilised hydrogen peroxide 
and stabilised tetramethylbenzidine were mixed in equal parts and added 
to the plates then incubated for 20 min.  50 µl of sulphuric acid was then 
added and the absorbance was then read at 450 nm with a correction at 
540 nm (Biochrom Ltd, Cambridge, UK).  The minimum detection limits 
were reported as 6.5 pg·ml-1 with an inter-assay variation of 4.7% and 
intra-assay variation of 2.3%.        
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2.2.3  sgp130 Analysis 
 Plasma sgp130 was measured in duplicate from K3EDTA treated 
tubes and measured in a commercially available ELISA kit (R&D systems, 
Abingdon, UK).  Samples were diluted 1:100 in calibrator diluent and were 
added to plates coated with mouse monoclonal antibody against sgp130 
with a buffered protein base.  The plates were incubated for 3 h and then 
washed in buffered surfactant.  A polyclonal antibody against sgp130 
conjugated to horseradish peroxidase was added to the plates and then 
incubated for 1 h and washed.  Stabilised hydrogen peroxide and 
stabilised tetramethylbenzidine were mixed together in equal parts and 
added to the plates which were incubated for 30 min.  Sulphuric acid was 
then added to the plates and the absorbance was read at 450 nm with a 
correction of 540 nm.  The minimum detection limit for sgp130 was 
reported as 0.08 ng·ml-1 with an inter-assay variation of 3.6% and intra-
assay variation of 5.5%.      
2.2.4  Glucose and Lactate Analysis 
 Plasma glucose and lactate was measured in duplicate from 
K3EDTA treated tubes with a Biosen C_line sport glucose/lactate analyser 
(EKF diagnostic, Magdeburg, Germany).  20 µl of plasma was added to a 
pre filled hemolysis solution and measured using an electro-chemical 
measuring principle.  
2.2.5  Cortisol Analysis 
 Plasma cortisol was measured in duplicate from serum tubes from 
a commercially available ELISA kit (BioVendor, Oxford, UK).  Samples 
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and standards were added to plates that were pre-coated with rabbit 
polyclonal antibody against cortisol followed by 100 µl of cortisol 
horseradish peroxidase.  The plates were incubated on a microplate 
shaker (Heidolph, Saffron Walden, UK) at 200 rev·min-1 for 45 min and 
then washed with a buffered surfactant (Bio Tek, Potton, UK).  150 µl of 
tetramethylbenzidine with hydrogen peroxide was added, then incubated 
on a microplate shaker for 15 min at 200 rev·min-1.  50 µl of sulphuric acid 
was then added to the plates and the absorbance was read at 450 nm 
(Biochrom Ltd, Cambridge, UK). The manufacturer’s instructions report a 
minimum detection limit of 0.4 µg∙dl-1 with an inter-assay and intra-assay 
variation  5.0-3.8% and 2.9-5.0% respectively. 
2.2.6  C Reactive Protein Analysis 
 Plasma C reactive protein was measured in duplicate from serum 
tubes using a high sensitivity C reactive protein (hsCRP) ELISA kit that is 
commercially available (Kalon Biological, Guildford, UK).  Samples were 
diluted 1:100 in stabilised buffered saline and added to plates that were 
pre-coated with sheep antibody against CRP.  The plates were incubated 
for 1 h then washed (Bio Tek, Potton, UK) with buffered surfactant.  100 µl 
of affinity purified sheep anti-CRP labelled with alkaline phosphatase was 
added and incubated for 1 h.  The plates were washed and 100 µl of 
substrate solution was added (4-nitrophenylphosphate 20 mg tablet 
dissolvedin 12 ml substrate buffer) and then incubated for 30 min.  100 µl 
of stop solution was added (50 g·L-1 EDTA solution) and the absorbance 
was read at 405 nm (Biochrom Ltd, Cambridge, UK).  Manufacturers 
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3.1  Abstract 
Interleukin-6 (IL-6) is a cytokine that can mediate numerous biological 
actions including fatigue. Circulating IL-6 increases during prolonged 
exercise, and furthermore, the signalling receptors sIL-6R and sgp130 are 
also increased. The variability of the response of these markers to 
exercise is unknown; therefore, we examined the changes in these 
markers to a preloaded time trial bout of running. Nine males performed 
three identical trials where participants ran at 60% vVO2max for 2 h 
interspersed with 30 s at 90% vVO2max every 10 min, followed by a 5-km 
time trial. Blood samples were drawn at baseline, following the 2-h bout, 
post time trial, 1 h post time trial and the following morning. Results 
showed that between subject variability (CVg) was greater than within-
subject variation (CVi) for the three markers. IL-6, sIL-6R and sgp130 
demonstrated a CVi of 15.3–25.5%, 15.0–17.6% and 6.2–9.4% variation, 
respectively, across the time points. When the data from the second and 
third trials were analysed independently, CVi was reduced which is 
supported by the time trial results for which CVi improve (4.7–2.4%). In 
conclusion, the results indicate that a large variation in response to 






3.2  Introduction 
Interleukin-6 (IL-6) is a multifunctional cytokine that has been 
associated with fatigue in healthy humans at rest (Spath-Schwalbe et al., 
1998) and during exercise (Robson et al., 2004).  During prolonged 
exercise IL-6 is released from contracting muscle into the circulation 
(Steensberg et al., 2000); in addition the soluble form of the IL-6 receptor 
(sIL-6R) is increased in circulation during (Gray et al., 2008) and after 
(Robson-Ansley et al., 2009) exercise which can act to mediate the 
actions and prolong the half life of IL-6 when it is combined in a IL-6/sIL-
6R complex (Levine et al., 2004).  This complex can instigate trans-
signalling through the ubiquitously expressed membrane bound receptor 
glycoprotein 130 (gp130) which would otherwise be unresponsive to IL-6 
alone (Jones et al., 2001).  The soluble form of gp130 (sgp130) may also 
increase in the circulation during exercise (Gray et al., 2008) and has the 
same affinity for IL-6/sIL-6R as the membrane bound receptor, therefore it 
has been suggested that sgp130 has a role as a regulator of the IL-6/sIL-
6R complex (Jones and Rose-John, 2002).  
Robson-Ansley et al. (2009) have proposed that if the circulating IL-
6 response to exercise can be blunted, the sensations of fatigue will be 
reduced, therefore potentially improving performance.  However in order 
to assess the effectiveness of attenuating plasma IL-6, it is important to 
first quantify the degree of biological variability of the response to 
exercise.  A small number of studies have examined the variability of 
repeated measurements of circulating plasma cytokines at rest including 
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IL-6 and report a coefficient of variation of 26-48% (Knudsen et al., 2008 
and Cava et al., 2000).  However at rest, circulating levels of IL-6 in 
healthy humans are typically very low (~1 pg·ml-1) and even a 50% 
increase is unlikely to be clinically significant.  To date, there is no 
published data on the biological variability of the plasma IL-6, sIL-6R and 
sgp130 response to prolonged exercise in healthy humans. 
Traditionally, time to exhaustion exercise trials have been used to 
quantify the response of biological systems to imposed stress and the 
effect of various interventions.  However, the inherent variability of open 
loop trials, such as time to exhaustion trials, is so large that it can often 
mask meaningful performance changes. This has led to the utilisation of 
closed loop performance protocols where the distance or total amount of 
work is set (Jeukendrup et al., 1996).  Certainly, time trials are more 
ecologically valid (Currell and Jeukendrup, 2008), but often the kinetics of 
a biological variable, such as plasma IL-6, would require a trial of such a 
long duration as to be unrealistic in a laboratory setting.  To overcome 
this, researchers have adopted a preload time trial format in which an 
initial constant load exercise component stresses the biological systems in 
order to initiate a response, and the efficacy of any intervention is 
assessed in a subsequent time trial (Russell et al., 2004).  Therefore, the 
purpose of this study was to investigate the variability of plasma IL-6 and 
soluble receptor response to a preloaded time trial protocol and the 




3.3  Methods 
3.3.1  Participants  
Nine trained male club runners and triathletes took part in the 
study.  Subject characteristics are presented in Table 3.1. Data are 
expressed as mean ± SD. 
Table 3.1.  Subject characteristics 
Age     27 ± 5 yr 
Height     181 ± 4 cm 
Body mass    72.4 ± 8.2 kg 




Habitual training distance (running)  38 ± 22 km per week 
 
Exclusion criteria included symptoms of infection and administration 
of anti-inflammatory drugs or vitamin supplementation in the four weeks 
prior to the study.  Participants gave written informed consent to the study, 
which was approved by the school research ethics committee at 
Northumbria University. 
3.3.2  Experimental Protocol   
The participants performed three of the same trials which were 
separated by one week.  The first, second and third trial are designated as 
trial A, B and C respectively.  To ensure subjects began each trial with 
similar levels of muscle glycogen, participants were given a high 
carbohydrate (8 g·kg-1) standardised diet (68% carbohydrate, 16% fat and 
16% protein) 24 h prior to each of the experimental trials.  They were 
asked to ensure they were well hydrated and to refrain from exercise, 
alcohol and caffeine 24 h prior to the study and during the 24 h post 
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exercise.  Participants began the trial in the morning before 9.00 am which 
is outlined in detail in chapter 2.  Water was consumed ad libitum during 
the first trial; the volume was recorded and replicated for the subsequent 
trials.  Following each trial, body mass was recorded and a standardised 
cereal bar was consumed (Nutragrain, Kellogs).  Laboratory 
environmental conditions were maintained throughout the study at 21.1 ± 
2.4°C and 45 ± 9% relative humidity. 
3.3.3  Blood Plasma Analysis 
IL-6, sIL-6R, sgp130, cortisol, glucose and lactate were all 
measured from blood plasma which is outlined in detail in chapter 2.  
Plasma C reactive protein was analysed on a high sensitivity Siemens 
Medical solutions Advia 2400, UK with intra- and inter-assay coefficient of 
variations of less than 4% and 5% respectively.   
3.3.4  Statistical Analysis 
Sample size was calculated using a spreadsheet from Hopkins 
(2006).  The data was analysed using the statistical package SPSS v. 16 
(SPSS inc., Chicago, IL).  To investigate if data were spherical, Mauchly’s 
test of sphericity was applied, with a Greenhouse-Geisser correction for 
any violations.  For trial and time analysis, a 3 x 5 (trial x time) repeated 
measures ANOVA was conducted with Bonferroni adjustments for multiple 
comparisons with a criterion for significance set at p<0.05.  Analysis of 
reliability was measured first with 3 trials, then the latter trials 
independently with trial A being stipulated as a habituation trial.  The 
within-subject (CVi) and between-subject (CVg) coefficient of variation 
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were analysed at each time point.  Within-subject intraclass correlation 
coefficient (ICC) was used to calculate reliability at each time point 
(Hopkins, 2000).  All data are expressed as mean ± SD.  
3.4  Results 
3.4.1  Physiological and Performance Data 
3.4.2  Preload 
During the preload component mean exercise intensity was 70 ± 
7%, 67 ± 5%, and 69 ± 6% of OV 2max for Trial A, B and C, respectively and 
was not significantly different between trials (p=0.10).  Mean heart rate 
(Trial A =149 ± 19 b·min-1, Trial B =148 ± 17 b·min-1; Trial C = 148 ± 19 
b·min-1 p=0.78), rating of perceived exertion (Trial A = 12 ± 1, Trial B = 12 
± 2, Trial C = 12 ± 2; p=0.19) and respiratory exchange ratio (Trial A = 
0.89 ± 0.04, Trial B = 0.88 ± 0.03, Trial C = 0.86 ± 0.06; p=0.35) were all 
similar for the preload components between trials. 
3.4.3  Time Trial 
 During the time trial, mean heart rate was similar between trials 
(Trial A =173 ± 14 b·min-1, Trial B =172 ± 14 b·min-1; Trial C = 172 ± 20 
b·min-1 p=0.81) along with rating of perceived exertion (Trial A = 16 ± 2, 
Trial B = 16 ± 1, Trial C = 16 ± 1; p=0.37).  The time trial was completed in 
mean times of 1406 ± 165 s (Trial A), 1381 ± 226 s (Trial B) and 1389 ± 
224 s (Trial C), which were not significantly different (p=0.85).  Between-
subject (CVg) coefficient of variation for time to completion for all three 
trials was 14.6% and within-subject (CVi) variation was 4.7% which 
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showed an intra-class correlation coefficient (ICC) score of 0.90.  When 
the data was excluded from trial A, between-subject (CVg) coefficient of 
variation increased to 16% and within-subject (CVi) variation was reduced 
to 2.4%.  The intra-class correlation coefficient (ICC) score was 0.96. 
3.4.4  IL-6 and Signalling Receptors 
Plasma IL-6 demonstrated a significant increase from baseline (0.7 
pg·ml-1) to PL (8.6 pg·ml-1)(p<0.001) and demonstrated a further 
significant increase (33.8%) (13.0 pg·ml-1) at PostTT (p<0.05).  IL-6 levels 
decreased 1hPost (10.9 pg·ml-1) and returned to baseline levels the 
following day.  No significant differences were observed between trials for 
IL-6 (p=0.24) (Figure3.1).     
There was a non significant rise in plasma sIL-6R levels (13.6%) 
from baseline (25.3 ng·ml-1) to PL (28.7 ng·ml-1) with a further significant 
increase at PostTT (31.0 ng·ml-1) (8.1%), which decreased at 1hPost from 
PostTT(29.3 ng·ml-1) (p<0.05).  No other significant differences were 
observed between trials for sIL-6R (p=0.87) (Figure 3.2).  Differentially 
spliced isoform of sIL-6R (DS-sIL-6R) showed no significant differences 
from baseline (p=0.14) with no differences between trials (p=0.80) (figure 
3.3). 
sgp130 response to exercise is shown in figure 3.4.  sgp130 was 
elevated in response to exercise at PL (p<0.05), there was a trend for 
sgp130 to remain elevated at PostTT (p=0.06) which decreased by 
1hPost.  Furthermore, there were no significant differences observed 
between trials (p=0.42). 
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 Circulating IL-6 levels prior to the time trial (PL) and percentage of 
velocity at OV 2max showed a significant negative correlation for trials A and 
B (trial A r -0.83, p<0.01. trial B r -0.72, p<0.05) while trial C showed a 
trend of a correlation (r -0.61, p=0.07) (figure 3.5). 
Figure 3.1.  The interleukin-6 response to the preload time trial protocol. 
 
 
*Significantly higher than Baseline (effect of time) (p<0.001)  **Significantly higher than Baseline 




































Figure 3.2.  The soluble interleukin-6 receptor (sIL-6R) response to the preload time trial 
protocol.  
 
  * Significantly higher than Baseline  (effect of time) (P<0.05).   
 
 
Figure 3.3 The differentially spliced soluble IL-6 receptor response to the preload protocol. 
 


















































 Figure 3.4  The sgp130 receptor response to the preload time trial protocol.    
 
     * Significantly higher than Baseline (effect of time) (P<0.05).  
 
Figure 3.5  Correlations between IL-6 at PL and running performance during the time trials.  
 
























































3.4.5  Variability of IL-6 and Signalling Receptors 
Between-subject variability was greater than within-subject variation 
for IL-6 and both sIL-6R and sgp130 (Table 3.2).  IL-6 CVg ranged from 
28.3-39.3% across the time points whereas CVi ranged from 15.3-25.5%.  
ICC showed a variable reliability across all time points with a range from 
0.18-0.80.  Results for sIL-6R demonstrated greater CVg than IL-6 (range 
36.1-39.6%) but a lower CVi than IL-6 (range 15.0-17.6%).  ICC was also 
higher for sIL-6R compared to IL-6 (range 0.65-0.80).  sgp130 had the 
lowest CVg (range 10.5-14.1%) and a CVi (range 6.2-9.4%) whilst the ICC 
range was between 0.47-0.75 across the time points.    
When the data from Trials B and Trial C were analysed 
independently from Trial A, IL-6 CVg ranged from 27.1-36.6% across the 
time points whereas CVi ranged from 13.9-19.7%.  ICC showed a varied 
reliability across all time points with a range from 0.47-0.8.  Results for 
sIL-6R demonstrated greater CVg than IL-6 (range 34.5-38.5%) but 
showed less CVi than IL-6 (range 7.6-13.7%).  A higher ICC was also 
displayed by sIL-6R compared to IL-6 (range 0.67-0.88).  The lowest 
coefficient of variation was demonstrated in sgp130 with a CVg range of 
9.7-12.8% and a CVi range of 4.5-7.9%.  However, sgp130 also 






Table 3.2.  Variability of IL-6, sIL-6R and sgp130 of all three trials. 
 
  Baseline PL  PostTT  1hPost  24hPost 
 
IL-6 
 CVi%  15.3  19.1  25.5  21.5  22.9   
 CVg%  31.4  33.1  34.2  39.3  28.3 
 ICC  0.80  0.76  0.55  0.67  0.18 
 
sIL-6R 
  CVi%  15.3  15.9  15.0  15.7  17.6 
  CVg%  36.1  38.6  39.6  37.4  38.1 
  ICC  0.80  0.79  0.75  0.76  0.65              
 
sgp130 
  CVi%  8.4  9.4  7.1  6.8  6.2 
  CVg%  14.1  13.6  11.2  11.1  10.5 
  ICC   0.72  0.47  0.75  0.73  0.70     
                                                                   
Preload component (PL)  Post time trial (PostTT) 1 h post time trial (1hPost) 24 h post baseline 
(24hPost) 
 
CVi within subject variation.  CVg between subject variation.  ICC Intraclass correlation coefficient. 
 
Table 3.3.  Variability of IL-6, sIL-6R and sgp130 of trial B and trial C. 
 
Baseline PL  PostTT  1hPost  24hPost 
 
IL-6 
 CVi%  15.2  13.9  19.7  16.5  17.5   
 CVg%  31.4  29.6  27.1  36.6  29.3 
 ICC  0.70  0.81  0.48  0.80  0.47 
 
sIL-6R 
  CVi%  10.7  11.1  11.3   7.6  13.7 
  CVg%  34.5  35.8  38.5  36.5  36.4 
  ICC  0.88  0.88  0.82  0.88  0.67              
 
sgp130 
  CVi%  7.5  7.9  4.5  5.5  6.1 
  CVg%  12.7  12.8  9.7  10.3  9.9 
  ICC  0.60  0.31  0.67  0.49  0.48     
                                                                   
Preload component (PL)  Post time trial (PostTT) 1 h post time trial (Post1h) 24 h post baseline 
(Post24h) 
 






3.4.6  Other Plasma Variables 
Blood metabolites, cortisol and C reactive protein (CRP) levels 
displayed a main effect of time, but no significant differences were 
observed between trials for glucose (p=0.15), lactate (p=0.29), cortisol 
(p=0.35) or CRP (p=0.53) at any time point.  Plasma cortisol levels were 
elevated PostTT which remained elevated at 1hPost compared to baseline 
(p<0.05) (table 3.4).  Circulating levels of CRP did not change PostTT but 
were elevated 24hPost (p<0.05).  Plasma glucose did not change 
significantly during or following exercise.   Lactate levels were higher at PL 
and PostTT compared to baseline (p<0.05) and had returned to baseline 
levels by 1hPost (table 3.4).  The reproducibility of the other circulating 
plasma variables for all three trials are shown in table 3.5.  The 
reproducibility of the other plasma variables were reduced when analysed 











Table 3.4.  Plasma glucose, lactate, cortisol and C reactive protein. 
 
 Baseline PL  PostTT  1hPost  24hPost 
 




Trial A 4.74±0.75 5.00±0.81 5.17±0.32 5.68±1.00  5.31±0.88 
Trial B 4.32±0.41 4.77±0.53 4.68±0.93 5.73±0.71*  4.53±0.88 






Trial A 1.73±0.67 2.49±0.80 3.48±1.09*  2.12±0.40 1.78±0.34 
Trial B 1.22±0.38 2.13±0.45* 3.55±1.15* 1.69±0.35  1.49±0.22 







Trial A  309±60   369±142  469±151   526±160**  290±95 
Trial B  281±93   345±90   460±66*  426±92*  274±56 






Trial A  0.2±0.1   -    0.2±0.1  -   2.7±1.6* 
Trial B  0.4±0.5  -   0.4±0.5  -   2.4±1.1* 
Trial C  0.3±0.2  -   0.3±0.1  -  2.2±0.7* 
 
Preload component (PL)  Post time trial (PostTT) 1 h post time trial (1hPost) 24 h post baseline 
(24hPost) 
 
* Significantly higher than Baseline (effect of time) (p<0.05).  ** Significantly higher than Baseline 

























3.5  Discussion  
The aims of the present study were to examine the reproducibility 
of the IL-6, sIL-6R and sgp130 response to a preload exercise protocol 
and the repeatability of a subsequent time trial performance.  Within-
subject variation (CVi) illustrates the relative dispersion of individual 
variability between trials whereas between-subject variation (CVg) 
represents group discrepancy; these measurements of reliability have 
been used in conjunction with ICC which allows the assessment of 
absolute agreement between trials to further elucidate the reliability of the 
inflammatory response.   
The IL-6 response showed a higher CVg than CVi, which may be 
indicative of individual endurance capacity since the participants were 
given a standardised diet for the 24 h prior to the exercise bout to control 
nutritional status and glycogen content.   CVi was highest PostTT which is 
possibly due to differences in the distribution of relative intensities during 
the time trial whereas a lower CVi was observed at PL where the intensity 
and duration had been externally imposed.   
The response of sIL-6R displayed high variability, but the coefficient 
of variation and ICC remained relatively constant for all time points.  The 
reliability of sIL-6R response to exercise is unreported, however, the 
baseline results from the present study are consistent with others (Dugue 
and Leppanen, 1998) although Ho et al. (2005) described a lower 
reliability (ICC 0.36) at rest than the present study.  
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A lower variation was observed for sgp130 than IL-6 and sIL-6R, 
furthermore, the ICC score remained constant throughout.  This could 
possibly be due to concentrations of spg130 being much greater than 
those for IL-6 and sIL-6R, therefore sgp130 is less affected by small 
changes induced by exercise.  To the best of our knowledge this is the 
first study to examine the variability of sgp130 at rest or during exercise.  
Excluding the data from Trial A improved the reliability scores for 
IL-6 and sIL-6R illustrating a reduced variation to an external factor such 
as exercise and furthermore, this indicates the importance of a habituation 
trial.  This interpretation is supported by the time trial results for which CVi 
and ICC improve (4.7% to 2.4% and 0.90 to 0.96 respectively) for which a 
habituation trial has been suggested previously (Currell and Jeukendrup, 
2008).  
The time trial data from the current study are consistent with other 
studies that found a 1-2.4% variation with preload treadmill protocols 
[Russell et al. 2004, Tyler and Sunderland, 2008) demonstrating that, 
following a habituation trial, the current protocol provides a reliable 
measure of performance.  Furthermore, greater circulating levels of IL-6 
negatively correlate with relative running performance.  This not only 
demonstrates that greater IL-6 levels can impair performance which is in 
accordance with previous work (Robson et al., 2004) but also reveals this 
effect in a dose dependant manner.  Furthermore, analysis of the findings 
demonstrated that a plasma IL-6 response <7pg∙ml-1 was associated with 
a time trial performance >80v OV 2max which may be a result of exercise 
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training.  Alternatively, these findings may also suggest that a low 
response of IL-6 may not impact on performance whereas a response 
>7pg∙ml-1 may begin to impair performance.  Therefore, if IL-6 can be 
manipulated above the range of variation during a preload, this may alter 
the performance throughout the time trial.   
The results from the study have demonstrated that within-subject 
variation is lower than between-subject variation for IL-6, sIL-6R and 
sgp130 in response to exercise.  This underlines the need to use a 
crossover design rather than a parallel separate group design when 
assessing biological markers in studies with low subject numbers.  
Although the variation of the circulating IL-6, sIL-6R and sgp130 response 
to exercise is large, these results provide boundaries for the interpretation 
of exercise induced changes in IL-6, sIL-6R and sgp130 and can provide a 
useful point of reference for meaningful differences when examining 
intervention protocols.   
DS-sIL-6R showed no effect from exercise in the present study.  To 
date, only one other study has examined the effect of exercise on DS-sIL-
6R who showed an increase 6 h following exercise (Leggate et al., 2010) 
indicating that the response of DS-sIL-6R is delayed. The cause of 
circulating DS-sIL-6R is unknown, however the results from the present 
study demonstrate that a small proportion of the total sIL-6R is derived 
from DS-sIL-6R (~0.5%), therefore the majority of the increase in plasma 
sIL-6R can be attributed to PC-sIL-6R.    
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In conclusion, this study has illustrated a large variation of IL-6, sIL-
6R and sgp130 in response to exercise and has also shown that within-
subject variability is lower than between-subject variation.  A habituation 
trial is needed to improve reliability of these biomarkers, and to reduce the 
variation of time trial performance.  Furthermore, the results of the study 
demonstrate that circulating levels of IL-6 negatively correlate with relative 
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4.1   Abstract 
Glutamine supplementation during exercise has often been reported to 
maintain or even elevate plasma glutamine levels but the impact on 
immune function is less clear.  It has been previously been shown that 
glutamine supplementation augments the exercise induced increase in 
circulating IL-6 by ~50%.  In addition, increased circulating IL-6 levels 
have been previously shown to heighten sensations of fatigue and impair 
exercise performance.  Therefore, we examined the effects of glutamine 
supplementation on circulating IL-6 and the subsequent effect on exercise 
performance.  Ten trained male runners ran at 60% vVO2max for 2 h 
interspersed with 30 s at 90% vVO2max every 10 min, followed by a 5-km 
time trial, supplemented with either glutamine or a placebo in a double 
blind randomised crossover manner. Blood samples were drawn at 
baseline, following the 2-h bout, post time trial, 1 h post time trial and the 
following morning.  No significant differences were observed between 
trials for circulating IL-6, sIL-6R or sgp130.  In addition, there was no 
significant difference between conditions for time trial performance; 
however the plasma IL-6 response to the preload was inversely correlated 
with relative time trial performance regardless of trial.  We conclude that 
glutamine supplementation during prolonged exercise does not alter the 
circulating IL-6, sIL-6R or sgp130 response.  However, the plasma IL-6 





4.2  Introduction    
 A high proportion of athletes have been reported to consume 
dietary supplements during training periods with the view to improve 
performance or to reduce the risk of illness (Froiland et al., 2004).  In 
particular, glutamine supplementation is used by athletes in order prevent 
muscle catabolism as well as improve immune function based on scientific 
literature.  Studies have shown the versatility of glutamine, which holds a 
range of functions including a role in neurological activity (Newsholme et 
al., 2003), acid-base balance (Taylor and Curthoys, 2003), maintenance of 
gastrointestinal integrity (van der Hulst, 1993) and also has an important 
metabolic role for immune cells (Newsholme and Parry-Billings, 1990). 
 Glutamine is a conditionally essential amino acid found within the 
body where plasma concentrations have typically been reported to be 
500-750 µmol·L-1 in fasted healthy humans (Walsh et al., 1998; Gleeson, 
2008), predominantly supplied by skeletal muscle.  Following prolonged 
exercise, plasma glutamine levels can be reduced (Robson et al., 1999; 
Parry-Billings et al., 1992) and one hypothesis for this reduction in plasma 
glutamine is due to an increased uptake by other organs, such as 
increased hepatic uptake to facilitate an increase in gluconeogenesis 
(Walsh et al., 1998).  Indeed, glutamine supplementation during exercise 
can enhance hepatic uptake of glutamine (Iwashita et al., 2005), and 
furthermore, gluconeogenesis in the kidneys has been shown to use 
glutamine as a precursor (Stumvoll et al., 1998) illustrating that an 
increased demand for glutamine during prolonged exercise could be due a 
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greater reliance on glutamine stimulated gluconeogenesis when muscle 
and liver glycogen levels become depleted.   
 Glutamine supplementation during exercise has often been 
reported to maintain or even elevate plasma glutamine levels but the 
impact on immune function is less clear (Rhode et al., 1998; Walsh et al., 
2000; Krzywkowski et al., 2001).  However, Hiscock et al. (2003) have 
demonstrated that glutamine supplementation augments the exercise 
induced increase in circulating IL-6 by ~50%, speculating that an 
increased uptake of glutamine into skeletal muscle from supplementation 
results in an increased IL-6 release into the circulation.  Increased 
circulating IL-6 levels have been previously shown to heighten sensations 
of fatigue (Spath-Schwalbe et al., 1998) and impair exercise performance 
(Robson et al., 2004).  Therefore, it is possible that glutamine intake 
during exercise may adversely affect performance through IL-6 mediated 
fatigue.  
 IL-6 typically increases its effectiveness in a range of biological 
actions when in the presence of its soluble receptor, sIL-6R.  Sickness 
behaviour symptoms that are commonly associated with IL-6 infusion are 
heightened and prolonged with the addition of sIL-6R (Schobitz et al., 
1995).  Therefore, the agonistic properties of sIL-6R may have a negative 
impact on exercise performance when combined in an IL-6/sIL-6R 
complex (Levine et al., 2004).  In chapter 3 we have demonstrated that 
circulating IL-6 negatively correlates with exercise performance.  However, 
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the effect of glutamine intake during prolonged exercise on IL-6 mediated 
performance is unknown.   
 Since the effect of glutamine supplementation on both the plasma 
IL-6 and sIL-6R have not been examined during prolonged exercise, we 
aimed to investigate the effect of glutamine intake on the response of 
these markers in relation to exercise performance.  We hypothesised that 
glutamine ingestion during prolonged exercise will result in an increase in 
plasma IL-6 and sIL-6R response which will impair subsequent time trial 
performance.  
4.3  Methods 
4.3.1  Participants  
Ten trained male runners took part in the study.  Mean ± SD age 
was 27 ± 6 yr height and body mass were 181 ± 4 cm and 73.4 ± 8.8 kg 
respectively and maximal oxygen uptake was 60 ± 4 ml·kg·min-1 whilst 
mean habitual training distance for running was 38 ± 28 kilometres per 
week.  Exclusion criteria included those taking anti-inflammatory drugs or 
vitamin supplementation.  All participants were free from any symptoms of 
infection in the 4 weeks prior to the study.   Participants gave written 
informed consent to the study which was given approval by the 
Northumbria University school ethics committee. 
4.3.2  Experimental Protocol   
Before the main trials, participants performed a familiarisation trial 
with at least one week separating each trial.  To ensure nutritional status 
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remained constant, a food diary was recorded 24 h prior to experimental 
trials with participants encouraged to consume foods that were rich in 
carbohydrates.  For the following trial, participants were instructed to 
replicate their diet they had previously recorded prior to trial 1.  Each 
participant was also asked to refrain from exercise, alcohol and caffeine 
24 h prior to the study and during the 24 h post exercise period.  Each 
participant arrived at the laboratory in the morning before 9:00 am after a 
12h fast.  Participants then began the trial which is outlined in detail in 
chapter 2.  Immediately before and at 30 min intervals during the preload 
bout, participants consumed 3 ml·kg-1 body mass of L-Glutamine (0.05 
g·kg-1) (MyProtein, UK) dissolved in lemon flavoured cordial or a taste 
matched placebo in a randomised crossover manner.  Laboratory 
environmental conditions throughout the study were 20.1 ± 1.2°C and 38 ± 
3% relative humidity  
4.3.3  Blood Plasma Analysis 
 Blood samples were immediately centrifuged at 3000 rpm for 10 
min aspirated and the supernatant was stored at -80°C until the day of 
analysis.   
Plasma glutamine was measured in duplicate using a commercially 
available assay kit (Bioassay systems, Hayward, CA, USA).  Samples 
were added to plates with 80 µl of working reagent including 2.5 µl of NAD 
and 14 µl MTT.  Samples were then incubated for 40 min before 100 µl 
stop reagent was added to the plates.  Samples were then ascertained 
through colorimetric determination at 540 nm     
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IL-6, sIL-6R, sgp130, cortisol, CRP, glucose and lactate were all 
analysed from blood plasma which is outlined in detail in chapter 2. 
 4.3.4  Statistical Analysis 
The data was analysed using the statistical package SPSS v. 16 
(SPSS inc., Chicago, IL).  To analyse if data were spherical, Mauchly’s 
test of sphericity was used, with a Greenhouse-Geisser correction for any 
violations.  For trial and time analysis, a 2x5 (trial x time) repeated 
measures ANOVA was conducted; post hoc analysis were used with 
Bonferroni corrections for multiple comparisons with a criterion for 
significance set at p<0.05.  For analysis of other physiological variables 
and time trial data, a paired samples t test was used with Bonferroni 
corrections used when appropriate.   All data are expressed as mean ± 
SD. 
4.4  Results 
4.4.1  Physiological Variables 
Table 4.1 illustrates the physiological variables during the preload bout.  
No significant differences were observed between PLA and GLN for 
exercise intensity, heart rate, rating of perceived exertion or respiratory 
exchange ratio.  
Table 4.1 Physiological variables during the preload bout. 
   Placebo   Glutamine  P value 
% OV 2max   69     ±  7  68     ±  5  0.33 
Heart rate (b·min
-1
)  146   ±  19  146   ±  20  0.96 
RPE    12     ±  1  12     ±  1  0.67 




4.4.2  Plasma Glutamine 
 Plasma glutamine levels did not show a significant effect of trial 
between the treatments (p=0.06).  However, during PLA, plasma 
glutamine levels fell from Baseline to PL (p=0.01) and remained low at 
PostTT whereas during GLN, plasma glutamine levels were maintained 
from Baseline to PL (p=0.70) which was reduced by PostTT (table 4.2).    
 4.4.3  Plasma IL-6, sIL-6R and sgp130 
 Plasma IL-6 showed a significant increase from Baseline to PL 
(p<0.01) and increased further by PostTT (p<0.001).  Plasma levels 
remained elevated at 1hPost (p<0.001) and returned to Baseline levels by 
24hPost.  No significant differences were observed between trials 
(p=0.33) (figure 4.1). 
 Circulating sIL-6R increased 5% from Baseline to PL however the 
results were not significant (p=0.49).  Furthermore, there was no 
significant difference in sIL-6R levels at PostTT compared to Baseline 
(p=0.08) following a 8.3% increase.  No differences were observed 
between the treatments for the sIL-6R response to exercise (p=0.85) 
(figure 4.2).  
 Plasma sgp130 demonstrated no significant differences between 
trials (p=0.18).  A non significant increase of 4.3% from Baseline to PL 
(p=0.10) was observed and furthermore, the increase of 7.6% at PostTT 
and 1hPost compared to Baseline was not significant (p=0.06).  Levels 
had returned to baseline the following morning (figure 4.3).  
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 Figure 4.1  Effect of glutamine supplementation on IL-6 response to  
 exercise. 
 
  * Significantly higher than Baseline (effect of time) (p<0.01)   
 
 
 Figure 4.2  Effect of glutamine supplementation on the plasma sIL-6R 






















































 Figure 4.3  Effect of glutamine supplementation on the sgp130  
 response to exercise 
 
 
4.4.4  Time Trial 
 During the time trial there was no significant difference between 
trials for heart rate (PLA, 180 b·min-1, GLN, 186 b·min-1) (p=0.21) or for 
RPE (PLA, 16; GLN, 16) (p=0.75).  Time to complete the time trials were 
1456 s for PLA and 1375 s for GLN which were not significantly different 
(p=0.39) (figure 4.4).  A significant negative correlation between IL-6 at PL 
and  relative running speed throughout the time trial was observed for both 



































 Figure 4.4  Time completed for each time trial. 
 
 Individual performance times in grey. Group mean in black 
 
Figure 4.5  Correlations between IL-6 at PL and running performance during the 
time trial. 
 














































4.4.5  Other Plasma Variables 
 The findings showed elevated plasma cortisol through an effect of 
trial (p=0.01). Cortisol increased from Baseline to PL which was not 
significant (p=0.44) but showed a further significant increase PostTT 
(p<0.001) which remained elevated 1hPost (p<0.05) then returned to 
Baseline values at 24hPost.  CRP did not increase at PostTT (p=0.34) but 
did significantly increase 24hPost (p<0.01), however, no differences were 
shown between trials (p=0.55) (table 4.2). 
 Plasma lactate increased from Baseline to PL (p=0.05) which 
increased further at PostTT (p<0.01).  Lactate levels were reduced at 
1hPost and returned to Baseline levels the following morning with no 
significant differences between trials.  Plasma glucose remained relatively 
unchanged throughout exercise then significantly decreased at 1hPost 
compared to PostTT (p<0.05).  Statistical analysis demonstrated elevated 













Table 4.2.  Plasma glucose, lactate, cortisol and C reactive protein.  




PLA 816±105  729±109
a
 745±76  -  - 
GLN 856±113  877±88  776±95  -  - 
 




PLA 4.79±0.45 4.67±0.81 5.18±0.82 4.57±0.59 4.92±0.45 
GLN
†






PLA 2.18±0.53 3.67±1.33* 6.32±2.50**  3.81±1.89 1.89±0.80 






PLA 330±71   372±85   704±231**   471±107*  265±68 
GLN
†






PLA  0.8±0.9   -    0.8±1.0   -    2.8±1.5* 
GLN  0.7±1.1  -   0.9±1.4   -    3.1±2.2* 
 
Preload component (PL)  Post time trial (PostTT) 1 h post time trial (1hPost) 24 h post baseline 
(24hPost) 
*Significantly higher than Baseline (effect of time)(p<0.05)  **Significantly higher than PL and 
Baseline (effect of time) (p<0.01) 
a
Significant reduction from Baseline (effect of time) (p<0.05)  
† 
GLN higher than PLA (effect of trial) (p<0.05) 
 
4.5  Discussion 
 The findings in this study show that glutamine intake during 
exercise does not alter the response of circulating IL-6 or sIL-6R when 
compared to a placebo, despite maintaining plasma glutamine 
concentrations.  Nor does glutamine intake alter exercise performance in a 
subsequent time trial. 
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 Following prolonged exercise, plasma glutamine levels are typically 
reduced.  We showed a 10.6% reduction in plasma glutamine following 
exercise which is consistent with Robson et al. (1999) who demonstrated 
that during prolonged exercise, plasma glutamine can fall by 11%.  On the 
other hand, the present study showed that the glutamine treatment 
maintained circulating concentrations which is in accordance with previous 
work (Rhode et al., 1998; Walsh et al., 2000; Krzywkowski et al., 2001), 
indicating that supplementation of this nature at regular intervals are 
sufficient to maintain plasma glutamine levels during prolonged exercise.  
However, no effect on the circulating IL-6 response to exercise is 
observed. 
 In contrast to our findings, work by Hiscock et al. (2003) 
demonstrated an augmented plasma IL-6 response following glutamine 
supplementation and reported that plasma glutamine levels could 
influence circulating IL-6 by means of either decreasing IL-6 clearance or 
by increasing IL-6 production due to increased uptake of glutamine to 
skeletal muscle.  It is unclear why the results differ between the present 
study and the study of Hiscock and colleagues (2003); differences in the 
mode of exercise employed would seem an unlikely explanation, however, 
differences in plasma IL-6 between studies may have occurred due to the 
time point at which the supplement was given.  In the present study, 
participants were given glutamine at baseline and then at 30 min intervals 
during the 2 h preload bout; whereas participants were supplemented at 
60 min and 105 min during the study by Hiscock and colleagues.  It could 
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be speculated that the augmented plasma IL-6 response from glutamine 
intake is transient which was captured by Hiscock and co workers and 
missed in the present study. 
 Although our findings showed no differences in circulating IL-6 
between treatments, the plasma IL-6 response to the preload was 
inversely correlated with relative time trial performance regardless of trial.  
These findings indicate that the magnitude of the plasma IL-6 response to 
an exercise preload bout can impact on subsequent exercise performance 
which is consistent with findings from the previous chapter.  The release of 
IL-6 into the circulation may act as a distress signal as a result of cellular 
or metabolic stress within skeletal muscle (Jurimae et al., 2011).  IL-6 has 
been shown to cross the blood brain barrier (Banks et al., 1994) which has 
been hypothesised to act as a fatigue signal (Gleeson, 2000).  The 
increased circulating IL-6 may interact with the brain and alter perception 
of effort during exercise in order to preserve energy.     
 Further analysis of the findings demonstrate that a circulating IL-6 
response below a threshold of ~7 pg·ml-1 is associated with a time trial 
performance above ~80% v OV 2max.  This suggests that there is a level of 
cellular or metabolic stress below which any IL-6 interaction with the brain 
could be tolerable, allowing participants to increase their performance 
throughout the time trial.  However, it appears that when an IL-6 response 
to the preload is above the threshold of ~7 pg·ml-1, it influences perception 
of effort at the relative intensity during the time trial.  
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 No change in either sIL-6R or sgp130 was observed in either 
condition.  Although increases in the signalling receptors have been 
previously reported (Gray et al., 2008; Leggate et al., 2010), The small 
change in the circulating receptors are in accordance with the findings in 
chapter 3.  It is likely that a significant difference was not seen due to the 
large inter-variability of sIL-6R and sgp130 and relatively low participant 
number.  Notably, neither sIL-6R nor sgp130 increased with exercise 
which may indicate that sgp130 reflects the activity of sIL-6R.  Rebouissou 
et al. (1998) have previously shown that an increase in sIL-6R activity is 
followed by an increase in sgp130.  The delayed actions of sgp130 could 
be to regulate the actions of the IL-6 complex to prevent excessive 
signalling. 
 The effects of nutritional interventions on the response of signalling 
receptors to exercise are unknown.  Since there was no increase in the 
signalling receptors, and there was no significant difference in plasma IL-6 
following glutamine supplementation, it is difficult to interpret whether 
nutritional interventions alter the signalling receptor response to exercise.  
Therefore, this needs further investigation. 
 Our findings showed increased cortisol concentrations following 
glutamine intake.  Since cortisol plays a role in glutamine transport (Jones 
et al., 2006), it could be speculated that excess glutamine following 
supplementation stimulates an increase in plasma cortisol levels in order 
to transport the excess glutamine to the liver.  In addition, cortisol plays a 
role in gluconeogenesis (Tayek and Katz, 1997); therefore it is possible 
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that cortisol can concurrently stimulate hepatic glucose production, 
thereby increasing plasma glucose concentrations, which was observed in 
our study.   
 Circulating CRP was not significantly different between glutamine 
ingestion and a placebo in response to exercise.  Our findings are in 
accordance with Castell et al. (1996) who found that the increase in 
circulating IL-6 following a marathon corresponded with circulating CRP 
16 h post marathon with no differences observed between glutamine 
supplementation and a placebo.   
 Our results indicate that glutamine supplementation during 
prolonged exercise does not alter circulating IL-6, its associated signalling 
receptors, nor does it affect exercise performance.  However, in 
accordance with previous work, the circulating IL-6 response to exercise 














The Effect of Pre-exercise Feeding 
Protocols on the IL-6 and Signalling 












5.1  Abstract 
 Carbohydrate loading protocols can maximise muscle glycogen 
levels and delay fatigue.  In addition, low muscle glycogen levels can 
increase plasma IL-6 levels which are associated with a reduction in time 
trial performance.  It is not known if a CHO loading protocol can reduce 
the plasma IL-6 response to exercise, subsequently improving time trial 
performance.  Therefore, we investigated the effects of two high CHO 
loading protocols (with and without a prior bout of glycogen depleting 
exercise), compared to a low CHO dietary protocol on the plasma 
response of IL-6 to exercise and the subsequent impact on exercise 
performance.  Eleven trained males performed a preloaded time-trial, 
running at 60% vVO2max for 2 h interspersed with 30 s at 90% vVO2max 
every 10 min, followed by a 5-km time trial.  Prior to each trial, participants 
consumed either a low carbohydrate diet (3 g·kg-1 body mass,)(Lo); a high 
carbohydrate diet (10 g·kg-1 body mass) (Hi) or performed a glycogen 
depleting exercise bout followed by a high carbohydrate diet (DepHi) prior 
to the exercise trials.  Results found improved time trial performance for Hi 
and DepHi compared to Lo, however, there were no significant differences 
between trials for the circulating IL-6 response to exercise.  However, 
plasma IL-6 levels prior to the time trial and percentage of velocity at OV
2max achieved during the time trial showed a negative correlation in all 
three trials.  Therefore, we conclude that a negative association between 
the plasma IL-6 response to a preload bout and subsequent time trial 
performance is not affected by altered dietary CHO intake.  
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5.2  Introduction 
 It is widely accepted that an athletes diet is an important aspect to 
the preparation regimen in the days prior to competition to increase 
muscle glycogen content and improve exercise performance (Rauch et al., 
1995) since CHO availability as a substrate can be a limiting factor to 
performance in prolonged sessions >90 min (Burke et al., 2004).  
Therefore, to optimise endurance exercise performance, athletes will 
consume a carbohydrate rich diet in order to maximise muscle glycogen 
levels and delay the onset of fatigue (Karson and Saltin, 1971; Hargreaves 
et al., 1984).  
 A variety of carbohydrate loading protocols have been developed in 
order to supercompensate muscle glycogen content (Bergstrom et al. 
1967; Sherman et al., 1981; Bishop et al., 2001).    CHO loading protocols 
may differ according to the timing, amount, type and form of ingested 
CHO, while other strategies include depletion of muscle glycogen followed 
by restoration of muscle glycogen with a high CHO diet (Goforth et al., 
1997).  A glycogen depleting exercise bout can increase muscle glycogen 
synthesis to a greater extent compared to a high CHO only diet (without 
glycogen depletion) (Roedde et al,. 1986; Goforth et al., 2003).  Therefore, 
it appears that a bout of glycogen depleting exercise prior to CHO loading 
is key to optimising muscle glycogen synthesis.   
  Skeletal muscle glycogen possesses several signalling factors that 
have a glycogen binding domain, and when activated, particularly during 
metabolic stress, are linked with an increase in IL-6 production 
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(MacDonald et al., 2003; Chan et al., 2004).  Steensberg et al., (2000) 
demonstrated that contracting skeletal muscle accounts for the increase in 
plasma IL-6 which is observed when muscle glycogen levels are low.  In 
the view of this, it would be reasonable to assume that a bout of glycogen 
depleting exercise followed by CHO loading would result in an increase of 
muscle glycogen levels and subsequently reduce the response of plasma 
IL-6 to exercise.  Although the impact of various glycogen depletion and 
restoration diet protocols on muscle glycogen levels have been 
investigated with the view to improve subsequent exercise performance, 
the effect of this type of protocol on the plasma IL-6 response to exercise 
has not been examined. 
 Previously we have shown that the magnitude of plasma IL-6 
response during an exercise preload bout was negatively associated with 
exercise performance during a subsequent time trial.  Consequently, if the 
plasma IL-6 response can be altered by manipulation of dietary CHO 
intake, then this may further clarify the link between plasma IL-6 and 
exercise performance.  In addition, the plasma concentration of the 
signalling receptor of IL-6 (sIL-6R) increases in response to prolonged 
exercise (Gray et al., 2008; Leggate et al., 2010) which increases the 
effectiveness of IL-6 as a CHO metabolism regulator and prolongs the half 
life of circulating IL-6 (Jones et al., 2001).  However, it is not known 
whether this occurs in humans during prolonged exercise.    
 Therefore, the aims of this study were to examine the effects of 
high CHO loading protocols, with and without a prior bout of muscle 
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glycogen depleting exercise, compared to a low CHO dietary protocol on 
the plasma response of IL-6 and sIL-6R to exercise and the subsequent 
impact on exercise performance.  It is hypothesised that the high CHO 
loading protocols will induce a lower plasma IL-6 and sIL-6R response to 
exercise compared to a low CHO diet with the glycogen depletion and 
restoration protocol being most effective. 
5.3  Methods  
5.3.1  Participants  
Eleven trained males volunteered for the study for which they gave 
written informed consent and was approved by the school research ethics 
committee at Northumbria University.  Exclusion criteria included 
symptoms of infection and administration of anti-inflammatory drugs 
including medication or vitamin supplementation in the four weeks prior to 
the study.  Subject characteristics are presented in Table 5.1. Data are 
expressed as mean ± SD.   
Table 5.1  Subject characteristics 
Age     27     ±   7 yr 
Height     182   ±   6 cm 
Body mass    80.2  ±   8.4 kg 




Habitual training distance (running)  22     ±   8 km·week
-1
 
5.3.2  Experimental Protocol   
 All participants performed a familiarisation trial before completing 
the three experimental trials with at least one week separating each trial.  
Trials were conducted in a randomised crossover design that was 
counterbalanced.  Prior to each trial, participants consumed isocaloric 
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diets that comprised a different proportion of carbohydrates.  Participants 
consumed either a low carbohydrate diet (Lo) (3 g·kg-1 body mass, 20% 
carbohydrate, 68% fat and 12% protein); a high carbohydrate diet (Hi) (10 
g·kg-1 body mass, 68% carbohydrate, 16% fat and 16% protein) or 
performed a glycogen depleting exercise bout followed by a high 
carbohydrate diet (DepHi) 48 h prior to the exercise trials outlined in 
chapter 2 (General Methods).  For the DepHi trial, participants arrived at 
the laboratory approximately 60 h prior to the main trial to complete an 
exercise protocol which aimed to deplete muscle glycogen stores. 
Participants ran at 70% OV 2max for 90 min which has previously been 
shown to deplete muscle glycogen (Tsintzas et al., 1996) then consumed 
the high carbohydrate diet the following morning and for the next 48 h.  All 
diets were calculated according to dietary analysis software (Microdiet, 
Downlee Systems Ltd, UK). 
48 h prior to the study and during the 24 h post exercise, 
participants were asked to ensure they were well hydrated and to refrain 
from exercise, alcohol and caffeine.  Participants began the trial in the 
morning before 9:00 am (outlined in detail in Chapter 2).  Water was 
consumed ad libitum during the trials and recorded.  Water consumed was 
similar for all three trials.  Following each trial, body mass was recorded.  
Laboratory environmental conditions throughout the study were 21.4 ± 
2.2°C and 42 ± 9% relative humidity. 
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5.3.3  Blood Plasma Analysis 
IL-6, sIL-6R, sgp130, cortisol, CRP, glucose and lactate were all 
measured from blood plasma (outlined in detail in Chapter 2).   
5.3.4  Statistical Analysis 
The data was analysed using the statistical package PASW v.18 
(SPSS inc., Chicago, IL).  To investigate if data were spherical, Mauchly’s 
test of sphericity was applied, with a Greenhouse-Geisser correction for 
any violations.  For trial and time analysis, a 3 x 5 (trial x time) repeated 
measures ANOVA was conducted with Bonferroni adjustments for multiple 
comparisons with a criterion for significance set at p<0.05, while a one-
way ANOVA was used to assess time trial times.  General estimating 
equation was applied to assess within-subject factors for correlation 
analysis.  All data are expressed as mean ± SD.  
5.4  Results 
5.4.1  Physiological and Performance Data 
5.4.2  Preload 
Exercise intensity during the preload was 66 ± 5%, 67 ± 6%, and 64 
± 7% of OV 2max for Lo, Hi and DepHi trials respectively and was not 
significantly different between trials (p=0.73).  Respiratory exchange ratio 
was also not significantly different (Lo = 0.89 ± 0.05, Hi = 0.91 ± 0.05, 
DepHi = 0.93 ± 0.08; p=0.35).  Mean heart rate (Lo =149 ± 16 b·min-1, Hi 
=149 ± 16 b·min-1; DepHi = 146 ± 18 b·min-1 p=0.14) were similar for the 
preload components between trials.  For ratings of perceived exertion, no 
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significant differences were observed between the trials (Lo = 13 ± 2; Hi = 
12 ± 1; DepHi = 12 ± 2, p=0.14). 
5.4.3  Time Trial 
Repeated measures ANOVA showed that running speed and time 
to complete the Lo time trial was significantly impaired compared to Hi 
(p=0.01) and DepHi (p<0.01) however, there were no differences 
observed between Hi and DepHi (p=1.00) (figure 5.1and figure 5.2).  A 
lower mean heart rate was recorded during the Lo time trial compared to 
Hi (p<0.05) (Lo =168 ± 9 b·min-1; Hi =180 ± 17 b·min-1; DepHi = 177 ± 17 
b·min-1). There were no differences between trials for RPE were observed 
during the time trial for RPE (Lo = 17 ± 1, Hi = 17 ± 1, DepHi = 17 ± 2, 
p=0.12).  
Figure 5.1 Speed during the time trials  
 






























   
 Figure 5.2 Individual times for the time trials 
 
*Significantly slower than Hi and DepHi (effect of trial).  Individual times (grey), geometric 
mean of group (black) 
5.4.4  IL-6 and Signalling Receptors 
 Analysis of plasma IL-6 revealed an outlier that influenced the 
statistical analysis when examining for differences.  Therefore the outlier 
was excluded from the statistical analysis and was presented on a 
separate figure.    
Plasma IL-6 demonstrated a 15 fold increase from baseline (0.5 
pg·ml-1) at PL (7.6 pg·ml-1)(p<0.01) and a 30 fold increase (14.8 pg·ml-1) at 
PostTT (p<0.01).  IL-6 levels decreased 1hPost to 11.0 pg·ml-1 and 
returned to baseline levels by the following morning.  No significant 
differences were observed between trials for IL-6 (p=0.11) (Figure 5.3a 


















An increase in plasma sIL-6R levels from baseline (36.4 ng·ml-1) to 
PL (39.8 ng·ml-1) (p<0.01) was observed with a further significant increase 
at PostTT (40.7 ng·ml-1) (p<0.01).  These levels remained elevated at 
1hPost (39.3 ng·ml-1) and returned to baseline levels by 24hPost.  No trial 
effect was observed for plasma sIL-6R (p=0.08) (figure 5.4).   
 The plasma response of sgp130 showed no differences between 
trials (p=0.46) and although no significant difference in plasma sgp130 
was observed from Baseline to PL (p=0.06), sgp130 was elevated in 
response to exercise PostTT compared to Baseline (p<0.01).  No other 
differences were observed for plasma sgp130 (figure 5.5).  
Figure 5.3a.  Group data for the interleukin-6 response to the preloaded time trial 
protocol 
 
*Significantly higher than Baseline (effect of time) (p<0.01)  **Significantly higher than 































Figure 5.4.  The soluble interleukin-6 receptor (sIL-6R) response to the preload time 
trial protocol.  
 
        





















































Figure 5.5.  The sgp130 receptor response to the preload time trial protocol.    
 









































Plasma IL-6 levels prior to the time trial (PL) and percentage of 
velocity at OV 2max achieved during the time trial showed a significant 
negative correlation in all three trials (Lo r -0.68, p<0.05; Hi r -0.63, 
p=0.05; DepHi r-0.67, p<0.05).  Quadrant analysis illustrated that plasma 
IL-6 at a threshold of ≥7 pg∙ml-1 was associated with achieving a relative 
performance of <80% v OV 2max during the time trial (figure 5.6a and 5.6b).  
Furthermore, the mean circulating IL-6 response was not associated with 
habitual running distance and OV 2max (figures 5.7 and 5.8) 
Figure 5.6a. Group data correlations and quadrant analysis between IL-6 at PL and 
running performance during the time trials.  
 


































Figure 5.6b. Outlier data correlations and quadrant analysis between IL-6 at PL and 
running performance during the time trials.  
 
 
Figure 5.7 Correlation between mean circulating IL-6 response to the preload and 

























































Habitual running distance (km∙week-1)
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Figure 5.8 Correlation between mean circulating IL-6 response to the preload and 
and maximal oxygen uptake 
 
 
5.4.5  Other plasma variables 
 No significant differences were observed between trials for plasma 
glucose and furthermore plasma glucose did not change significantly 
during or following exercise (p=0.30).  Circulating lactate significantly 
increased at PL compared to Baseline (p<0.05) and showed a further 
significant increase PostTT (P<0.01), which began to fall at 1hPost.  
Plasma lactate was lower at PostTT during Lo compared to Hi (p<0.05).  
Plasma cortisol levels showed a non significant rise at PL (p=0.39) which 
was significantly elevated at PostTT and remained elevated at 1hPost 
compared to Baseline (p<0.05).  Circulating levels of CRP were not 
significantly different between trials and did not significantly change at 







































Table 5.2.  Plasma glucose, lactate, cortisol and CRP responses to the pre-exercise 
feeding protocols 
 Baseline PL  PostTT  1hPost  24hPost 
 




Lo     6.25±0.74 6.01±0.92 5.56±1.53 5.73±0.88 6.10±0.86 
Hi 6.84±1.42 6.54±1.09 6.71±1.15 5.95±0.97 6.39±0.89 






Lo     1.07±0.28 2.10±0.81* 4.64±2.50**
†
 1.78±0.46 1.25±0.35 
Hi 1.60±0.57 2.59±1.59* 7.22±2.61**
†
 2.15±0.70 1.65±0.60 






Lo 624±243  852±349  1280±290** 1089±291** 419±205 
Hi 565±173  707±311  1084±353** 958±347 ** 410±190 






Lo 0.7±0.6  -  0.8±0.6  -  4.3±3.4 
Hi 0.5±0.4  -  0.5±0.5  -  4.8±4.3 
DepHi 0.5±0.4  -  0.5±0.2  -  4.0±3.0 
 
* Significantly higher than Baseline (effect of time) (p<0.05) ** Significantly higher than 
Baseline and PL (effect of time) (p<0.05) 
†
 Significantly lower during Lo compared to Hi 
(p<0.01) 
 
5.5  Discussion 
 The present study sought to examine the effects of different pre-
exercise dietary protocols on the plasma IL-6 response to exercise and 
what impact this response had on subsequent time trial performance.  
Although plasma IL-6 and sIL-6R increased in response to exercise, no 
significant differences were observed between the trials.  An improved 
performance during the time trial was observed for the high carbohydrate 
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loading protocols, with and without prior glycogen depletion, compared to 
the low carbohydrate diet.   
 An improved exercise performance following high CHO diets 
compared to a low CHO diet has been reported extensively (Walker et al., 
2000; Lambert et al., 2001; Rauch et al., 2005) with muscle glycogen 
levels being the predominant factor related to the differences in exercise 
performance.  The increased CHO availability from muscle glycogen 
allows for spared CHO oxidation rate from circulating blood glucose 
throughout prolonged exercise (Coggan and Coyle, 1991).  This also 
allows the participant to maintain a higher intensity during the time trial 
when compared to a low glycogen trial.  Our findings also demonstrate 
that no significant difference in performance was seen between the two 
high carbohydrate trials, indicating that a glycogen depletion and 
restoration protocol is no more beneficial than a high CHO diet alone in 
terms of exercise performance of this nature.  Whether this is due to a lack 
of difference in muscle glycogen, or indeed, a difference in muscle 
glycogen, which did not translate to an increase in performance is 
unknown since we did not measure muscle glycogen in the current study.      
 Although there were no significant differences observed in the 
plasma IL-6 response to exercise between the trials, the plasma IL-6 
response showed a strong negative correlation with relative exercise 
performance during the time trial in all three trials.  Indeed, individuals who 
exhibited a greater plasma IL-6 response to the preload tended to perform 
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a slower time trial performance when expressed as a percentage of 
maximal aerobic velocity, regardless of dietary CHO intake. 
 Our data suggests that a higher circulating IL-6 concentration 
following a bout of prolonged exercise is associated with lower 
subsequent relative exercise performance.  Since elevations in IL-6 have 
been shown to induce fatigue at rest (Spath-Schwalbe et al., 1998), during 
daily activities (Ferrucci et al., 2002; Cappola et al., 2003) and during 
exercise (Robson et al., 2004), it is plausible that IL-6 acts as a fatigue 
signal, interacting with the brain, subsequently altering perception of effort 
during the time trial.  The relationship between IL-6 and fatigue during 
exercise has been previously demonstrated (Robson et al., 2004) and it 
has since been suggested that IL-6 acts as a mediator between muscle 
and brain (Pedersen and Febbraio, 2005).  Therefore, the concentration of 
circulating IL-6 may indicate to the brain the magnitude of stress and 
result in an altered pacing strategy during the time trial. 
 Analysis of the findings indicates that a circulating IL-6 response 
below a threshold of ~7 pg·ml-1 is associated with a time trial performance 
above ~80% v OV 2max.  This may be interpreted that a low IL-6 response to 
exercise, below 7 pg·ml-1, indicates a low stress response and little 
disruption to homeostasis, therefore allowing participants to maintain their 
relative performance throughout the time trial.  When the circulating IL-6 
response is >7 pg·ml-1, it increases the perception of effort for a given 
intensity and subsequently lead reduce relative exercise intensity during 
the time trial.   
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 Endurance training is associated with a multitude of adaptations 
including changes to metabolic enzymes (Gollnick et al., 1982), increases 
in muscle glycogen storage (Hickner et al., 1997), increases in fatty acid 
transport and an increased reliance on lipids as a substrate during sub 
maximal exercise (Kiens et al., 1993); all potentially resulting in a lower 
plasma IL-6 response to a bout of prolonged exercise (Fischer et al., 
2004; Gokhale et al., 2007).  Therefore, a reduced plasma IL-6 response 
to prolonged exercise could be due to differences in habitual training 
volume.  However, we found no association between habitual weekly 
running distance and the plasma IL-6 response to exercise.  Furthermore, 
the plasma IL-6 response was not associated with maximal oxygen 
uptake, suggesting that neither training volume nor aerobic fitness 
attributed to the differences in the IL-6 association with time trial 
performance. 
 Circulating sIL-6R levels increased following the preload exercise 
bout, peaking at PostTT which is consistent with previous work (Gray et 
al., 2008; Leggate et al., 2010).  The role of upregulated sIL-6R levels in 
prolonged exercise is unknown.  One hypothesis is that an upregulation of 
sIL-6R can improve the binding capacity to IL-6 and therefore improve IL-6 
signalling as a complex (Booth and Company, 2009).  As sIL-6R is an 
agonist of IL-6, it may influence time trial performance.  However, no 
differences were observed in plasma sIL-6R between the trials and 
furthermore, no correlations were observed between sIL-6R and exercise 
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performance, indicating that sIL-6R is not influenced by CHO ingestion 
during prolonged exercise.   
 Plasma sgp130 increased significantly at PostTT which is 
consistent with our previous work (Chapter 3) and research elsewhere 
(Gray et al., 2008).  The effect of sgp130 is in contrast to the cognate 
membrane bound gp130 by acting antagonistically, preventing IL-6/sIL-6R 
signalling.  In the circulation, sgp130 can bind to the IL-6/sIL-6R complex, 
presenting a molar excess which is biologically inactive (Jostock et al., 
2001).  Therefore, the similar response between the trials is probably 
explained by the plasma sIL-6R response to exercise.  Increases in 
sgp130 follow increases in sIL-6R in order to modulate the actions of sIL-
6R, possibly regulating excessive signalling (Rebouissou et al., 1998). 
 As has been previously demonstrated, circulating cortisol increased 
in response to prolonged exercise (Farrell et al., 1983; Buono et al., 1986; 
Coiro et al., 1988; Tabata et al., 1991).  Plasma cortisol increases in 
response to prolonged exercise have been associated with metabolic 
stress, resulting in activation of the HPA axis.  However, since no 
significant differences were observed between the trials and blood glucose 
was similar, it would suggest that muscle and liver glycogen levels were 
sufficient to maintain circulating blood glucose levels regardless of pre 
CHO loading regimen.  This is also reflected by similar responses 
observed in circulating IL-6 which can also act as an independent 
stimulator of cortisol (Tsigos et al.,1997; Bethin et al., 2000)  
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 Circulating C reactive protein was not different between trials, 
which is most likely due to the similar response observed in plasma IL-6. 
Although there was an approximate 7-fold increase in CRP the following 
morning, the concentrations were not significantly different from baseline 
(p=0.09) which is in contrast to previous work (Strachen et al., 1984; 
Castell et al., 1996; Seigal et al., 2001; Miles et al., 2006).  It is likely that 
the lack of significance is due to the large variability between participants 
and relatively low number of participants.    
 In conclusion, our findings demonstrate a strong inverse 
relationship between the plasma IL-6 response to a preload bout and 
subsequent relative time trial performance, which was not affected by 
altered dietary CHO intake.  Furthermore, we have demonstrated that a 
prior bout of glycogen depleting exercise before a high CHO diet is no 
more beneficial than a high CHO alone for exercise performance following 
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6.1  Abstract 
 Carbohydrate supplementation can delay the onset of fatigue and 
improve exercise performance through different pathways including 
suppressing fatigue signals.  Furthermore, increased levels of plasma IL-6 
have fatigue inducing properties which are associated with reduced time 
trial performance.  CHO supplementation during prolonged exercise can 
markedly reduce the appearance of IL-6 in circulation in response to 
prolonged exercise.  However, it is unknown if attenuating circulating IL-6 
will subsequently improve exercise performance.  Therefore, we 
investigated the effects of CHO supplementation on the circulating IL-6 
response to exercise and the subsequent impact on performance.  Nine 
trained male runners performed a preloaded time-trial, consisting of a 2 h 
run at 60 vVO2max interspersed with 30 s runs at 90% vVO2max at 10 
min intervals, followed by a 5 km time trial.  Participants were 
supplemented with 2 ml·kg-1 body mass of an 8% carbohydrate solution or 
a taste matched placebo in a randomised crossover manner at 20 min 
intervals.  Results showed that CHO supplementation attenuated the 
plasma IL-6 response post preload by 49% which correlated well with an 
8% improvement in time-trial performance.  In conclusion, we have shown 
that the CHO-related improvement in performance is associated with the 
atteunuation of circulating IL-6 during exercise. 
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 6.2  Introduction 
 During prolonged exercise, fatigue is inevitable and results in the 
inability to maintain a given work output.  CHO supplementation can 
reverse or delay the onset of fatigue and improve exercise performance 
which is achieved through central and peripheral pathways.  Mouth rinse 
of a CHO solution has been shown to improve 1 h running performance 
(Rollo et al., 2010), acting possibly through activation of reward centres of 
the brain (Chambers et al., 2009) or by suppressing fatigue signals 
(Pottier et al., 2010).  Furthermore, CHO ingestion during exercise may 
also reduce fatigue by maintaining blood glucose concentration, allowing 
CHO oxidation rates from circulating glucose to be maintained (Coyle et 
al., 1986) while sparing both liver glycogen (Jeukendrup et al., 1999) and 
muscle glycogen stores (Erickson et al., 1987; Yaspelkis et al., 1993; 
Stellingwerff et al., 2007).  
 When intramuscular glycogen levels become depleted from 
prolonged exercise contracting skeletal muscle releases IL-6 into the 
circulation (Nieman et al., 1998; Steensberg et al., 2000; Keller et al., 
2001; Cox et al., 2007), which increases in a dose dependant manner 
relative to both the intensity (Ostrowski et al., 2000) and the duration of 
exercise (Fischer, 2006) as the body relies more on blood glucose as a 
source of energy (Coggan and Coyle, 1991; Stellingwerf et al., 2007).  
When released into the circulation, IL-6 can act as a glucose regulator to 
stimulate hepatic glucose production (Febbraio et al., 2004)  
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 As well as a glucose regulator, increased plasma IL-6 has fatigue 
inducing properties and furthermore, worsens mood state and reduces the 
ability to concentrate when in the circulation (Spaith-Schwalbe et al., 
1998).   Resting plasma IL-6 levels have been associated with impaired 
functional performance such as lower walking speed (Taafe et al., 2000), 
lower muscle strength of the lower extremities (Visser et al., 2002) and 
lower grip strength (Bautmans et al., 2007).   Furthermore, an increase in 
circulating IL-6 can also impair athletic performance in athletes (Robson et 
al., 2004).  
 Carbohydrate supplementation during prolonged exercise can 
markedly reduce the appearance of IL-6 in circulation in response to 
prolonged exercise (Nehlsen-Cannarella et al. 1997; Utter et al., 1999; 
Starkie et al., 2001; Febbraio et al., 2003).  Since IL-6 mRNA is unaffected 
by CHO ingestion during prolonged exercise within skeletal muscle 
(Starkie et al., 2001; Febbraio et al., 2003), it has been speculated that 
CHO supplementation attenuates the release of IL-6 into the circulation 
and not the production of IL-6.  In addition, CHO ingestion during exercise 
reduces liver glycogenolysis and gluconeogenesis (Jeukendrup et al., 
1999) therefore reducing the need for IL-6 to stimulate glucose production. 
 Therefore, it is possible that CHO supplementation during 
prolonged exercise will result in a lower circulating IL-6 response, 
attenuating a stress signal which will subsequently improve exercise 
performance.  Accordingly, the present study intended to determine the 
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impact of CHO ingestion during prolonged exercise on the responses of 
plasma IL-6 and the subsequent time trial performance.    
6.3  Methods 
6.3.1  Participants 
Nine trained male runners took part in the study.  Participant 
characteristics are displayed in table 6.1.  Exclusion criteria included those 
taking medication including anti-inflammatory drugs or vitamin 
supplementation.  All participants were free from any symptoms of 
infection in the four weeks prior to the study.   Participants gave written 
informed consent to the study which was given approval by the 
Northumbria University school ethics committee. 
 
 
Table 6.1  Subject characteristics 
 Age (yr)     26     ±  6 
 Height (cm)    181   ±  6 
 Body mass (kg)    73.5  ±  7.4 
 Maximal oxygen uptake (ml·kg·min
-1
) 58     ±  4 
 Weekly habitual training (km)  40     ± 18 
Data are expressed as mean ± SD 
 
6.3.2  Experimental Protocol   
 Participants performed a familiarisation trial prior to the 
experimental trial.  To ensure nutritional status was similar, participants 
were given a food diary to record dietary intake 24 h prior to experimental 
trials.  For the following trial, participants were instructed to replicate their 
diet as previously recorded.  Participants were also asked to refrain from 
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exercise, alcohol and caffeine 24 h prior to each trial and during the 24 h 
following the exercise period.  Each participant arrived at the laboratory in 
the morning before 09:00 after a 12 h fast and began the trial which is 
outlined in detail in Chapter 2.  Immediately before and at 20 min intervals 
during the preload bout, participants consumed 2 ml·kg-1 body mass of an 
8% carbohydrate solution or a taste matched placebo in a randomised 
crossover manner.  Substrate oxidation rates were calculated according to 
Frayn (1983).  Following the time trial, blood samples were taken, body 
mass was recorded and a further 2 ml·kg-1 of carbohydrate or placebo was 
consumed.  Laboratory environmental conditions throughout the study 
were 20.0 ± 1.4°C and 38 ± 6% relative humidity 
6.3.3  Blood Plasma Analysis 
 Blood samples were immediately centrifuged at 3000 rpm for 10 
min aspirated and the supernatant was stored at -80°C until the day of 
analysis.  IL-6, sIL-6R, sgp130, cortisol, CRP, glucose and lactate were all 
analysed from blood plasma - see general methods (Chapter 2). 
 6.3.4  Statistical Analysis 
The data were analysed using the statistical package SPSS v. 16 
(SPSS inc., Chicago, IL).  To analyse if data were spherical, Mauchly’s 
test of sphericity was used, with a Greenhouse-Geisser correction for any 
violations.  For trial and time analysis, a 2 x 5 (trial x time) repeated 
measures ANOVA was conducted; post hoc analysis were used with 
Holme Bonferroni corrections for multiple comparisons with a criterion for 
significance set at p<0.05.  For analysis of other physiological variables 
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and time trial data, a paired samples t test was used with Holme 
Bonferroni corrections applied when appropriate.   All data are expressed 
as mean ± SD. 
6.4  Results 
6.4.1  Physiological Data 
 During the preload there were no significant differences in mean 
exercise intensity, heart rate, respiratory exchange ratio or substrate 
oxidation rate between trials. Mean RPE during the preload was lower for 
CHO compared to PLA (table 6.2). 
 
Table 6.2  Physiological variables and substrate oxidation during the preload. 
   Placebo   Carbohydrate  P value 
% OV 2max   73     ±  4               75     ±  3  0.52 
Heart rate (b·min
-1
)  151   ±  17               149   ±  15  0.37 
RPE    13     ±  1               12     ±  1  0.05 
†
 
RER    0.84  ±  0.04  0.83  ±  0.04  0.65 
CHO oxidation rate (g·min
-1
) 1.83  ±  0.63  1.85  ±  0.47  0.47 
Fat oxidation rate   (g·min
-1
) 0.79  ±  0.25  0.84  ±  0.20  0.84 
 
†
 Significantly lower in CHO than PLA (p≤0.05) 
 
6.4.2  Plasma IL-6 and Receptor Responses 
Figure 6.1 shows that during PLA, circulating IL-6 increased 9.2 
fold from baseline to PL (p<0.01) with a further increase observed PostTT 
(p<0.001).  IL-6 levels were lower by 1hPost but remained elevated 
(p<0.001), and had returned to baseline levels by the following morning.  
CHO attenuated the IL-6 response post preload by 49% (p<0.05) which 
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remained 41% lower at PostTT (p<0.01) and 39% (p<0.01) lower at 
1hPost.   
Plasma sIL-6R levels were significantly increased by 12.8% in both 
trials from baseline to PostTT (p<0.05) and 1hPost (p<0.05) but returned 
to baseline values by the following morning.  No differences were 
observed between trials (p=0.88) (figure 6.2). 
The plasma sgp130 response to exercise is shown in figure 6.3.  Plasma 
sgp130 showed a significant increase at PostTT (9.7%) (p<0.05) which 
were maintained at 1hPost (p<0.05) but returned to baseline by 24hPost.  
Although sgp130 increased with exercise, no differences were observed 
between trials (p=0.35). 
 Figure 6.1. Effect of CHO supplementation on IL-6 responses.  
 
 †CHO signifcantly lower than PLA at the corresponding time points  





























 Figure 6.2 Effect of CHO supplementation on sIL-6R responses  
 
  * Significantly higher than baseline (effect of time) (p<0.05) 
 
























































6.4.3  Time Trial Data 
 The mean running speed during the 5 km time trial was higher 
during CHO (13.2 ± 1.9 km∙h-1) compared to PLA (12.3 ± 2.2 km∙h-1) 
(p<0.01) (figure 6.4) resulting in a faster completion time (p<0.05) (figure 
6.5).  During the time trial heart rate was significantly higher in CHO (184 
± 13 b∙min-1 vs. 174 ± 12 b∙min-1) (p<0.05) however there were no 
differences in RPE (p=1.00). 
 A significant negative correlation was observed between IL-6 and 
relative running performance during PLA (r=-0.76 p<0.05) however, the 
relationship was not maintained during CHO (r= -0.52 p=0.15) (figure 6.6).  
No correlation was found between the difference in running speed and the 
difference in IL-6 (r=0.06 p=0.88) when all participants were examined; 
however, when outliers more than three standard deviation away from the 
mean are excluded (Healy, 1979; Weiss and Hilgenfeld, 1997), the 














 Figure 6.4  Running speed during the time trial. 
 
  † 
CHO significantly higher than PLA (effect of trial) (p<0.01) 
  














































Figure 6.6 Correlation between circulating IL-6 at PL and running performance 
during the time trial. 
 
  PLA p<0.05;  CHO p=0.15 
  
Figure 6.7 Correlation between difference in IL-6 at PL and difference in  speed 
during the time trial 
 
Correlations for all participants (broken line) (p=0.88) and with the excluded outliers who 





























6.4.4  Other Plasma Variables 
 Table 6.3 demonstrates that plasma glucose remained relatively 
unchanged throughout the exercise and time trial period during PLA.  
Plasma glucose increased during CHO and showed a significant 
difference compared to PLA at PL (p<0.01).  Plasma cortisol was not 
different between trials (p=0.14) but did increase for both trials at PL 
(p≤0.05) and showed a further increase at PostTT (p<0.01) which 
remained elevated at 1hPost (p<0.01).  Cortisol levels had returned to 
baseline levels by the following morning (Table 6.3).  C reactive protein 
(CRP) remained unchanged post time trial compared to baseline (p=0.82) 
however, a significant increase was observed 24hPost (p<0.01).  No 
significant differences were observed between trials for CRP (p=0.17) 
(Table 6.3). 
Table 6.3  Plasma glucose, cortisol and CRP responses to carbohydrate 
supplementation. 
 Baseline PL  PostTT  1hPost  24hPost 
 




PLA      5.01±1.17 5.14±1.39
†
 5.29±1.26 4.68±1.02 5.60±1.16 
CHO 5.13±0.54 7.02±1.27
†






PLA 456±152  801±373* 1212±412* 1047±407* 385±115 






PLA 0.5±0.6  -  0.6±0.6  -  3.3±2.1* 
CHO 0.3±0.2  -  0.3±0.2  -  2.6±1.8* 
 
* Significantly higher than baseline (p≤0.05) 
†




6.5  Discussion 
The aims of the present study were to investigate the effect of 
carbohydrate supplementation on the response of plasma IL-6 and the 
signalling receptor to exercise and the association with time trial 
performance.  Our findings demonstrate that CHO ingestion reduced the 
plasma IL-6 response to exercise, which was associated with an 
improvement in exercise performance during the time trial.  CHO 
supplementation during exercise did not alter the response of the 
circulating receptors sIL-6R or sgp130. 
The finding that CHO intake during prolonged exercise reduces 
circulating IL-6 is in accordance with previous work (Nehlsen-Cannarella 
et al., 1997; Starkie et al., 2001; Bishop et al., 2002) suggesting that IL-6 
release is related to CHO metabolism during exercise.  CHO 
supplementation has been shown to spare muscle glycogen content 
during prolonged exercise (Yaspelkis et al., 1993; Tsintzas et al., 1996; 
Stellingwerf et al., 2007).  However, this has not consistently been 
observed (Coyle et al., 1986; Flynn et al., 1987; Starkie et al., 2001; 
Febbraio et al., 2003).  Furthermore, work from Starkie et al. (2001) and 
Febbraio et al. (2003) showed that the IL-6 mRNA within contracting 
skeletal muscle is unaffected by CHO intake during exercise whilst a 
reduction in IL-6 was seen in the circulation.  This indicates that CHO 
intake suppresses the release of IL-6 into the circulation from skeletal 
muscle, rather than IL-6 synthesis.  It is presently unclear how CHO 
supplementation reduces circulating IL-6 levels; although, it could be 
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speculated that CHO ingestion reduces the number of transporters 
allowing the IL-6 protein to transport from skeletal muscle into the 
circulation.  Nonetheless, inhibiting the release of IL-6 from skeletal 
muscle attenuates the global actions of IL-6.  
6.5.1  IL-6 as a Mediator between Muscle and Central Regions 
 IL-6 can interact between muscle cells and other organs, such as 
the brain (Banks et al., 1994; Watkins et al., 1995).  Since IL-6 in 
circulation can induce sensations of fatigue (Spaith-Schwalbe et al., 1998) 
and also impair exercise performance (Robson et al., 2004).  We propose 
that the release of IL-6 into the circulation from skeletal muscle during 
prolonged exercise acts as a signalling protein to provide feedback on 
metabolic stress when CHO availability stores are compromised.  This 
may in turn protect the body from energy depletion during exercise.  Work 
from Rauch et al. (2005) demonstrated that reduced CHO availability 
alters pacing strategy and they speculated that exercising muscle releases 
a metabolic signal or ‘glycostat’.  In the present study, seven of the nine 
participants demonstrated a reduction in circulating IL-6 with CHO 
ingestion which correlated with an increase in speed during the time trial 
run.  This supports the proposal that an attenuated IL-6 response following 
CHO intake reduces the central effect whereby attenuating the sensation 
of fatigue or effort results in an increase in performance.  
 CHO supplementation during prolonged exercise reduces ratings of 
perceived exertion (RPE), particularly towards the end of exercise 
(Burgess et al., 1991; Utter et al., 1999; Utter et al., 2004).  In the present 
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study, ratings of perceived exertion were lower during CHO following the 
preload bout of exercise which was accompanied with a 49% reduction of 
circulating IL-6.  No differences were observed in RPE during the time 
trial; however, although perception of effort was the same, the mean 
speed was higher during the CHO trial.  Therefore the circulating IL-6 
response may influence perception of effort which impacts on subsequent 
exercise performance. 
The mechanisms regulating IL-6, perception of effort and 
performance could be the physiological link of IL-6 with serotonergic 
pathways.  Increased serotonin or 5-hydroxytryptophan (5-HT) activity in 
the brain is known to be associated with depressed mood, lethargy, sleep 
and appetite regulation (Cooper et al., 2003) and centrally mediated 
fatigue.   Increased 5-HT activity during prolonged exercise can alter 
sensation of effort leading to a reduction in motor unit recruitment (Davis 
and Bailey, 1997) and alter exercise performance (Bailey et al., 1993).  
Intravenous infusion of IL-6 into rats increases concentrations of 
tryptophan, a precursor of 5-HT synthesis (Wang and Dunn et al., 2001), 
which increases 5-HT release from particular regions of the rat brain 
(Zhang et al., 2001).  Furthermore, an increase in 5-HT following IL-6 
infusion is concurrent with a reduction in dopamine (Song et al., 1999), a 
neurotransmitter linked to increased motivation and arousal (Davis et al., 
2000).  Robson et al. (2004) demonstrated that infusion of IL-6 into well 
trained athletes potentiated the release of prolactin, a marker of 
serotonergic activity (Chandler and Blair, 1980), and impaired exercise 
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performance.  Therefore, although we did not measure any markers of 
central activity, it could be possible in the present study that attenuating 
peripherally produced IL-6 inhibits centrally mediated effects by reducing 
serotonergic activity and the associated sensations of fatigue and 
consequently, preserves performance.      
6.5.2  Signalling Receptors 
An increase in circulating sIL-6R levels post time trial and 1 h 
following the time trial was unaltered by CHO intake.  This indicates that 
sIL-6R lacks a direct role in CHO metabolism during exercise.  These 
findings are in accordance with Leggate and colleagues (2010) who found 
that an increase in plasma sIL-6R in response to exercise is not intensity 
related which lends support to the notion that sIL-6R does not play a direct 
role in CHO metabolism during exercise.   
Circulating sgp130 increased post time trial however there were no 
differences between trials indicating that circulating sgp130 is not related 
to CHO metabolism during exercise, therefore, the mechanisms for 
sgp130 production and release into the circulation in response to exercise 
remain unclear.  sgp130 has been previously reported as an antagonist to 
IL-6/sIL-6R signalling since sgp130 can bind to the IL-6/sIL-6R complex, 
presenting a molar excess which is biologically inactive (Jostock et al., 
2001).  It is possible that the increase in sgp130 regulates the actions of 
sIL-6R signalling since an increase in sIL-6R is accompanied by an 
increase in sgp130 (Rebouissou et al., 1998). 
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6.5.3  Other Systemic Markers 
Plasma cortisol significantly increased during exercise but was not 
significantly different between trials, which supports previous work 
(Tsintzas et al., 1996; Bishop et al., 2001).  Prolonged exercise has been 
shown to consistently increase CRH (Tabata et al., 1991; Inder et al., 
1998) leading to an increase in ACTH (Fraioli et al., 1980; Inder et al., 
1998) subsequently raising glucocorticoid concentrations such as cortisol 
(Few, 1974; Kuoppasalmi et al., 1980; Kindermann et al., 1982; Utter et 
al., 1999) when exercise is at an intensity >60% OV 2max (McCarthy and 
Dale, 1988).  Although the majority of research has shown a reduced 
response of plasma cortisol following CHO supplementation during 
exercise (Murray et al., 1991; Utter et al., 1999; Bishop et al., 2002; Chen 
et al., 2009), our data did not show any significant effect (p=0.14).  
Therefore, it is likely that the large inter-individual variation and low subject 
number are the basis of the lack of statistical significance required.  
Circulating CRP significantly increased the following morning but 
was not significantly different between trials.  An increase in circulating 
CRP 16 h post exercise has been previously shown  (Castell et al., 1996; 
Robson-Ansley et al., 2009) with peak concentrations occurring at 24 h 
post exercise (Strachan et al., 1984).  Our observation that plasma CRP is 
not altered by CHO intake is in accordance with previous work (Scharhag 
et al., 2006); indicating that attenuation of IL-6 does not translate to a 
reduced CRP response.  Since plasma IL-6 was blunted by 43% across all 
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the time points, this suggests that during exercise, plasma IL-6 is not the 
sole stimulator of CRP.   
In conclusion, the results from the study show that CHO 
supplementation during prolonged exercise can improve time trial 
performance during prolonged exercise.  The findings suggest that the 
CHO-related atteunuation of circulating IL-6 during exercise may be 
another mechanism to explain the previously reported ergogenic effect of 
CHO ingestion during exercise.  The improvement in performance does 

















Part II. The Effect of Carbohydrate 














7.1  Abstract 
 Hepcidin is an antimicrobial peptide which regulates circulating iron 
to control iron homeostasis.  Previous research has shown that cytokines 
play a role in the release of hepcidin.  In particular, IL-6 is a key mediator, 
which can induce hepcidin during inflammatory states and during exercise.  
Previously, we have shown that CHO ingestion during prolonged exercise 
attenuates the circulating IL-6 response.  However it is unknown what 
impact this has on circulating hepcidin and iron levels.  Therefore, the 
purpose of this study was to investigate the impact of attenuated plasma 
IL-6 on circulating hepcidin and iron responses.   The samples taken for 
chapter 6 were analysed for plasma hepcidin, iron and ferritin.  Results 
found that hepcidin increased in response to exercise.  However, although 
CHO supplementation attenuated plasma IL-6, no differences were 
observed for plasma hepcidin, iron or ferritin. Therefore, in conclusion, we 
have shown that plasma hepcidin increases in a similar fashion to IL-6 
during prolonged exercise; however, the hepcidin response was not 










7.2  Introduction 
 Iron deficiency is a common disorder in both trained and untrained 
populations and is particularly prevalent among athletes who participate in 
endurance type events (Looker et al., 1997; Schumacker et al., 2002).  
Iron is essential for oxygen delivery and neurotransmitter synthesis, 
therefore a deficiency in this mineral may impair athletic performance.  
Individuals with iron deficiency or anaemia have a lower OV 2max, and lower 
endurance capacity (Haas and Brownlie, 2001; Hinton et al., 2000) which 
can result in the early onset of fatigue and reduce exercise performance.  
Causes of exercise associated iron deficiency are multifaceted and 
include damage to red blood cells as a result of vigorous muscle 
contraction and foot strike during running (Telford et al., 2003), however, 
the peptide, hepcidin may play a key role in the regulation of iron 
metabolism during exercise (Nemeth et al., 2003). 
 Hepcidin is an antimicrobial peptide which plays a role in host 
defence against invading pathogens (Krause et al., 2000; Park et al., 
2001) which is predominantly produced and released from hepatocytes 
(Park et al., 2001) regulating circulating iron to control iron homeostasis 
(Nicolas et al., 2002, Nemeth et al., 2003; Nemeth et al., 2004; Rivera et 
al., 2005).  In the murine model, over expression of hepcidin leads to 
anaemia (Nicolas et al., 2002) and mice that are infused with hepcidin can 
display an 80% reduction of serum iron (Rivera et al., 2005).  In humans, 
increased levels of hepcidin are subsequently followed by a delayed 
decrease in serum iron levels (Kemna et al., 2005).   
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 Research indicates that cytokines play a role in the hepatic release 
of hepcidin both in vitro and in vivo (Nemeth et al., 2003; Nemeth et al., 
2004; Kemna et al., 2005).  When IL-6 antibodies are added to cell 
culture, LPS induced hepcidin is blocked (Nemeth et al., 2004).  Infusion 
of LPS into humans also increases urinary hepcidin concentrations which 
are mediated by an increase in circulating IL-6 (Kemna et al., 2005).  
Furthermore, this effect is also observed when humans are infused with 
rhIL-6 (Nemeth et al., 2004), indicating that IL-6 is both a key mediator in 
the inflammatory induced hepcidin response and can also induce hepcidin 
per se.    
 Prolonged exercise can stimulate an increase in circulating IL-6 
from skeletal muscle, particularly when muscle glycogen levels are low 
(Steensberg et al., 2000, Keller et al., 2001).  Since IL-6 can play a key 
role in the release of hepcidin from hepatocytes, it can be assumed that 
the exercise induced IL-6 can initiate a hepcidin response.  Research from 
Roecker et al. (2005) established from female athletes that after a 
marathon, increases in urinary hepcidin occur immediately post race with 
peak hepcidin concentrations occurring the following day.  Later work by 
Peeling et al. (2009) demonstrated that an increase in circulating IL-6 
following exercise preceded an increase in urinary hepcidin. 
 Taken together, the literature suggests that an association between 
plasma IL-6 and hepcidin concentrations exist which can subsequently 
reduce plasma iron concentrations.  Therefore we hypothesised that a 
reduced plasma IL-6 response to exercise following CHO intake will 
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reduce the hepcidin response and subsequently maintain plasma iron 
levels the following morning.  Accordingly, the aim of this study was to 
examine the effect of CHO supplementation during prolonged exercise on 
the plasma response of hepcidin and its subsequent effect on plasma iron 
and ferritin concentrations.        
7.3  Methods 
7.3.1  Participants  
Nine trained male runners took part in the study, of which the 
participant characteristics and methods are outlined in chapter 6.  All 
participants were free from any symptoms of infection in the 4 weeks prior 
to the study and gave written informed consent to the study which was 
given approval by the Northumbria University school ethics committee. 
7.3.2  Blood Analysis 
 Blood samples were immediately centrifuged at 3000 rpm for 10 
min aspirated and the supernatant was stored at -80°C until the day of 
analysis.  IL-6 was analysed from blood plasma which is outlined in detail 
in chapter 2. 
7.3.3  Hepcidin Analysis 
Plasma hepcidin was analysed from K3EDTA treated tubes and was 
measured by mass spectrometry incorporating stable isotope labelled 
synthetic hepcidin as an internal standard as described previously (Ward 
et al., 2008).   Briefly, 100 ng labelled hepcidin was added per ml of 
plasma.  The spiked plasma was then diluted 5-fold in 8 M urea, 1% 
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CHAPS, 20 mM ammonium bicarbonate and incubated at room 
temperature for 30 min.  Following a 10-fold dilution in 20 mM ammonium 
bicarbonate, the samples were applied to Cu2+ loaded ProteinChip Arrays.  
After a 60 minute incubation the arrays were washed with 20 mM 
ammonium bicarbonate, rinsed with distilled water, dried and the samples 
overlayed with 1 µl saturated sinapinic acid in 50% acetonitrile, 0.5% 
trifluoroacetic acid.  Mass spectra were acquired on a PBS IIc time-of-
flight analyser (Ciphergen) and the hepcidin concentration in the plasma 
calculated from the intensity ratio of the endogenous and spiked hepcidin 
peaks (m/z 2790 and 2800 respectively).  The hepcidin in each plasma 
sample was measured in duplicate using independent technical replicates.    
7.3.4  Ferritin Analysis 
Serum ferritin was measured in duplicate on the Adiva Centaur which is 
comprised of a two site sandwich immunoassay using two anti-ferritin 
antibodies.  The first antibody is a polyclonal goat antibody against ferritin, 
labelled with acridinium ester.  The second antibody is a monoclonal 
mouse antibody against ferritin that is covalently coupled to paramagnetic 
particles.  The samples were incubated, exposed to a magnetic field and 
then washed.  Hydrogen peroxide was then added and the RLU was then 
measured in the luminometer.   
7.3.5  Iron Analysis 
Serum iron was measured using the Olympus method.  TPTZ (2,4,6-Tri(2-
pyridyl)-5-triazine) was used as the chromogen in an acidic medium.  
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Hydrochloric acid and sodium ascorbate was added and was 
bichromatically measured at 590 nm. 
 7.3.6  Statistical Analysis 
The data were analysed using the statistical package SPSS v. 16 
(SPSS inc., Chicago, IL).  To analyse if data were spherical, Mauchly’s 
test of sphericity was used, with a Greenhouse-Geisser correction for any 
violations.  For trial and time analysis, a 2x5 (trial x time) repeated 
measures ANOVA was conducted; post hoc analysis were used with 
Holme Bonferroni corrections for multiple comparisons with a criterion for 
significance set at p<0.05.  For analysis of other physiological variables 
and time trial data, a paired samples t test was used with Holme 
Bonferroni corrections used when appropriate.   All data are expressed as 
mean ± SD. 
7.4  Results 
7.4.1  Physiological and Time Trial Data 
 During the preload there were no significant differences for mean 
exercise intensity, heart rate or respiratory exchange ratio between trials.  
Table 7.1  Physiological variables and substrate oxidation during the preload  
   Placebo   Carbohydrate  P value 
% OV 2max   73 ± 4   75 ± 3   0.52 
Heart rate (b·min
-1
)  151 ± 17   149 ± 15   0.37 





7.4.2  Plasma Variables 
 Circulating IL-6 increased 9.2 fold from pre exercise to PL (p<0.01) 
during PLA with a further increase observed PostTT (p<0.001).  IL-6 levels 
were reduced 1hPost but remained elevated (p<0.001) and had returned 
to baseline levels the following morning.  CHO attenuated the IL-6 
response post exercise by 49% (p<0.05) which was also 41% lower 
PostTT (p<0.01) and 39% (p<0.01) lower 1hPost (Chapter 6). 
 Plasma hepcidin showed a significant increase from Baseline to PL 
(p<0.01) which remained elevated until 1hPost (p<0.05) then returned to 
baseline values 24hPost.  Although a significant increase in plasma 
hepcidin was observed, no significant differences were seen between PLA 
and CHO (p=0.45) (figure 7.1) 
 Figure 7.1.  Effect of CHO supplementation on plasma hepcidin 
































 Plasma iron increased from Baseline to PL (p<0.05), however,  
plasma levels remained reletively constant until 1hPost and was 
significantly reduced at 24hPost (p<0.05) compared to other time points 
(figure 7.2).  No significant differences were observed between trials for 
plasma iron. 
 
 Figure 7.2.  Effect of CHO supplementation on plasma iron 
 
*Significantly higher than baseline (p<0.05) **Significantly lower than any other time point 
































 Plasma ferritin remained relatively constant throughout the trial.  
There was no effect of time (p=0.61) and furthermore, there were no 
differences between PLA and CHO (p=0.91) (figure 7.3). 
 
 
































 During PLA plasma hepcidin showed a good correlation with 
plasma IL-6 (r=0.76, p<0.001) however, during CHO a lower correlation 
was observed  (r=0.33, p<0.02) (figure 7.4 and 7.5). 
 Figure 7.4.  Correlation betweeen hepcidin and IL-6 during PLA 
 
Significant correlation between plasma hepcidin and plasma IL-6 during PLA (p<0.001)  
  
 Figure 7.5. Correlation between hepcidin and IL-6 during CHO 
 























































7.5  Discussion 
The aim of the present study was to examine the effect of the 
attenuated IL-6 response to exercise from CHO supplementation on the 
subsequent response of plasma hepcidin, iron and ferritin.  An increase in 
plasma IL-6 correlated well with an increase in plasma hepcidin which led 
to a subsequent decrease in plasma iron the following morning during the 
placebo; however, the reduced plasma IL-6 response from CHO intake did 
not result in an attenuated response of plasma hepcidin which 
subsequently, did not alter the plasma iron or ferritin response to exercise. 
In agreement with other studies, we found that plasma IL-6 and 
hepcidin increased in response to exercise during PLA.  Furthermore, a 
strong correlation was observed between the two circulating peptides.  
Previous work has demonstrated increases in plasma IL-6 and urinary 
hepcidin (Peeling et al., 2009a; Peeling et al., 2009b) which supports the 
concept that exercise induced hepcidin is linked to the plasma IL-6 
response to prolonged exercise.   
 Although we have illustrated a strong correlation between plasma 
IL-6 and plasma hepcidin, this relationship is weakened when CHO is 
consumed during exercise.  On this basis we speculate that circulating IL-
6 is not solely responsible for the plasma hepcidin response to prolonged 
exercise, and other mechanisms are involved in the increase in circulating 
hepcidin.  Work by Wrighting and Andrews (2006) demonstrated that IL-6 
induces hepcidin through the STAT3 signalling pathway and reported that 
STAT3 is necessary for increased hepcidin expression.  This was later 
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confirmed by Pietrangelo et al. (2007) who illustrated that IL-6 did not 
increase hepcidin expression in hepatocytes in STAT3 deficient mice.  
Since IL-6 activates the JAK/STAT signalling pathway (Heinrich et al., 
2003), this provides a rationale for the association between IL-6 and 
hepcidin levels;  however other peptides can stimulate the JAK/STAT 
signalling pathway which results in an increase in hepcidin concentrations. 
 Hepcidin transcription in macrophages and hepatocytes occurs in 
IL-6 deficient mice, indicating that hepcidin expression occurs through 
both IL-6 dependent and independent pathways (Lee et al., 2005).  It can 
therefore be considered that the increase in exercise induced hepcidin is 
due to the activation of STAT3.  STAT3 has been shown to have multiple 
stimulators including cytokines, growth factors amongst other stimuli 
(Campbell et al., 1995; Heinrich et al., 1998; Zong et al., 2000).  
Furthermore, prolonged exercise is associated with a multitude of 
hormonal, immune and biochemical changes which can potentially 
activate STAT3 signalling.  For instance, growth hormone (GH) and insulin 
growth factor I (IGF-I) have been shown to increase with exercise 
(Schwarz et al., 1996; Kraemer et al., 2004) both of which can activate 
STAT3 (Campbell et al., 1995; Zong et al., 2000).  Therefore, it is possible 
that another exercise induced peptide is involved with hepcidin release 
through activation of STAT3.    
 The finding that plasma iron levels were reduced 24 h following 
exercise is in accordance with previous work (Pattini et al., 1990) but is in 
contrast with others (Peeling et al., 2009a; Peeling et al., 2009b).  The 
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studies by Peeling and colleagues involved an exercise bout of shorter 
duration than that of the present study resulting in a lower hepcidin 
response which may have had no impact on circulating iron 
concentrations.  A number of studies have reported that hepcidin is 
responsible for a reduction in serum iron (Nemeth et al., 2004; Ramey et 
al., 2010; Kemna et al., 2005); caused by the actions of ferroportin 
(Ramey et al., 2010).  Ferroportin is responsible for the export of iron and 
acts to regulate the release of iron into the circulation, and is situated on 
the surface of many cells such as intestinal enterocytes, macrophages 
and hepatocytes.  Hepcidin binds to ferroportin causing it to internalise 
and degrade (Nemeth et al., 2004).  This results in iron being retained 
within the cell and subsequently leads to a decrease in circulating free iron 
levels.  These events counter regulate iron overload but also play a role in 
host defence against invading pathogens.  Depriving pathogenic 
bacterium of iron can impair growth of the bacterium since an increase in 
iron is required with increased production of bacteria (Abdul-Tehrani et al., 
1999).  However, the stored form of iron, ferritin was not altered by 
exercise or by CHO intake which provides further support of this, 
indicating that plasma hepcidin alters plasma free iron concentrations, 
whereas the stored form of iron is not altered.   
 Since the attenuated response of IL-6 from CHO intake did not alter 
the plasma iron response compared to a placebo, this highlights the 
strong relationship between serum iron and hepcidin.  Although CHO 
intake during prolonged exercise did not reduce the plasma hepcidin 
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response, further research is warranted to determine if other interventions 
could influence hepcidin concentrations to help maintain iron levels during 
the post exercise recovery period.  
 In conclusion, we have shown that plasma hepcidin increases in a 
similar fashion to IL-6 during prolonged exercise; however, unlike IL-6, the 
hepcidin response was not blunted by CHO ingestion.  This indicates that 
exercise induced IL-6 is not the predominant cause of the increase in 
plasma hepcidin and is due to other mediators such as STAT3.  
Attenuation of hepcidin by other supplements or interventions is warranted 































 The primary aim of the thesis was to examine the influence of the 
systemic response of IL-6 to exercise on subsequent time trial 
performance using a preloaded time trial protocol.  Findings from chapter 
3 initially determined the magnitude of the plasma IL-6 response to the 
preloaded time trial protocol, of which, we have quantified the variation.  
The findings also show that a negative correlation occurs between the 
response of plasma IL-6 to the preload bout and the subsequent 
performance during the time trial.  Consequently, it was hypothesised that 
manipulation of the IL-6 response to the preload using nutritional 
interventions would clarify the influence of circulating IL-6 on subsequent 
time trial performance. 
 Glutamine supplementation during prolonged exercise does not 
impact on the circulating IL-6 response to the preload and furthermore, 
time to complete the time trial is not altered by glutamine supplementation 
(Chapter 4).  In addition, altered dietary CHO intake prior to the protocol 
does not alter the mean plasma IL-6 response (Chapter 5).  Conversely, 
CHO intake during a preload bout of exercise attenuates the plasma IL-6 
response by 49% which is also accompanied by an 8% improvement in 
performance in the subsequent time trial (Chapter 6).  However, the 
reduction in plasma IL-6 did not translate to a reduction in plasma hepcidin 
(Chapter 7). 
 Regardless of the nutritional intervention employed, a consistent 
finding in the series of studies is that the systemic IL-6 response to the 
preload bout negatively correlates with relative exercise performance 
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during the time trial.  This indicates that the magnitude of the IL-6 
response to the preload bout is associated with performance when 
expressed in relative terms.  Furthermore, the correlations demonstrate 
that a low IL-6 response to the preload bout of exercise (<7 pg·ml-1) is 
often associated with a higher fractional aerobic utilisation during the time 
trial (>80% v OV 2max) indicating a relationship between circulating IL-6 
levels and exercise performance. Although these findings show an 
association between plasma IL-6 responses and exercise performance, 
the results do not specify causality.  Therefore, assessing the manipulated 
plasma IL-6 response to exercise, and the subsequent influence on time-
trial performance can give more indication of the role of circulating IL-6 in 
exercise.  
8.1  Nutritional Manipulation of the IL-6 Response 
 It has been previously established that CHO supplementation 
during exercise improves performance; however mechanisms responsible 
for this improvement are unclear (Coyle and Coggan, 1991; Stellingwerff 
et al., 2007; Rollo et al., 2010).  Our findings from chapter 6 show that 
CHO intake during exercise reduces the circulating IL-6 response.  We 
speculate that this may be one of several potential mechanisms by which 
CHO supplementation can improve performance. 
 The level of circulating IL-6 has been suggested to be a marker of 
altered homeostasis during prolonged exercise and intensive training 
periods (Ostrowski et al., 1998; Robson-Ansley et al., 2007; Jurimae et al., 
2011).  Since IL-6 can cross the blood brain barrier (Banks et al., 1994), it 
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is speculated that IL-6 acts as a ‘distress’ signal, indicating peripheral 
cellular stress relating to increased ROS activity and also metabolic stress 
relating to substrate availability.  Increases in circulating IL-6 induced by 
the preload bout of exercise may therefore increase signalling to regions 
of the brain, influencing pacing in the subsequent time trial in order to 
conserve energy stores.  In contrast, the attenuation of the plasma IL-6 
response with CHO intake could lower the distress signal and reduce the 
sensations of fatigue, which could translate to a potential improvement in 
speed during the time trial.  The findings of this thesis may lend support to 
the previous hypothesis that feedback from the peripheries can influence 
efferent command, taking into account metabolic status, in order to 
complete a physical task (Ulmer, 1996; Lambert et al., 2005).   
 Findings from chapter 4 demonstrate that glutamine 
supplementation does not alter the circulating IL-6 response to exercise.  
However, there was a significant increase in circulating glucose levels.  
Since circulating IL-6 was not influenced by an increase in circulating 
glucose levels per se, this highlights the fact that the synthesis and 
release of IL-6 is influenced by other forms of CHO availability such as 
muscle glycogen (Steensberg et al., 2000; Keller et al., 2001).  As a result 
of prolonged exercise, critically low muscle glycogen levels can reduce 
exercise performance; and it has been reported that cyclists pace 
themselves according to some form of metabolic signal or ‘glycostat’ 
related to muscle glycogen concentrations (Rauch et al., 2005).  
Therefore, in accordance with this previous work, we propose that low 
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muscle glycogen can instigate a release of IL-6 into the circulation which 
can alter the sensation of fatigue and influence pacing strategy.  It is 
possible that IL-6 exerts its effects through a number of different pathways 
including neurotransmitter activity, the neural circuitry level or exerting its 
effects at the subconscious level.  
 Chapter 5 demonstrates that altering dietary CHO intake prior to 
exercise in order to manipulate muscle glycogen levels did not alter the 
mean IL-6 response to exercise.  This may indicate that trained runners 
have sufficient CHO availability to complete a protocol of this nature, 
therefore, the requirement of IL-6 as a mediator of glucose production is 
not altered.  Indeed, it is possible that CHO supplementation during rather 
than prior to exercise has a more pronounced effect on IL-6 
concentrations.  Nonetheless, in accordance with results from previous 
chapters, the plasma IL-6 response showed a strong negative correlation 
with relative exercise performance during the time trial, indicating that a 
large circulating IL-6 response is associated with a noticeable decrement 
in performance.   
8.2  Threshold Analysis of IL-6 Mediated Performance 
 A consistent finding in this series of studies is that regardless of the 
intervention employed, the systemic IL-6 response to the preload bout 
negatively correlates with relative exercise performance during the time 
trial.  However, it is noticeable that performance does not decline in a strict 
dose dependant manner with increasing IL-6 concentration, since the error 
from the correlation trendline increases with the increases in the IL-6 
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response (figures 3.5, 4.5, 5.6a and 6.6).  In light of this, we propose that 
a threshold may exist where a plasma IL-6 response above this threshold 
may indicate substantial cellular stress and/or limited CHO availability, 
subsequently impacting on performance, although the performance 
decrement varies between individuals.  In contrast, a response below this 
threshold has minimal, if any, impact on exercise performance. 
 The reasons for the individual differences in performance to 
elevated IL-6 concentrations are unclear.  An obvious explanation is 
differences in training status.  An interaction between the circulating IL-6 
response to exercise and endurance training has previously been 
established (Fischer et al., 2004; Gokhale et al., 2007).  Endurance 
training can lead to improvements in exercise metabolism, including 
spared muscle glycogen during exercise and increased muscle glycogen 
storage capacity (Gollnick et al., 1973; Henriksson and Reitman, 1976; 
Hurley et al., 1986), which can reduce and/or delay the plasma IL-6 
response to exercise.  In accordance with this, we have found that there 
are negative correlations between markers of training status (habitual 
weekly running distance and OV 2max), the IL-6 response to exercise and 
time to complete the 5 km time trial.  
 On this basis, it is difficult to determine whether circulating IL-6 
directly impacts on performance or if endurance training improves 
performance and that a reduced IL-6 response is a consequence of 
training.  However, when time trial performance is expressed relative to 
velocity at OV 2max, there is still an inverse relationship between IL-6 and 
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performance but training status does not consistently correlate with 
performance.  Not only does this provide further support that the IL-6 
response to the preload influences subsequent performance; but this also 
indicates that this occurrence is independent of habitual running distance 
and OV 2max.  Consequently, since training status is not solely responsible 
for the IL-6 mediated decrement in performance, the mechanisms for 
individual differences of the IL-6 response remain unclear and other 
factors must play a role.  Indeed, fiber type composition will play a role in 
exercise metabolism which may influence the IL-6 response to exercise.  
Furthermore, it has been previously shown that genetic predisposition 
influences the IL-6 response to an endotoxemia challenge (Fishman et al., 
1998) and that some individuals are predisposed to produce greater levels 
of IL-6 (Bonafe et al., 2001).  Therefore, to decipher the differential 
response of plasma IL-6 to prolonged exercise, further work must be 
directed not only towards phenotype characteristics, but also genotypes of 
the IL-6 gene polymorphisms which may impact on the IL-6 response.  
8.3  Signalling Receptors 
 The soluble signalling receptor of IL-6, sIL-6R, can bind to IL-6 to 
form an IL-6/sIL-6R complex which increases the half life of IL-6 (Gerhartz 
et al., 1994) and also increases its potency (Marz et al., 1999).  However, 
to regulate excessive signalling, the soluble trans-signalling receptor of the 
complex, sgp130 can also bind to the complex leading to inactivity due to 
a molar excess (Jostock et al., 2001).  During exercise, increases in the 
circulating receptors have been observed; however, a consistent finding of 
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this thesis was that nutritional interventions did not alter the systemic sIL-
6R or sgp130 response to exercise.  Although glutamine supplementation 
and CHO loading protocols did not alter the circulating IL-6 response, 
CHO supplementation blunted the IL-6 response by 49% whereas the 
signalling receptors were unaffected.  Collectively this indicates that the 
responses of IL-6 signalling receptors are not responsive to metabolic 
changes associated with CHO oxidation during prolonged exercise.  In 
addition, Leggate et al. (2010) have demonstrated that the plasma 
response of sIL-6R is not related to differences in exercise intensity when 
matched for total exercise load.  
 sIL-6R and sgp130 are also not related to relative or absolute 
exercise performance.  Additionally, markers of training status such as 
habitual weekly running distance and OV 2max are not associated with 
resting levels or the exercise induced response of sIL-6R or sgp130.  
These findings are in contrast to those reported for skeletal muscle where 
the density of IL-6R locally is increased in response to exercise training 
(Keller et al., 2005; Akerstrom et al., 2009).  It is possible that within 
skeletal muscle, the increase in IL-6R may have a sensitising effect on IL-
6 following endurance training which could reduce the circulating response 
of IL-6 to exercise. 
 IL-6R is predominantly located on the cell surface within skeletal 
muscle (Keller et al., 2005), liver cells (Jones et al., 1999) and leukocytes 
(Jones et al., 2005).  However during prolonged exercise, it is unknown 
which cells are the predominant source of circulating sIL-6R, making it 
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difficult to fully ascertain the role of sIL-6R during exercise.  In addition, it 
is unknown what impact circulating sIL-6R has on tissue specific functions.  
However, the observation that circulating sIL-6R is unresponsive to 
manipulation of CHO metabolism, and is not influenced by exercise 
intensity (Leggate et al., 2010) may suggest that the increased circulating 
sIL-6R is not due to metabolic stress.  A physical task such as exercise 
can induce many biochemical changes, and although circulating sIL-6R 
does not increase in response to infusion of rhIL-6 (Robson-Ansley et al., 
2006) it is possible that circulating sIL-6R is upregulated by some other 
signalling factor to increase the potency of IL-6 which can respond to a 
diverse range of stress signals.        
 Leggate et al. (2010) have shown that the IL-6/sIL-6R complex is 
upregulated by two fold in circulation during exercise.  However, the assay 
procedure used in the present series of studies was unable to differentiate 
between complex bound and free forms of IL-6 and sIL-6R.  Therefore is it 
difficult to determine whether an upregulation of the complex occurred 
during exercise.  From this, we do not know whether the attenuation of 
circulating IL-6 following CHO supplementation downregulates IL-6 and 
sIL-6R binding to form a complex, or indeed if the IL-6/sIL-6R is 
upregulated as a compensatory mechanism. 
8.4  Other Systemic Markers  
 We have demonstrated that circulating CRP is consistently 
elevated the morning following the preloaded time trial (Chapter 3).  
However, no significant differences were observed in plasma CRP 
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between trials following either glutamine supplementation (Chapter 4) or 
manipulating dietary CHO prior to exercise (Chapter 5) or manipulating 
CHO intake during exercise (Chapter 6).  This could be attributed to the 
similar responses that were observed in systemic IL-6 since it has been 
previously been shown that IL-6 can stimulate CRP production following 
exercise (Strachen et al., 1984; Scharhag  et al., 2006).  However, the 
observation that a reduced IL-6 response following CHO intake did not 
attenuate CRP production (Chapter 6) suggests that the exercise-induced 
CRP is not totally dependent on circulating IL-6; and that some other 
mechanism stimulates CRP production and release.   
 IL-1β, TNFα and IFNγ have all shown to be stimulators of CRP 
(Heinrich et al., 1990); however, it is unlikely that these pro-inflammatory 
cytokines are responsible for the increase in CRP in this series of studies 
since prolonged exercise produces a minimal response from pro-
inflammatory cytokines (Ostrowski et al., 1999).  It is also possible that 
that the exercise induced elevations in IL-6 may initiate CRP release, 
however, this may not be a dose dependent relationship and may be 
regulated on an individual basis which explains large inter-individual 
variances seen in the present series of studies.   
 The acute phase protein, hepcidin, has recently been proposed as 
a regulator of iron stores that may be involved in exercise-induced iron 
deficiency or anaemia (Peeling et al., 2008, Peeling et al., 2009).  Since 
IL-6 has been shown to induce circulating hepcidin levels (Nemeth et al., 
2004; Kemna et al., 2005), it seems plausible that a reduced IL-6 
 149 
 
response to exercise would dampen the response of systemic hepcidin.  
However, in chapter 7 we demonstrated that the attenuated IL-6 response 
from CHO supplementation did not alter the hepcidin response.  Since the 
plasma hepcidin response did not alter with CHO supplementation, it 
could be hypothesised that the exercise-induced plasma hepcidin 
response is related to some other signalling factor.  For IL-6 signalling to 
occur, the JAK/STAT signalling pathway is employed through STAT1 and 
STAT3 (Gerhartz et al., 1996).  It has been previously been shown that 
STAT3 is necessary for increased hepcidin expression (Wrighting and 
Andrews, 2006; Pietrangelo et al., 2007).  Therefore the association 
between increased systemic IL-6 and hepcidin concentrations seen during 
the placebo trial could be attributed to activation of STAT3 signalling.  
However, STAT3 has been shown to have other stimulators such as 
growth factors (Campbell et al., 1995; Heinrich et al., 1998; Zong et al., 
2000), which may increase in response to prolonged exercise and that are 
unresponsive to CHO intake.  It is therefore possible that exercise-induced 
STAT3 expression increased hepcidin concentrations and not the IL-6 per 
se.    
 Collectively, these findings show that although the exercise-induced 
increases in circulating IL-6, CRP and hepcidin are observed; the 
circulating CRP and hepcidin concentrations are unaltered by 
manipulating circulating IL-6 levels.  Therefore their release is not due to 
IL-6 per se but possibly other signalling factors.  
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8.5  Conclusions 
 In the present thesis we have demonstrated that the plasma IL-6 
and signalling receptors display a repeatable response to a preloaded 
time trial protocol, of which, the increase in IL-6 concentration was 
attenuated by CHO intake during exercise.  In addition, the magnitude of 
the reduced plasma IL-6 response following CHO intake is related to an 
improvement in running speed during the time trial. However, the 
attenuation of the plasma IL-6 response does not translate to a reduction 
of the circulating hepcidin response to exercise.  Our findings also show 
that the IL-6 response to exercise is not altered by dietary CHO intake 
prior to exercise or by glutamine supplementation during exercise; but 
despite the nutritional intervention employed, the findings consistently 
show that a lower circulating IL-6 response to the preload is associated 
with improved relative exercise performance during the time trial, which is 
independent of training status.   
 The findings from the thesis highlight the complexity of IL-6 in the 
circulation and add further awareness of IL-6 as a stress marker.  The 
magnitude of the IL-6 response to the preload bout can act as a marker to 
indicate an athlete’s stress response to exercise and can also explain the 
differences observed in subsequent exercise performance.  The 
improvement in performance following attenuation of the IL-6 response 
with CHO supplementation is in accordance with the literature of IL-6 as a 
fatigue inducing protein.  Therefore, during competition of long duration, 
athletes should consume CHO products in order to minimise the IL-6 
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stress response to optimise performance.  However, IL-6 has been 
previously shown in the literature to be a key mediator in the adaptation 
responses to exercise training and metabolism.  Therefore, in light of the 
present findings, our results support the model of ‘train low, compete high’ 
where athletes should incorporate consuming low carbohydrates during 
particular training sessions to maximise training adaptations.  However 
during competition, high carbohydrates should be consumed to minimise 
stress and fatigue signals such as IL-6.     
 Future research should be directed towards the differential 
response of circulating IL-6 to exercise, including phenotype and genotype 
characteristics.  In addition, research should examine the threshold further 
at which circulating IL-6 impacts on performance.   
 In conclusion, effective manipulation of the circulating IL-6 
response to exercise can improve performance.  However, this does not 
alter the response of the IL-6 signalling receptors or biomarkers 
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                                        PROJECT DETAILS 
 
TITLE OF PROJECT: The repeatability of the cytokine response to prolonged 
exercise. 
Principal Investigator: Ian Walshe 
Investigator contact details:      Phone: 07745520939 
                                                      Email: ian.walshe@unn.ac.uk 
 
 
1. What is the purpose of the project? 
In this project we are investigating a model of an exercise bout that can induce a 
messenger molecule (cytokine) response and to ascertain the variation of the 
response from this model.  Furthermore, we are investigating the performance 
effects of an induced cytokine response from this model. 
 
2. Why have I been selected to take part? 
You have asked to participate because you are male and aged between 18 and 
35.  You will also be involved in regular endurance running. 
3. What will I have to do?  For the experiment you will be asked to visit the 
laboratory on four occasions: 
Visit One –  
Suitability for the study: 
Initially you will complete a health-history questionnaire concerning your past and 
present health status in private.  It is important to be entirely honest and point out 
any known health problems, even if they seem trivial.  We will also need to know 
if you have been on medication at any time during the four weeks prior to the 
study. At this time we will also ask you to fill out a questionnaire regarding your 




O2max Test: Providing that you are suitable for the study and you feel that you 
want to be involved, you will then perform a treadmill exercise test to volitional 
exhaustion in order to determine your aerobic capacity (V
.
O2max).  You will start 
by running on a treadmill at 8.0 kph and the speed will be increased by 2.0 kph 
every three minutes until volitional fatigue.  We will collect gas samples from you 
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(you will wear a nose clip and breathe through a mouthpiece and we will collect 
your expired air) and record your heart rate.   
Visit one will last no more than 1 hour and can take place at any time of day. 
Visits Two, Three and Four-  
Pre- exercise:  For the 24 hours before visits three and four we will ask you not 
to train or drink alcohol (it will affect your resting baseline immune values).  We 
will also need you to make sure that you do not eat or drink any caffeine-
containing foods and drinks for 24 hours before these visits. In addition we will 
provide you with standardised food to eat in the 24 hours before your trial, this 
helps to standardise your responses to the exercise test.  We will also ask you to 
refrain from eating and drinking sports drinks12 hours before the trial but you can 
drink as much water as you like.   
Before the test, you will be asked to go to the lavatory and then we will record 
your body mass.  You will then be asked to provide a urine sample (in private) 
and a saliva sample.  After sitting quietly for 10 minutes, we will then take a 
resting blood sample from the antecubital vein in the arm.  You will then be asked 
to perform a test of memory (word recall).   
Exercise Bouts: Visit two will give you a chance to familiarise yourself to the 
exercise test and to the methods of data collection that you may be unfamiliar 
with such as blood sampling and using the treadmill controls.  On this visit, you 
will be asked to run at a speed that is equivalent to an exercise intensity that is 
60% of your speed atV
.
O2max for 2 hours.  Every 10 minutes you will be required 
to run for 30 seconds at a speed that is 90% of your speed at V
.
O2max.  During 
the exercise we will analyse gas samples using a mouth piece and record your 
heart rate.  Following this, you will be asked for another blood sample and 
allowed 5 minutes rest before performing a 5 kilometre time trial.  You will be 
asked to run the time trial as fast as possible.  During the trial, you will be 
informed of the distance you have run throughout the trial.  Following the trial, 
you will be asked for al urine, saliva and blood sample.  The test of memory will 
also be performed at this time.  Final blood samples will then be taken one hour 
after exercise and approximately 24 hours after exercise.    Visits two, three and 
four must take place in the morning and will last no more than 3.5 hours each. 
At all visits you will be asked to fill in a health questionnaire to confirm your 
fitness to participate in the study on that day. 
 
4. What are the exclusion criteria (i.e. are there any reasons why I should 
not take part)?  
Exclusion criteria will include being unaccustomed to vigorous exercise and 
experience of any symptoms of infection in the four weeks prior to the study or at 
any point during the study. 
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5. Will my participation involve any physical discomfort? 
You may feel some discomfort towards the end of the exercise periods 
associated with long distance running due to the fatiguing nature of the tests 
6. Will my participation involve any psychological discomfort or 
embarrassment? 
No 
7. Will I have to provide any bodily samples (i.e. blood, saliva)? 
Pre exercise you will be asked to provide a saliva sample, blood sample from the 
antecubital vein in the arm and a urine sample in private.  After the exercise bout 
you will be asked for a blood sample from the antecubital vein.  After the time trial 
you will be asked for saliva, blood and urine samples as specified with pre 
exercise. 
8. How will confidentiality be assured? 
You will only be known by a number to protect anonymity.  All data will be kept in 
a locked cabinet or computerised and accessed via a password which will be 
done in accordance with the Data Protection Act. 
9. Who will have access to the information that I provide? 
Only the principle investigator and supervisor will have access to information that 
you provide.   
10. How will my information be stored / used in the future? 
All data will be kept in a locked cabinet or computerised and accessed via a 
password which will be done in accordance with the Data Protection Act.  Data 
may be used for publication in the form of a scientific paper, presented at a 
conference or both.  Any data used can not be linked to you. 
11. Has this investigation received appropriate ethical clearance? 
Yes 
12. Will I receive any financial rewards / travel expenses for taking part? 
You will be paid £70 on completion of your participation. A further £30 will be 
given to the participant with the quickest average time trial. 
13. Can I withdraw from the project? 
You can withdraw from the project at any point without providing reasons for 
doing so and without prejudice. 
14. If I require further information who should I contact and how? 
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 For further information please contact myself by telephone on 07745520939 or 






























TITLE OF PROJECT: The effect of carbohydrate ingestion on the 
inflammatory response to exercise. 
Principal Investigator: Ian Walshe 
Investigator contact details: 
Phone: 07745520939     
Email: ian.walshe@unn.ac.uk 
This project is funded by: Biotechnology and Biological Sciences Research 
Council and GlaxoSmithKline 
Number of participant points / payment: £90 
1. What is the purpose of the project? During prolonged exercise messenger 
molecules (cytokines) have been shown to increase in blood circulation and may 
cause fatigue.  The purpose of this project is to examine the effect of 
carbohydrate ingestion on cytokines and subsequently the affect on fatigue. 
2. Why have I been selected to take part? 
You have asked to participate because you are male and aged between 18 and 
40 years.  You will also participate in regular endurance running and be able to 
complete a 2 hour bout of running 
3. What will I have to do? 
For the experiment you will be asked to visit the laboratory on four occasions: 
Visit One –  
Suitability for the study: 
Initially you will complete a health-history questionnaire concerning your past and 
present health status in private.  It is important to be entirely honest and point out 
any known health problems, even if they seem trivial.  We will also need to know 
if you have been on medication at any time during the four weeks prior to the 
study. At this time we will also ask you to fill out a questionnaire regarding your 
training habits.  Any answers you give will be kept in strict confidence. 
V
.
O2max Test: Providing that you are suitable for the study and you feel that you 
want to be involved, you will then perform a treadmill exercise test to volitional 
exhaustion in order to determine your aerobic capacity (V
.
O2max).  You will start 
by running on a treadmill at 8.0 kph and the speed will be increased by 2.0 kph 
every three minutes until volitional fatigue.  We will collect gas samples from you 
(you will wear a mask and we will collect your expired air) and record your heart 
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rate.  Visit one will last no more than 1 hour and can take place at any time of 
day. 
Visit Two 
Exercise Bout: Visit two will give you a chance to familiarise yourself to the 
exercise test and to the methods of data collection that you may be unfamiliar 
with such as using the treadmill controls.  On this visit, you will be asked to run at 
a speed that is equivalent to an exercise intensity that is 60% of your speed atV
.
O2max for 1 hour.  Every 10 minutes you will be required to run for 30 seconds at 
a speed that is 90% of your speed atV
. O2max.  
 You will also be asked to consume 2ml/kg of the carbohydrate drink every 20 
minutes during the exercise bout. During the exercise bout we will analyse gas 
samples using a mouth piece and record your heart rate.  Following this, you will 
be allowed 5 minutes rest before performing a 5 kilometre time trial.  You will be 
asked to run the time trial as fast as possible.  During the trial, you will be 
informed of the distance you have run throughout the trial.  Following the trial you 
will be asked to perform another grip strength test.  Visits two will last 
approximately 1.5 hours and can take place any time of day. 
Visit 3 and 4 
Pre- exercise:  For the 24 hours before visit two we will ask you not to train or 
drink alcohol (it will affect your resting baseline immune values).  We will also 
need you to make sure that you do not eat or drink any caffeine-containing foods 
and drinks for 24 hours before these visits (see the attached sheet). We will also 
ask you to refrain from eating 12 hours before the trial but you can drink water.   
Before the test, you will be asked to go to the lavatory and then we will record 
your body mass.  You will then be asked to consume 2ml/kg of a carbohydrate 
drink and will then be asked to perform a grip strength test using a hand grip 
dynamometer. 
Visit 3 and 4 will consist of the same protocol as used in visit 2 however; the 
exercise trial will be 2 hours in duration followed by a 5km time trial.  Before the 
exercise bout you will be asked to consume a carbohydrate drink or a taste 
matched placebo in a randomised order (2ml/kg) whilst during the exercise bout 
you will asked to consume the same drink (2ml/kg) every 20 minutes.  Pre 
exercise you will be asked for a blood sample and a grip strength test as well as 
body mass.  Following the exercise bout you will be asked for another blood 
sample and grip strength test before taking part in the time trial. Further blood 
samples and grip strength tests will be asked for immediately post time trial, 1 
hour post and 24 hour post exercise. 
At all visits you will be asked to fill in a health questionnaire to confirm your 




4. What are the exclusion criteria (i.e. are there any reasons why I should 
not take part)?  
Exclusion criteria will include being unaccustomed to running for 2 hours and 
experience of any symptoms of infection in the four weeks prior to the study or at 
any point during the study. 
5. Will my participation involve any physical discomfort? 
You may feel some discomfort towards the end of the exercise periods 
associated with long distance running due to the fatiguing nature of the tests.  
You may experience some bruising from blood sampling, however this is normal 
and pain will be minimal. 
6. Will my participation involve any psychological discomfort or 
embarrassment? 
No 
7. Will I have to provide any bodily samples (i.e. blood, saliva)? 
You will be asked for blood samples at pre exercise, post exercise, post time 
trial, 1 hour post time trial and 24 hours post time trial. 
8. How will confidentiality be assured? 
You will only be known by a number to protect anonymity.  All data will be kept in 
a locked cabinet or computerised and accessed via a password which will be 
done in accordance with the Data Protection Act. 
9. Who will have access to the information that I provide? 
Only the principle investigator and supervisor will have access to information that 
you provide 
10. How will my information be stored / used in the future? 
All data will be kept in a locked cabinet or computerised and accessed via a 
password which will be done in accordance with the Data Protection Act.  Data 
may be used for publication in the form of a scientific paper, presented at a 
conference or both.  Any data used cannot be linked to you. 
11. Has this investigation received appropriate ethical clearance? 
Yes 
12. Will I receive any financial rewards / travel expenses for taking part? 
You will be paid £90 on completion of your participation. A further £30 will be 




13. How can I withdraw from the project? 
If you wish to withdraw from the project, you can inform me by email, telephone 
or in person.  You can withdraw from the project at any point without providing 
reasons for doing so and without prejudice.   
14. If I require further information who should I contact and how? 
For further information please contact myself by telephone on 07745520939 or 

























TITLE OF PROJECT: The effect of glutamine ingestion on the inflammatory 
response to exercise. 
Principal Investigator:  Ian Walshe 
Investigator contact details: 07745520939     
Email:  ian.walshe@unn.ac.uk   
This project is funded by: Biotechnology and Biological Sciences Research 
Council and GlaxoSmithKline Nutritional Healthcare 
 Payment: £90 
1.  What is the purpose of the project?  
During prolonged exercise messenger molecules (cytokines) have been shown 
to increase in blood circulation and may cause fatigue.  The purpose of this 
project is to examine the effect of glutamine (a form of protein) ingestion on 
cytokines and subsequently the affect on exercise performance. 
2.  Why have I been selected to take part?  
You have asked to participate because you are male and aged between 18 and 
40 years.  You will also be endurance trained and participate in regular 
endurance running and be able to complete a 2 hour bout of running. 
3.  What will I have to do?  
For the experiment you will be asked to visit the laboratory on four occasions: 
Visit One –  
Suitability for the study: 
Initially you will complete a health-history questionnaire concerning your past and 
present health status in private.  It is important to be entirely honest and point out 
any known health problems, even if they seem trivial.  We will also need to know 
if you have been on medication at any time during the four weeks prior to the 
study. At this time we will also ask you to fill out a questionnaire regarding your 
training habits.  Any answers you give will be kept in strict confidence. 
V
.
O2max Test: Providing that you are suitable for the study and you feel that you 
want to be involved, you will then perform a treadmill exercise test to volitional 
exhaustion in order to determine your aerobic capacity (V
.
O2max).  You will start 
by running on a treadmill at 8.0 kph and the speed will be increased by 2.0 kph 
every three minutes until volitional fatigue.  We will collect gas samples from you 
(you will wear a mask and we will collect your expired air) and record your heart 





Pre- exercise:  For the 24 hours before visit two we will ask you not to train or 
drink alcohol (it will affect your resting baseline immune values).  We will also 
need you to make sure that you do not eat or drink any caffeine-containing foods 
and drinks for 24 hours before these visits (see the attached sheet). We will also 
ask you to refrain from eating and drinking 12 hours with the exception of water.   
Before the test, you will be asked to go to the lavatory and then we will record 
your body mass.  You will then be asked to consume 5ml/kg of body mass of 
flavoured water and will then be asked to perform a grip strength to fatigue test 
using a hand grip dynamometer. 
Exercise Bout: Visit two will give you a chance to familiarise yourself to the 
exercise test and to the methods of data collection that you may be unfamiliar 
with such as using the treadmill controls.  On this visit, you will be asked to run at 
a speed that is equivalent to an exercise intensity that is 60% of your speed atV
.
O2max for 2 hours.  Every 10 minutes you will be required to run for 30 seconds 
at a speed that is 90% of your maximum speed.  You will be given lemon 
flavoured water at 30 minute intervals throughout the trial which will be the same 
for visits 3 and 4. During the exercise bout we will analyse gas samples using a 
mouth piece and record your heart rate.  Following this, you will be allowed 5 
minutes rest before performing a 5 kilometre time trial.  You will be asked to run 
the time trial as fast as possible.  During the trial, you will be informed of the 
distance you have run throughout the trial however, not made aware of the time 
elapsed.  Following the trial you will be asked to perform another grip strength 
test.  Visits two will last approximately 3.5 hours and can take place any time of 
day. 
Visit 3 and 4: Visit 3 and 4 will consist of the same protocol as used in visit 2.  
Before the exercise bout you will be asked to consume 0.05g per kilogram of 
body mass of glutamine powder in flavoured water or a taste matched placebo in 
a randomised order before the exercise bout. Whilst during the exercise bout you 
will be given the same amount of flavoured water that was consumed in the 
familiarisation trial with added glutamine (0.05g per kilogram of body mass) in 
one of the trials.  Pre exercise you will be asked for a venous blood sample from 
the arm and a grip strength test as well as body mass.  Following the exercise 
bout you will be asked for another blood sample and grip strength test before 
taking part in the time trial. Further blood samples and grip strength tests will be 
asked for immediately post time trial, 1 hour post time trial and the following 
morning. 
At all visits you will be asked to fill in a health questionnaire to confirm your 





4.  What are the exclusion criteria (i.e. are there any reasons why I should 
not take part)?  
Exclusion criteria will include being unaccustomed to running for 2 hours and 
experience of any symptoms of infection or injury in the four weeks prior to the 
study or at any point during the study. 
5.  Will my participation involve any physical discomfort?  
You may feel some discomfort towards the end of the exercise periods 
associated with long distance running due to the fatiguing nature of the tests.  
You may experience some bruising from blood sampling, however this is normal 
and pain will be minimal. 
6.  Will my participation involve any psychological discomfort or 
embarrassment? 
No 
7.  Will I have to provide any bodily samples (i.e. blood, saliva)?  
You will be asked for blood samples at pre exercise, post exercise, post time 
trial, 1 hour post time trial and the following morning. 
8.  How will confidentiality be assured?  
You will only be known by a number to protect anonymity.  All data will be kept in 
a locked cabinet or computerised and accessed via a password which will be 
done in accordance with the Data Protection Act. 
9.  Who will have access to the information that I provide?  
Only the principle investigator and supervisor will have access to information that 
you provide.   
10.  How will my information be stored / used in the future?  
All data will be kept in a locked cabinet or computerised and accessed via a 
password which will be done in accordance with the Data Protection Act.  Data 
may be used for publication in the form of a scientific paper, presented at a 
conference or both.  Any data used cannot be linked to you. All records will be 
kept confidential except for review by representatives of GlaxoSmithKline and/or 
Northumbria University Ethics Committee representatives and regulatory 
authorities. 
 





12.  Will I receive any financial rewards / travel expenses for taking part? 
You will be paid £90 on completion of your participation. A further £30 will be 
given to the participant with the quickest average time trial compared to their 
maximum speed. 
13.  How can I withdraw from the project? 
If you wish to withdraw from the project, you can inform me by email, telephone 
or in person.  You can withdraw from the project at any point without providing 
reasons for doing so and without prejudice.   
14.  If I require further information who should I contact and how? 
For further information please contact myself by telephone on 07745520939 or 





















 PARTICIPANT INFORMATION 
TITLE OF PROJECT: The effect of pre exercise feeding protocols on the 
inflammatory response to exercise. 
Principal Investigator:  Ian Walshe 
Investigator contact details: 07745520939     
Email:  ian.walshe@unn.ac.uk   
This project is funded by: Biotechnology and Biological Sciences Research 
Council and GlaxoSmithKline Nutritional Healthcare 
 Payment: £100 
1.  What is the purpose of the project?  
Many runners before competition may perform carbohydrate loading protocols to 
increase muscle glycogen and to increase performance.  During prolonged 
exercise messenger molecules of the immune system (cytokines) have been 
shown to increase in blood circulation and may cause fatigue.  The purpose of 
this project is to examine the effect of pre exercise feeding protocols on cytokine 
receptor and the affect on exercise performance. 
2.  Why have I been selected to take part?  
You have been asked to participate because you are male and aged between 18 
and 40 years.  You will also be endurance trained and participate in regular 
endurance running and be able to complete a 2 hour bout of running. 
3.  What will I have to do?  
For the experiment you will be asked to visit the laboratory on six occasions: 
Visit One 
Suitability for the study: 
Initially you will complete a health-history questionnaire concerning your past and 
present health status in private.  It is important to be entirely honest and point out 
any known health problems, even if they seem trivial.  We will also need to know 
if you have been on medication at any time during the four weeks prior to the 
study. At this time we will also ask you to fill out a questionnaire regarding your 
training habits.  Any answers you give will be kept in strict confidence. 
V
.
O2max Test: Providing that you are suitable for the study and you feel that you 
want to be involved, you will then perform a treadmill exercise test to volitional 
exhaustion in order to determine your aerobic capacity (V
.
O2max).  You will start 
by running on a treadmill at 8.0 kph and the speed will be increased by 2.0 kph 
every three minutes until volitional fatigue.  We will collect gas samples from you 
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(you will wear a mask and we will collect your expired air) and record your heart 
rate.  Visit one will last no more than 1 hour and can take place at any time of 
day. 
Visit Two 
Pre- exercise:   
Before the test, you will be asked to go to the lavatory and then we will record 
your body mass.  You will then be asked to perform a grip strength to fatigue test 
using a hand grip dynamometer using your dominant hand. 
Exercise Bout: Visit two will give you a chance to familiarise yourself to the 
exercise test and to the methods of data collection that you may be unfamiliar 
with such as using the treadmill controls.  On this visit, you will be asked to run at 
a speed that is equivalent to an exercise intensity that is 60% of your speed atV
.
O2max for 2 hours.  Every 10 minutes you will be required to run for 30 seconds 
at a speed that is 90% of your maximum speed.  You can consume water ad 
libitum which will be recorded and replicated for the main trials. During the 
exercise bout we will analyse gas samples using a mouth piece and record your 
heart rate.  Following this, you will be allowed 5 minutes rest before performing a 
5 kilometre time trial.  You will be asked to run the time trial as fast as possible.  
During the trial, you will only be informed of the distance you have run throughout 
the trial however and not made aware of the time elapsed.  Following the trial you 
will be asked to perform another grip strength test.  Visit two will last 
approximately 3 hours and can take place any time of day. 
Visits 3 to 6 (Main trials): During the remaining visits you will complete the 
same exercise task as in visit 2 under three separate conditions where we will 
manipulate your pre-exercise diet. The 3 conditions are as follows: 
1. Low carbohydrate diet 
2. High carbohydrate diet 
3. High carbohydrate supercompensation diet (2 visits) 
 
Pre-exercise diets: For the Low and High carbohydrate conditions you will be 
provided with food for the 48 hours prior to the trial. It is important that you only 
eat the foods given to you. For main trial 3 you will also be required to come in to 
the laboratory 3 days before the main trial to perform a glycogen depleting 
protocol which will consist of running at 70% of your maximal aerobic speed for 
90 minutes to ensure that your muscles are depleted of glycogen. Following this 
you will be given the high carbohydrate diet to consume over the next 2 days, 
this will maximise the glycogen resynthesis and supercompensate your muscle 
glycogen levels. Please note the order of these conditions will be randomised so 




Exercise bout: The main trials will consist of the same exercise protocol as used 
in visit 2. We will also take some additional measures. Before the exercise bout 
you will be asked for a venous blood sample from the arm and a grip strength 
and fatigue index test as well as body mass.  During the exercise bout you will be 
asked to consume the same amount of water that was consumed in visit 2.  
Following the exercise bout you will be asked for another blood sample and grip 
strength test before taking part in the 5 km time trial. Further blood samples and 
grip strength tests will be asked for immediately post time trial, 1 hour post time 
trial and the following morning, 24 hours from pre exercise.  The main trials need 
to take place in the morning and will last approximately 3.5 hours. 
 Pre-test preparation: In addition to consuming the diets provided, for the 48 
hours before the main trials we will also ask you not to train or drink alcohol (it 
will affect your resting baseline immune values).  We will also need you to make 
sure that you do not eat or drink any caffeine-containing foods and drinks for 24 
hours before these visits (see the attached sheet). We will also ask you to refrain 
from eating and drinking for the 12 hours before the start of the main trial with the 
exception of water.   
At all visits you will be asked to fill in a health questionnaire to confirm your 
fitness to participate in the study on that day. 
4.  What are the exclusion criteria (i.e. are there any reasons why I should 
not take part)?  
Exclusion criteria will include being unaccustomed to running for 2 hours and 
experience of any symptoms of infection or injury in the four weeks prior to the 
study or at any point during the study.  Exclusion criteria also include if you have 
diabetes or metabolic disorder, allergies or suspected allergies to foods and any 
contraindications of exercise. 
5.  Will my participation involve any physical discomfort?  
You may feel some discomfort towards the end of the exercise periods 
associated with long distance running due to the fatiguing nature of the tests. 
You may experience some bruising from blood sampling, however this is normal 
and pain will be minimal. 
6.  Will my participation involve any psychological discomfort or 
embarrassment? 
No 
7.  Will I have to provide any bodily samples (i.e. blood, saliva)?  
You will be asked for venous blood samples from the arm during the main trials 





8.  How will confidentiality be assured?  
You will only be known by a number to protect anonymity.  All data will be kept in 
a locked cabinet or computerised and accessed via a password which will be 
done in accordance with the Data Protection Act. 
9.  Who will have access to the information that I provide?  
Only the principal investigator and supervisor will have access to information that 
you provide.  All records will be kept confidential except for review by 
representatives of GlaxoSmithKline and/or Northumbria University Ethics 
Committee representatives and regulatory authorities. 
10.  How will my information be stored / used in the future?  
All data will be kept in a locked cabinet or computerised and accessed via a 
password which will be done in accordance with the Data Protection Act.  Data 
may be used for publication in the form of a scientific paper, presented at a 
conference or both.  Any data used cannot be linked to you. 
11.  Has this investigation received appropriate ethical clearance? 
Yes, the study and its protocol has received full ethical approval from the School 
of Psychology & Sport Sciences Ethics Committee. If you require confirmation of 
this please contact the Chair of this Committee, stating the title of the research 
project and the name of the principal investigator: 
Chair of School of Psychology & Sport Science Ethics Committee, 
Northumberland Building, Northumbria University, Newcastle upon Tyne, NE1 
8ST. 
12. Will I receive any financial rewards / travel expenses for taking part? 
You will be paid £100 on completion of your participation. A further £30 will be 
given to the participant with the quickest average time trial compared to their 
maximum speed. 
13. How can I withdraw from the project? 
If you wish to withdraw from the project, you can inform me by email, telephone 
or in person.  You can withdraw from the project at any point without providing 
reasons for doing so and without prejudice.   
14. If I require further information who should I contact and how? 
If you would like further information on the study please contact the principal 
investigators on the contact emails listed above. If you would like to discuss the 
study, withdraw your data or register a complaint please contact the chair of the 




INFORMED CONSENT FORM 
Principal Investigator: Ian Walshe 
Participant Number: __________ 
 
I have read and understood the Participant Information Sheet.   
I have had an opportunity to ask questions and discuss this study and 
I have received satisfactory answers.                    
I understand I am free to withdraw from the study at any time, without having to 
give a reason for withdrawing, and without prejudice.                          
I agree to take part in this study.                                                
I would like to receive feedback on the overall results of the study at the email 
address given below.  I understand that I will not receive individual feedback on 
my own performance.                                                                
Email address…………………………………………………  
Signature of participant.......................................................    
Date.....……………….. 
(NAME IN BLOCK LETTERS)............................................ 
Signature of Parent / Guardian in the case of a minor  
......................................................................................... 
Signature of researcher.......................................................    
Date.....……………….. 












FOR USE WHEN TISSUE IS BEING REMOVED BUT NOT STORED 
Principal Investigator: Ian Walshe 
Participant Number: __________ 
 
I agree that the following tissue or other bodily material may be taken and used 
for the study:  
 
Tissue/Bodily material Purpose Removal Method 
Blood plasma 
 








I understand that if the material is required for use in any other way than that 
explained to me, then my consent to this will be specifically sought. I understand 
that I will not receive specific feedback from any assessment conducted on my 
samples, but should any kind of abnormality be discovered then the investigator 
will contact me.  
 
Signature of participant.......................................................    
Date.....……………….. 
Signature of Parent / Guardian in the case of a minor             
.......................................................................................        
Date.....……………….. 













Pre-exercise test questionnaire 
Participant number ……………………………….. 
As you are participating in exercise within this laboratory, please can you 
complete the following questionnaire. Your co-operation is greatly appreciated. 
 
All information within this questionnaire is considered confidential. 
Where appropriate please circle your selected answer: 
1. How would you describe your current level of activity? 
Sedentary moderately active highly active 
2. How would you describe your current level of fitness? 
Very unfit moderately fit      trained      highly trained 
3. How would you consider your current body weight? 
Underweight  ideal     slightly overweight                         
very overweight 
4. Smoking habits: 
Currently non- smoker Yes / No 
A previous non-smoker Yes / No 
If previous smoker, how long is it since you stopped? ………… years 
A regular smoker  Yes / No of ……… per day 
An occasional smoker  Yes / No of ……… per day 
5. Alcohol consumption: 
Do you drink alcohol Yes / No 
If yes then do you: 
 Have an occasional drink   Yes / No  
 Have a drink every day   Yes / No  
 Have more than one drink per day             Yes / No 
6. Have you consulted your doctor within the last six months? Yes / No  




7. Are you currently taking any medication       Yes / No 
If yes please give details to the test supervisor 
Are you currently taking any supplements               Yes / No 





8. Do you suffer from any food intolerances or allergies?       Yes / No 
 
9. Do you suffer from: 
 







10. Do you suffer from, or have you suffered from, any heart complaint?  
 
    Yes / No 
 
11. Is there a history of heart disease in your family? Yes / No 
 
12. Do you currently have any form of muscle joint injury? Yes / No 
 
13. Do you currently suffer with underlying infection?           Yes / No 
 
14. Have you had any reason to suspend your training in the last two weeks? 
 





15.  Is there anything to your knowledge that may prevent you from 
successfully completing the test(s) that have been outlined to you? 
 
                                     Yes / No 
 
If yes please give details to the test supervisor: 
 

























Physical Activity Questionnaire 
The following questions are designed to give us an indication of 
your current level of physical activity and fluid intake during 
exercise.  
 
Participant Number: _________                             Date: ____________       
 
Are you currently ENDURANCE TRAINING?         YES         NO        . 
If Yes, how many days each week do you usually train? _________                 
How many minutes does each session last? ____________                             
What is your weekly mileage for running?  _____________                    
What is your weekly mileage for cycling?  _______________ 
Are you involved in any of the following training programmes? 
Weight training              Interval training               Skills training       . 
If Yes, how many days each week do you usually train? __________ 
How many minutes does each session last? ____________   
Do you normally consume fluids during training?  YES         NO        .  





           
